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Abstract
Acute myeloid leukaemia (AML) is characterised by an accumulation of immature blasts 
that fail to fully differentiate. Leukaemia is organised as a hierarchy, which is maintained 
by leukaemic stem cells (LSC). To identify molecular differences between normal 
haematopoietic stem cells (HSC) and LSC, we performed microarray analysis and found 
that haematopoietic cell kinase (HCK) is overexpressed in LSC. Thus, by knocking-down 
HCK in leukaemic cells or overexpressing it in stem cell enriched fractions, we should be 
able to evaluate its role in leukaemogenesis.
Since LSC are difficult to culture in vitro, we started to validate HCK silencing in 
leukaemic cell lines, Mono-mac-6 (MM6), U937 and Fujioka/P31, which highly express 
HCK. In all cell lines studied, no more than 50% silencing could be achieved, even when 
a short-hairpin anti-HCK was cloned into a lentiviral backbone to follow the long-term 
effect of HCK silencing. Decrease in kinase activity was confirmed using kinase assay 
and phospho-specific antibody recognising the activated HCK kinase. We show that 
HCK silencing does not affect the cell cycle, proliferation, differentiation or apoptosis of 
the cell lines. However, using methylcellulose assay, we observe a significant change in 
MM6 colony morphology caused by a decrease in their migration properties. Moreover, 
using phospho-flow cytometry, G-CSF and GM-CSF signal transduction towards STAT5 
could be proven to occur via HCK in MM6, but not in Fujioka/P31 or U937 cells.
HSC enriched umbilical cord blood cells were also transduced with a lentivirus encoding 
p59HCK. Overexpression of p59HCK in these cells led to their enhanced erythroid 
differentiation at the expense of myeloid differentiation underlined by the activation of c- 
Raf, ERK and STATS.
Overall, this study can be used as a preliminary set up for further investigation of the role 
of HCK in normal human stem cells and in primary AML samples in vivo.
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A bbreviation  list
Abbreviation Meaning
2% FCS: PBS supplemented with 2% FCS
293T-HEK cells: Human embryonic kidney epithelial cells 293 expressing a large T antigen
ABL or v-abl: Abelson murine leukemia viral oncogene homolog 1
ACK1: Activated Cdc42-associated kinase 1
ADAM15: A disintegrin and metallopeptidase domain 15
ADD3: Adducin 3
AF1Q: ALL1-fused gene from chromosome lq
AF9: ALL1 fused gene from chromosome 9
AKAP13: A kinase (PRKA) anchor protein 13
Akt or AKT: v-akt murine thymoma viral oncogene homolog
ALL: Acute lymphoblastic leukaemia
AML: Acute myeloid leukaemia
AML1: Acute myeloid leukemia 1
ANKRD12: Ankyrin repeat domain 12
ANP32E: Acidic (leucine-rich) nuclear phosphoprotein 32 family, member E
APC: Antigen-Presenting Cell
APC: Allophycocyanin
APL: Acute promylocytic leukaemia
ATP: Adenosine tri-phosphate
ATRA: All-trans retinoic acid
P2M: Beta-2-microglobulin
BAALC: Brain and acute leukemia, cytoplasmic
BclxL: Basal cell lymphoma-extra large
BCR: Break point cluster region
BCR: B-Cell Receptor
BDT: BigDye Terminator
BFU-E: Blast forming unit-Erythrocyte
Blk: B lymphoid tyrosine kinase
BM: Bone marrow
bp: Base pair
BRD2: Bromodomain containing 2
BSA:
C/EBPa or
Bovine serum albumin
CEBPA: CCAAT/enhancer binding protein (C/EBP) alpha
CAP350: Centrosomal protein 350
CBF: Core binding factor
CBFA2: Core binding factor A2
CCND3: CyclinD3
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CD: Cluster of differentiation
Cdc42: Cell division cycle 42
cddB: Cyclododecanone to dodecanoic diacid B
CDK: Cyclin dependant kinase
cDNA: Complementary desoxyribonucleic acid
CFAC assay: Cobblestone area-forming cell assay
CFC assay: Colony forming cell assay
CFU-E: Colony forming unit-Erythroid
CFU-G: Colony forming unit-Granulocyte
CFU-GEMM: Colony forming unit-Granulocyte erythroid monocyte megakaryocyte
CFU-GM: Colony forming unit-Granulocyte monocyte
CFU-M: Colony forming unit-Monocyte
CHS1: Chediak-Higashi syndrome 1
CIP: Calf Intestinal Phosphatase
c-KIT v-kit Hardy-Zuckerman 4 feline sarcoma viral oncogene homolog
CLL: Chronic lymphoid leukaemia
CLP: Common lymphoid progenitors)
CML: Chronic myeloid leukaemia
CMP: Common myeloid progenitors)
CMV: Cytomegalovirus
CNTF: Ciliary neurotrophic factor
C02: Carbon dioxyde
CV-1 (simian) in Origin carrying the SV40 genetic material (African Green
COS cells: Monkey Kidney Fibroblast Cell)
cPPT: Central polypurine tract sequence
CR: Complete remission
c-Raf or Raf: v-raf-1 murine leukemia viral oncogene homolog 1
CREB: cAMP responsive element binding protein
CREBBP: CREB binding protein
Crk: v-crk sarcoma virus CT10 oncogene homolog
CRUK: Cancer Research UK
Csk: c-src tyrosine kinase
Ct: Cycle threshold
CT: Cardiotropin-1
CTLA4: Cytotoxic T-lymphocyte-associated protein 4
CXCR4: Chemokine (C-X-C motif) receptor 4
DAP12: DNAX-activating protein of molecular mass 12 kilodaltons
DAPI: 4,6 -diamidino -2 -phenylindoiole
DC: Dendritic Cell
DEK: DEK oncogene (DNA binding)
DLEU2: Deleted in lymphocytic leukaemia 2 (non-protein coding)
DMEM: Dulbecco’s Modified Eagle’s Medium
DMSO: Dimethyl-sulphoxide
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DNA: Deoxyribonucleic acid
dNTPs: Desoxy ribonucleotides
DOCK 180: Dedicator of cytokinesis 180
DRD2: Dopamine receptor D2
DTT: 1,4-Dithiothreitol
E2F: E2F transcription factor
EDTA: Ethylene diamine tetra-acetic acid
EGF: Epidermal growth factor
eGFP: Enhanced green fluorescent protein
EGTA: Ethylene glycol tetraacetic acid
ELMO: Engulfment and cell motility 1
EmGFP Emerald green fluorescent protein
ENL: Eleven-nineteen leukaemia
EPO or Epo: Erythropoietin
EpoR: Erythropoietin receptor
ErbB: Erythroblastic leukemia viral (v-erb-b) oncogene homolog
ERG: v-ets erythroblastosis virus E26 oncogene homolog
ERK: Extracellular signal-regulated kinases
ES cells: Embryonic stem cells
ETO: Eight twenty-one
EVI1: Ecotropic viral integration site 1
FAB: French British American
FACS: Fluorescence-activated cell sorting
FAK: Focal adhesion kinase
FcR: Receptors for the Fc portion of immunoglobulin antibodies
FCS: Fetal calf serum
FGR or v-Fgr Gardner-Rasheed feline sarcoma viral (v-fgr) oncogene homolog
FISH: Fluorescent in situ hybridisation
FITC: Fluorescein isothiocyanate
FLT3: Fms-like tyrosine kinase 3
Flt3-L: Fms-like tyrosine kinase 3 ligand
F0X03: Forkhead box 03
Fuji: Fujioka/P31
FYB: FYN binding protein
Fyn: FYN oncogene related to SRC, FGR, YES
FynB: Fyn isoform highly expressed in the brain
FynT: Fyn isoform mainly found in T-cells
g: Grams
g: Gravity
GAPDH: Glyceraldehyde-3-phosphate dehydrogenase
GAS7: Growth arrest specific 7
GAT A Globin transcription factor 1
G-CSF: Granulocyte-colony stimulating factor
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GFP: Green fluorescent protein
GH: Growth hormone
GH-R: Growth hormone receptor
GLYA or Gly-A Glycophorin A
GM-CSF: Granulocyte-macrophage colony-stimulating factor
GMP: Granulocyte/macrophage progenitor
Grb2: Growth factor receptor-bound protein 2
GTPase: Guanine triphosphate hydrolase
GvH disease: Graft versus host disease
GvL disease: Graft versus leukaemia disease
H&E: Haematoxilin and eosin
HCK or Hck: Haematopoietic cell kinase
HDAC: Histone deacetylase
HgC12 Mercuric chloride
HIST2H2AA: Histone cluster 2, H2aa
HIV-1: Human immunodeficiency virus 1
HLF: Hepatic leukemia factor
HOXA9: Homeobox A9
H-RAS: v-Ha-ras Harvey rat sarcoma viral oncogene homolog
HSC: Haematopoietic stem cell(s)
IFNAR: Interferon alpha receptor
IFNy: Interferon gamma
IFNGR: Interferon gamma receptor
IL: Interleukin
IL6R: Interleukin 6 receptor
IMDM: Iscove’s Modified Dulbecco’s Medium
IRES: Internal ribosome entry site
ITAM: Immunoreceptor tyrosine-based activation motif
ITD: Internal tandem duplication(s)
ITIM: Immunoreceptor tyrosine-based inhibitory motif
JAK: Janus kinases(s)
JNK: c-Jun NH2-terminal kinase
JunB; Jun B proto-oncogene
kbp: Kilobase pair
kDa: Kilodalton
KIR: Killer inhibitoiy receptor(s)
K-RAS or KRAS: v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog
KTLS: c-Kit+/Thy 1 -/Lineage-/Scal +
KYNU: Kynureninase (L-kynurenine hydrolase)
L: Litre
LB: Luria-Bertani
LCK or Lck: Lymphocyte-specific protein tyrosine kinase
LEF1: Lymphoid enhancer-binding factor 1
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Leu-cam: Leucocyte cell adhesion molecules
LIF: Leukaemia inhibitory factor
Lin: Lineage
Lin': Lineage negative
Lin+: Lineage positive
LPS: Lipopolysaccharide
LSC: Leukaemic Stem Cell(s)
LTC-IC: Long term culture-initiating cell(s)
LYN or Lyn: v-yes-1 Yamaguchi sarcoma viral related oncogene homolog
M: Molar
Macl: Macrophage 1
MAC30: Meningioma-associated protein
MAPK: Mitogen-activated protein kinase
MCS: Multiple cloning site
M-CSF: Macrophage colony-stimulating factor
MDS: Myelodysplastic syndrome
MDS1: Myelodysplastic syndrome 1
MEF: Murine embryonic fibroblast
MEK: MAP kinase or ERK kinase
MEM: Minimal Essential Medium (Eagle's)
MFI: Mean fluorescence intensity
Mg2+: Magnesium ion
pg: Micrograms
pL: Microlitre
miRNA: Micro RNA
MK.L1: Megakaryoblastic leukemia (translocation) 1
mL: Mililitre
MLL: Mixed lineage leukaemia
MM6: Mono-mac-6
Mn2+: Manganese ion
MNC: Mononuclear cell(s)
MOI: Multiplicity of infection
Mono: Mono-mac-6
MOPS: 3-(N-morpholino)propanesulphonic acid
MPD: Myeloproliferative disease
MRC: Medical Research Council
MRD: Minimal residual disease
mTOR: Mammalian target of rapamycin
MYH11: Myosin heavy chain 11
MYST3: MYST histone acetyltransferase (monocytic leukemia) 3
NaF: Sodium Fluoride
NBS1: Nijmegen breakage syndrome 1 (nibrin)
NEB: New England Biolabs
10
Nef protein: Negative factor protein
NF1: Neurofibromin 1
Nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor
NFKBIA: alpha
NK cells: Natural killer cell(s)
NK: Normal karyotype
NKTR: Natural killer-tumor recognition sequence
NOD: Non-obese diabetic
NOG: NOD/SCID/IL-2Rgamma
NPM1: Nucleophosmin 1
N-RAS or NRAS: Neuroblastoma RAS viral (v-ras) oncogene homolog
n-Src: Neuronal Src
NT: Non-transfectd
NT: Non-transduced
NTC: Non-template control
NUP214: Nucleoporin 214kDa
NUP98: Nucleoporin 98kDa
NUSAP1: Nucleolar and spindle associated protein 1
OptiMEM: Reduced serum medium modification of MEM
ORF: Open reading frame
OSM: Oncostatin M
ovHCK: Overexpressing HCK
pl20Cbl: Cas-Br-M (murine) ecotropic retroviral transforming sequence
PAGE: Polyacrylamide gel electrophoresis
PAK: p21 protein (Cdc42/Rac)-activated kinase
PB: Peripheral blood
PBS: Phosphate buffered saline
PCNA: Proliferating cell nuclear antigen
PCR: Polymerase chain reaction
PD1: Programmed cell death 1
PDGF: Platelet derived growth factor
PDGFR: Platelet derived growth factor receptor
PE: Phycoerythrin
PE-Cy7: Phycoeiythrin-cyanine dye Cy7
PEI: Polyethylenimine
PFA Paraformaldehyde
PGK: Phosphoglycerate kinase
pHl: Promoter HI
PI3K: Phosphoinositide-3-kinase
PIAS: Protein inhibitors of activated STATs
Piml: Proviral integration site 1
PIR-B: Paired-immunoglobulin like receptor-B
PML: Promyelocytic leukaemia
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PMN: Polymorphonuclear leukocyte
PPII: Polyproline type II
PRC1: Protein regulator of cytokinesis 1
PRL: Prolactin
PTD: Partial tandem duplication
PTEN: Phosphatase and tens in homolog
PTK: Protein tyrosine kinase
PTP1B: Protein tyrosine phosphatase, non-receptor type 1
PTPeC: Cytosolic isoform of protein tyrosine phosphatase, receptor type, E
PTPN11: Protein tyrosine phosphatase, non-receptor type 11
PTP-PEST: Protein Tyrosine Phosphatase PEST
PU.l: PU boxl
qPCR: Quantitative PCR
qRT-PCR: Quantitative real-time PCR
-R: Receptor
RA: Retinoic acid
RA70: sre kinase associated phosphoprotein 2
ras-related C3 botulinum toxin substrate 1 (rho family, small GTP binding
Rac: protein Racl)
RACGAP1: Rac GTPase activating protein 1
Rapl: Ras associated protein 1
RARA or RARa: Retinoic acid receptor alpha
Ras GTPase: Ras guanine triphosphate hydrolase
RAS or Ras: Rat sarcoma 2 viral oncogene homolog
RasGAP: Ras GTPase activating protein
Rb: Retinoblastoma
RBM15: NA binding motif protein 15
Rho: Ras homolog gene family
RIPA: Radio Immuno Precipitation Assay
RNA: Ribonucleic acid
RNAi RNA interference
rpm: Revolutions per minute
RPMI: Roswell Park Memorial Institute
RPN1: Ribophorin I
RRM2: Ribonucleotide reductase M2 polypeptide
RSV: Rous sarcoma virus
RT: Real time
RT: Room temparature
RUNX1: Runt related transcription factor 1
RUNX1T1: Runt-related transcription factor 1; translocated to, 1 (cyclin D-related)
SAP: Shrimp alkaline phosphatase
Seal: Stem Cell Antigen-1
SCF: Stem Cell Factor
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SCID: Severe combined immunodeficiency
SCL: Stem cell leukaemia
SDF1: Stromal cell-derived factor-1
SDS: Sodium dodecylsulphate
Sffv: Spleen focus forming virus
SFK: Src family kinase(s)
sh: Short hairpin
SHI: Src homology 1
SH2: Src homology 2
SH3: Src homology 3
SH4: Src homology 4
She: SHC (Src homology 2 domain containing) transforming protein
shHCK: Short hairpin ahti-HCK
SHIP1: SH2-domain-containing inositol phosphatase 1
Shpl orSHPl: SH2-domain-containing phosphatase 1
Shp2 or SHP1: SH2-domain-containing phosphatase 2
SHPS-1: Src homology 2 domain-containing phosphatase substrate-1
SH-PTP1: Src homology domain-containing protein tyrosine phosphatase
shRNA: Short hairpin RNA
si: siRNA
SIN: Self-inactivating
siRNA: Small interfereing RNA
SIRPa: Signal-regulatory protein alpha
SLC03A1: Solute carrier organic anion transporter family, member 3A1
SL-IC: SCID leukaemia initiating cell(s)
SLP-76: SH2 domain containing leukocyte protein of 76kDa
SOC: Super Optimal Broth + catobolite repression
SOCS: Supressors of cytokine signalling
SRC or c-Src: v-src sarcoma (Schmidt-Ruppin A-2) viral oncogene homolog
SRC: SCID repopulating cell(s)
STAT: Signal transducer and activator of transcription
SUMO: Small ubiquitin-like modifier
Syk: Spleen tyrosine kinase
TAE: Tris-acetate-EDTA
TBC1D16: TBC1 domain family, member 16
TBE: Tris-borate-EDT A
TBS: Tris buffered saline
TBST: Tris buffered saline supplemented with 0.1 % Tween
TCR: T-Cell Receptor
TE: Tris-EDTA
TEL(ETV6): TEL oncogene (ETS variant 6)
Thyl: Thy-1 cell surface antigen
TKD: Tyrosine kinase domain
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TNFp: Tumor necrosis factor-beta
TOPI: Topoisomerase (DNA) I
TP53: Tumor protein 53
TP A: 12-O-Tetradecanoyl-phorbol-l 3-acetate
TPO: Thrombopoietin
TPR: Translocated promoter region
TREM-2: Triggering receptor expressed on myeloid cells 2
TRIB1: Tribbles homologue 2
TRIM38: Tripartite motif-containing 38
TXNDC7: Thioredoxin domain containing 7 (protein disulphideisomerase)
TYK2: Tyrosine kinase 2
TYROBP: TYRO protein tyrosine kinase binding protein
UCB: Umbilical cord blood
UCP2: Uncoupling protein 2 (mitochondrial, proton carrier)
UK: United Kingdom
UTR: Untranslated region
UV: Ultra violet
Vav: vav guanine nucleotide exchange factor
VLA: Very late antigen
WASP: Wiskott-Aldrich syndrome protein
WHO: World Health Organisation
WIP: WASP-interacting protein
WPRE: Woodchuck hepatitis virus posttranscriptional regulatory element
WT1: Wilms Tumour 1
XTT: Tetrazolium salt
Yes or c-Yes: v-yes Yamaguchi sarcoma viral oncogene homolog 1
YFP: Yellow fluorescent protein
Yrk: Proto-oncogene tyrosine-protein kinase Yrk
ZAP70: Zeta-chain (TCR) associated protein kinase 70kDa
ZNF216: Zinc finger protein 216
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Chapter I
I Introduction 
1. Acute Myeloid Leukaemia
1.1 AML: the disease
1.1.1 Four main types of leukaemias
Leukaemia is a malignant bone marrow disease with blood infiltration characterised by 
the clonal expansion and proliferation of an abnormal precursor cell from either the 
lymphoid or myeloid lineage. Leukaemia accounts for approximately 3% of all cancers in 
the United Kingdom. Depending on the rapidity of the clinical progression of the disease, 
the leukaemia is defined as acute or chronic. The acute leukaemias, acute lymphoblastic 
and acute myeloid leukaemia (ALL and AML respectively), are characterised by a rapid 
onset of the disease and the accumulation of immature precursor cells in the bone 
marrow. The accumulation of these so called leukaemic blasts provokes a bone marrow 
failure resulting in cytopenia. The chronic leukaemias, chronic myeloid leukaemia and 
chronic lymphoid leukaemia (CML and CLL respectively) have a more sluggish course 
than acute leukaemias and are characterised by the proliferation of fully mature but 
abnormal cells (Figure 0.1).
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Fisure 1.I: Photomicrograph images o f the four main classes o f leukaemia.
Top Left: Acute Lymphocytic Leukaemia characterised by darkly stained lymphoblasts. 
Top Right: Acute Myeloblastic Leukaemia characterised by blasts with a prominent 
nucleoli (red arrow) and cytoplasmic granules (black arrows). Bottom Left: Chronic 
Lymphocytic Leukaemia characterised by predominantly small, mature lymphocytes. 
Bottom Right: Chronic Myelocytic Leukaemia characterised by predominantly normal- 
appearing cells with intermediate maturity. Images taken and edited from http.V/health. 
allrefer.com/.
1.1.2 Incidence
Grouped together, leukaemias are the ninth most common cancer in men and tenth in 
women. However, leukaemia is the most common cancer of childhood. About a third of 
childhood malignancies are leukaemias, o f which 80% are ALL, 15% are AML and 
around 5% are CML. In adults, CLL and AML are the most common leukaemias, 
representing 35% and 30% o f the newly diagnosed cases respectively. ALL account for 
12% of the cases and CML for 10% (source: www.leukemia-lvmphoma.oru).
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1.1.3 Risk factors
Age is an important risk factor in the development o f leukaemia. In childhood 
leukaemias, zero to four years old children are the most at risk to develop the disease. In 
adults, incidence is higher for people over 50 years old and increases exponentially from 
there. Gender is also a minor risk factor for leukaemia development with 5% more males 
being diagnosed with leukaemia than females, (http://info.cancerresearchuk.org/cancer 
STAT/tvpes/leukaemia/incidence/: Figure 1.2). The focus o f this study will be AML in 
adults, therefore symptoms, diagnosis, classification and remission rates will only be 
discussed for this particular cancer in the following sections.
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Fisure 1.2: Number o f new cases and age specific incidence rates o f leukaemias by sex 
(UK 2004).
Histogram bars showing the number o f newly diagnosed cases in 2004 and graphic lines 
showing the specific incidence rate per 100,000 population in 2004 per age class and 
gender.
Another important risk factor is the cytogenetic profile o f the leukaemia, this criterium 
will also influence response to chemotherapy and will be discussed in section 1.1.5. In 
any case, an early diagnosis and treatment can improve remission rates, particularly in 
younger adults.
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1.1.4 Symptoms and diagnosis of AML
Common symptoms experienced by the patient include fatigue, abnormal bleeding and 
bruising and increased susceptibility to infections. All those features are actually the 
manifestation of bone marrow failure caused by the accumulation of immature blasts in 
the bone marrow and are unrelated to the proliferative nature of the blast cells 
themselves. Indeed, leukaemia is originated by an impaired capacity of the bone marrow 
to properly produce mature haematopoietic cells that leads to cytopenias. The observed 
fatigue is therefore due to anaemia, which can also account for a possible shortness of 
breath. Thrombocytopenia causes the abnormal bleeding and bruising and neutropenia 
and leukopenia are the source of the vulnerability to infections.
Leukaemic blasts eventually infiltrating the blood stream allow for one of the first 
diagnosis of acute myeloid leukaemia that is clinically defined as a patient presenting 
more than 20% blast cells in their bone marrow. Among other tests, this diagnosis has to 
be confirmed by bone marrow biopsy. In case of dissemination of the blast cells to other 
organs, symptoms such as bone or joint pain, enlarged lymph nodes and abdominal pain 
due to an enlarged spleen or liver can add up to the symptoms of an abnormal 
haematopoiesis.
1.1.5 Classification
Traditionally, AMLs were classified based on the morphology of the blast cells found in 
the peripheral blood or the bone marrow of the patient. To this purpose, staining with the 
dyes haematoxilin and eosin (H&E staining), allowing a clear distinction between the 
volumes corresponding to the nucleus and the cytoplasm of the cells, gave the basis for 
the French American British (FAB) classification. The FAB classification comprises 
eight subclasses, MO to M7, which, if superimposed on a normal haematopoietic tree, 
correspond to distinct blocks in differentiation (Figure /. 5).
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Fisure 1.3: Repartition o f the eight FAB subclasses on the haematopoietic tree.
FAB MO and M l AML correspond to poorly differentiated cells. FAB M5 and M4 AML 
correspond to a block in the monocytic maturation process. FAB M2 and M3 AML 
correspond to a block in the granulocytic maturation process. FAB M6 AML correspond 
to a block in maturation o f  cells from the erythrocytic lineage while FAB M7 AML 
correspond to a block in maturation o f cells from the megacaryocytic lineage.
Table 1.1 indicates the frequency o f occurrence of each subtype o f AML as well as their 
prognosis. Figure 1.4 shows the morphology of the leukaemic blasts encountered in each 
FAB subclass. Different FAB types tend to have different prognosis outcomes, although 
this is based on the underlying genotype o f the disease.
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FAB
Subtype Name
Approximate % 
of adult AML 
patients
Prognosis 
compared to 
average for AML
MO Undifferentiated AML 5% Worse
Ml Myeloblastic leukaemia with minimal maturation 15% Average
M2 Myeloblastic leukaemia with maturation 25% Better
M3 Promyelocytic leukaemia (APL) 10% Best
M4 Myelomonocytic leukaemia 20% Average
M4 eos Myelomonocytic leukaemia with eosinophilia 5% Better
M5 Monocytic leukaemia 10% Average
M6 Erythroid leukaemia 5% Worse
M7 Megakaryoblastic leukaemia 5% Worse
Table LI: FAB classification of AML.
The French-American-British (FAB) classification system divides AML into 8 subtypes, 
MO through to M7, based on the type o f  cell from which the leukaemia develops and its 
degree o f  maturity. Diagnosis is made based on the phenotype o f  the cells. Different FAB 
types tend to have different prognosis outcomes, although this is based on the underlying 
genotype o f the disease.
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Fisure 1.4: AML blasts morphology according to the FAB classification.
(A) FAB Ml invasive myeloblasts (xlO). (B) FAB M2 myeloid blasts with granular 
cytoplasm (xlO). (C) FAB M3 large granular blasts (xlOO). (D) FAB M3 multi granular 
blasts (xlOO). (E) FAB M4 large myeloblast and two monocytes (xlOO). (F) FAB M5 
large blasts with large cytoplasm and condensed chromatin (xlOO). (G) FAB M6 
erylhroblasts and monoblasts (xlOO). (H) FAB M7 megakaryocytic blasts (xlOO).
Thus, the FAB classification system divides AML into 8 subtypes based on the type o f 
cell from which the leukaemia develops and its degree o f maturity. Although not 
completely obsolete, it has recently been replaced by the World Health Organisation 
(WHO) classification system which also takes into account more recent additional tools 
o f diagnosis such as cytogenetics and the antecedents o f the patient in terms o f  
myelodysplastic syndrome (MDS) or chemotherapy (Harris et al., 1999).
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AML with recurrent 
cytogenetic translocations
• AML with t(8;21)(q22;q22) AML 1 /CBFa-ETO
• Acute promyelocytic leukaemia: AML with 
t(l 5;17)(q22;ql2) PML-RARa and variants
• AML with abnormal bone marrow eosinophils: 
inv(16)(pl3;q22) and t(16;16)(pl 3;q22) CBFp- 
MYH1
AML with 1 lq23 MLL 
abnormalities
• With prior MDS
• Without prior MDS
AML with MDS, therapy 
related
• Alkalating agent related
• Epipodophyllotoxin related
• Other types
AML not otherwise 
categorised
• AML minimally differentiated
• AML without maturation
• AML with maturation
• Acute myelomonocytic leukaemia
• Acute monocytic leukaemia
• Acute erythroid leukaemia
• Acute megakaryocytic leukaemia
• Acute basophilic leukaemia
• Acute panmyelosis with myelofibrosis
Table L2: WHO classification (adaptedfrom(Harris et al., 1999%
The current classification system for AML, developed by the WHO takes into account 
cytogenetics and attempts to provide more prognostic information about the disease.
Cytogenetics is nowadays an important tool in diagnosis of leukaemias (Mrozek and 
Bloomfield, 2008). Indeed, about 65% of acute leukaemias are characterised by non- 
random chromosomal translocations and 45% of AML patients have a normal karyotype 
(Marcucci et a l , 2005b). The Philadelphia chromosome -the hallmark of CML- was 
discovered in 1960 and corresponds to the first chromosomal translocation to have been 
characterised. The subsequent intensive studies using fluorescent in situ hybridisation
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(FISH) allowed for the identification of more than a hundred chromosomal abnormalities 
which have been proven to segregate AML in different prognosis groups: favourable, 
intermediate and poor {Table I.3; Figure 1.5).
Risk group Abnormality 5 year survival Relapse rate
Favourable
t(8;21) 
t( 15; 17) 
inv( 16)
70% 33%
Intermediate
Normal
+8
+21
+22
del(7q)
del(9q)
Abnormal llq23 
All other structural/ 
numerical abnormalities
48% 50%
Poor
-5
-7
del(5q) 
Abnormal 3q 
Complex
15% 78%
Table 1.3: AML cytogenetic risk groups (adapted from  (Grimwade et ah, 1998).
Hierarchical prognostic classification, derived taking into consideration the influence o f  
additional cytogenetic abnormalities on outcome, and used for directing treatment 
approach in the current MRC AML 12 trial The presence o f  certain genetic 
abnormalities indicates whether the AML will respond favourably or poorly to therapy. 
Prognosis may also be used to determine the nature o f the therapy given, with more 
aggressive treatment for disease with adverse cytogenetics.
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MRC A M L10,12 Trial*: O verall Survival
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Fin lire 1.5: Overall survival o f prognostic risk groups in (le novo AML (adapted from  
(Grimwade et al., 1998)
Overall survival o f patients with AML is highly influenced by the genetics behind the 
disease. In the MRC AML 10 and 12 trials, at 10 years, 65% of patients with favourable 
cytogenetics remained alive, 37% and 16% with intermediate and adverse cytogenetics 
survived for the same period o f time respectively.
A correlation between the age o f the patient and the cytogenetic risk group has also been 
observed, with younger people having the tendency to develop leukaemia of the 
favourable group. Although AML with normal karyotype is classified within the 
intermediate prognosis group, recent research has shown that the presence o f certain 
mutations can be used to further risk stratify. This point will be discussed in section 1.4.1 
(Mrozek et al., 2007b).
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1.1.6 Therapies and their outcome
Choice of therapy is based on the WHO class within which a given leukaemia falls and 
the age of the patient. Patients are first given induction therapy to reduce the size of the 
bulk leukaemia followed by consolidation and maintenance therapy aimed at further 
reducing the number of leukaemic cells and achieving complete remission (CR). 
Complete remission for AML is defined as a blast cell count going back below 5% of the 
total bone marrow cells with recovery of normal haematopoiesis. Although maintenance 
therapy is then given during post-remission to prevent relapse, 60-70% patients do 
relapse and die of their disease (Liu Yin et a l, 2001).
Overall the best CR rates are obtained for patients younger than 60 undergoing a standard 
course of induction therapy, usually reaching an initial CR rate of 60-75% (Appelbaum et 
a l, 2001). Specifically patients with acute promyelocytic leukaemia (APL) achieve up to 
80% CR rate based on the propensity of all-trans retinoic acid (ATRA) to induce 
differentiation of the AML FAB M3 leukaemic blasts (Warrell et a l, 1991). Thanks to 
intensive post remission therapy, the overall survival at 5 years subsequently exceeds 
50% for patients with favourable cytogenetics. Patients from the intermediate risk group 
mostly undergo allogeneic haematopoietic stem cell transplantation if they match a 
suitable donor, while those without a suitable donor receive intensive post remission 
chemotherapy. Bone marrow transplantation increases the rate of successful therapies 
since it allows for the delivery of larger doses of chemotherapy to patients that could 
otherwise not be treated so well. However, it is only offered to rather fit patients since the 
conditioning treatment prior to transplantation is quite drastic. Despite potential graft 
versus host disease (GvH disease), allogeneic transplantation can also give rise to graft 
versus leukaemia effect (GvL effect) where donor immune cells kill residual leukaemic 
cells thus increasing the success of the therapy (Horowitz et a l, 1990). However, patients 
falling into the poor cytogenetic risk group, which are most often older people, hardly 
exceed 50% initial response to induction therapy and their overall survival at 5 years 
remains below 20%, regardless of the type of post remission therapy they undergo (Byrd 
et a l, 2002; Visani et a l,  2001). Therapy for these patients provides the greatest 
. challenge to AML research since it shows that more targeted therapies are essentially
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needed. Moreover, when dealing with older patients, therapies need to be less severe 
since these patients are unable to tolerate intensive chemotherapy (Stone et a l , 2004). In 
addition, the development of resistance to chemotherapy is becoming a major concern 
since it leads to less effective subsequent therapies in the case of relapsed leukaemias. 
Eventually the novel targeted therapies would generally not only benefit the older poor 
prognostic group but younger patients as well (Morgan and Reuter, 2006).
1.2 Normal haematopoiesis as a background for understanding leukaemia
1.2.1 Haematopoietic stem cells and haematopoietic hierarchy
AML being the result of an aberrant and malignant haematopoiesis, the normal 
haematopoietic hierarchy can be used as a background for understanding where 
leukaemias are originating.
The proportions of red and white blood cells in the normal blood are constantly 
maintained via a homeostatic process by the haematopoietic system. Since most mature 
haematopoietic cells are relatively short lived, they need to be replaced at a high rate. 
Indeed, between birth and death, the body of a human being is thought to produce 
approximately 1016 blood cells. The turnover of cells in the haematopoietic system in an 
average individual weighing 70kg is estimated to be 1012 cells per day, including 200 
billion erythocytes and 70 billion neutrophilic leukocytes. This remarkable turnover is 
kept up by a small population of pluripotent haematopoietic stem cells (HSC), which 
have the peculiar capacity to be able to balance self-renewal versus differentiation into 
precursor cells, making them able to sustain the entire hierarchy of haematopoietic cells 
throughout the life of an individual (.Figure 1.6).
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Fisure 1.6: Haematopoietic hierarchy (adaptedfrom www.dentaiarticles.com).
The variety o f cells in normal blood is constantly being maintained by the haematopoietic 
system, a hierarchy o f cells which is driven by the pluripotent haematopoietic stem cell 
which has the ability to self-renew and is able to produce all mature cells o f the blood 
lineage. Common myeloid and lymphoid progenitors have limited self-renewal capacity 
and are restricted to differentiate into their specific lineages. As cells become 
increasingly differentiated, their ability to self-renew decreases as well.
In vivo, HSC can give rise, by asymmetric division, to two daughter cells with different 
fates; one o f them being identical to the original HSC and the other being able to 
differentiate into an immature, more committed, progenitor (Ho, 2005). In order to 
maintain a haematopoietic stem pool available throughout the lifetime o f an individual 
without outgrowth o f immature precursor cells, a tight regulation o f HSC division is 
therefore necessary.
As cells become more differentiated, they progressively lose their ability to self-renew, 
get committed towards a specific lineage and ultimately acquire more specialised 
functions required for an efficient immune system. Common myeloid and lymphoid 
progenitors have limited self-renewal capacity and are restricted to differentiate into their 
specific lineages due to regulation o f expression of specific sets o f genes.
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Mature blood cells each exert specific immune functions and can be separated into four 
major groups: the erythrocytes which are the oxygen carrying red blood cells, the 
megakaryocytes which produce platelets and are responsible for blood clotting, the 
granulocytes (basophils, eosinophils and mainly neutrophils) and monocytes which are 
involved in innate and adaptive immunity, all of which are of myeloid origin. The last 
group is of lymphoid origin, primarily consisting of T-cells and B-cells, playing an 
essential role in adaptive immunity.
1.2.2 Haematopoietic stem cells localisation and their prospective isolation
Human HSC represents approximately one in every 10,000 -  15,000 cells in the bone 
marrow and are devoid of cell surface markers characteristic of more mature 
haematopoietic cells (Kondo et a l , 2003). Their rarity and difficulty to access proned 
scientists to develop a variety of assays based on limited dilutions and cell surface marker 
depletion rather than on basic cell morphology or density. Although the development of 
assays for prospective isolation of stem cells is still ongoing, in vivo xenotransplantation 
models exploiting the property of stem cells being able to self-renew are nowadays the 
best way to know that true stem cells are being worked with. Over the years, assays 
becoming progressively more selective for stem cells, the definition of what stem cells 
are and the understanding of haematopoiesis have greatly improved. The various in vitro 
and in vivo assays used to specifically study progenitors, stem cells and self-renewal 
potential will be described below.
1.2.2.1 In vitro assays
The first assays developed were in vitro assays trying to reproduce stimuli encountered 
by stem and progenitor cells in vivo. The colony forming cell assay (CFC assay) involves 
the seeding of haematopoietic cells into a semi-solid, methylcellulose based medium 
supplemented with a specific set of cytokines that promotes differentiation and 
proliferation of haematopoietic progenitor cells.
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The long-term culture initiating cells assay (LTC-IC assay) involves the culture of 
haematopoietic cells with stromal feeder layers and a specific set of cytokines for a 
period of five weeks followed by a CFC assay. The LTC-IC assay is an attempt to 
recreate, in vitro, a niche environment specifically able to maintain cells with a more 
extensive proliferative ability, including the quiescent stem cells. These cells are able to 
form colonies, or cobblestone area, beneath the stromal layer and the subsequent 
assessment of progenitor formation by CFC assay allows for the retrospective evidence of 
successful stem cells maintenance and characterisation of their differentiation potential. 
Besides, committed cells and progenitors exhausting their proliferative potential within a 
few weeks are no longer part of the culture (Breems et a l , 1994; Ploemacher et a l , 
1989). Although the LTC-IC assay gives access to more primitive cells than the CFC 
assay, it does not allow to study the full potential of the primitive cells maintained since it 
does not allow for the assessment of the lymphoid potential of the propagated cells. Other 
assays were therefore developed where initially growing cells in a lymphoid supportive 
environment followed by a switch to a myeloid supportive environment allowed for 
multilineage potential assessment (Hao et a l , 1998; Miller et a l , 1999).
Alltogether, these assays are used for study of both human and mouse haematopoiesis, 
relying each on a specific cocktail of murine or human cytokines. Although the CFC and 
LTC-IC assays narrow the window of analysis to study the proper haematopoietic stem 
cells, these assays remain limited by requirements for external stimulation by cytokines 
and growth on an adequately supporting stromal layer, which does not exactly replicate 
endogenous conditions. Indeed, the composition of the bone marrow includes not only 
stromal cells but also stromal stem cells, haematopoietic progenitor cells, mature and 
maturing red and white blood cells as well as megakaryocytes maturing into platelets. 
This dynamic environment is therefore far more complicated in terms of kinetics of 
cytokine production than the environment created in the in vitro assays. Observing 
growth of cells in an endogeneous microenvironment where they would receive the 
appropriate signals would consequently definitely help in overcoming these limitations.
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1.2.2.2 In vivo assays
In vivo models were first developed for studying mouse haematopoiesis using 
transplantation models involving inbred mice. Transplantation of haematopoietic cells 
from mice into genetically similar mice allow the observation of the growth of primitive 
haematopoietic cells for a significant period of time (Morrison and Weissman, 1994; 
Osawa et al. , 1996; Spangrude et a l, 1988). Since similar transplantation models cannot 
be used to study human haematopoiesis, for obvious ethical reasons, the use of 
immunocompromised mouse models offers the possibility to study human 
haematopoietic cells in a xenotransplantation system.
Three types of models are being currently used which have differences in their 
permissivity for human cells engraftment. The severe combined immunodeficiency 
(SCID) mutation in mice causes a lack of functional T and B lymphocytes, therefore 
allowing cytokine stimulated human cells to develop in the marrows of these mice 
without immune rejection (Lapidot et a l, 1992). Human cells able to repopulate the bone 
marrow of SCID mice after an incubating period of 6 weeks are termed short term SCID 
repopulating cells (short term SRC) while the ones able to repopulate the bone marrow of 
SCID mice after an incubating period of 12 weeks are termed long term SCID 
repopulating cells (Dick et a l, 1997).
When mice with the SCID mutation are crossed with mice presenting a non-obese 
diabetic (NOD) phenotype, NOD/SCID mice in addition to a lack of functional T and B 
lymphocytes, show an impaired natural killer (NK) and antigen-presenting cell (APC) 
function, allowing the engraftment of human cells in these mice without the need for 
cytokine prestimulation (Cashman et a l, 1997; Larochelle et a l, 1996; Shultz et a l, 
1995). Given ideal conditions, the NOD/SCID model can therefore support multilineage 
(B-cell and myeloid) engraftment for over 3 months and can also support secondary 
engraftment (Hogan et a l, 1997). Indeed secondary engraftment is to date the only assay 
proving the prospective isolation of a fraction of cells containing the true haematopoietic 
stem cells.
Crossing NOD/SCID mice with mice deficient for p2 microglobulin (giving rise to 
NOD/SCI D/p2mf~ mice) allows a higher engraftment efficiency for both primary and
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secondary transplantation (Kollet et a l , 2000) while crossing NOD/SCID mice with mice 
deficient for interleukin-2RY (giving rise to NOD/SCID/IL-2Ry’ ", or NOG, mice) further 
improves the permissivity of the mice (Ito et al, 2002). Both resulting mouse strains, 
NOD/SCID/p2m_/’ and NOD/SCID/IL-2Ry'/', are currently equally used for assessing the 
self-renewal, proliferation and differentiation of human haematopoietic stem cells.
1.2.2.3 Cell surface phenotyping
The establishment of mouse xenotransplantation models revolutionised the stem cell field 
by allowing further progress to be made into isolating pure HSC. Since primitive human 
haematopoietic cells, including the HSC, do not express certain cell surface markers that 
are associated with mature blood cell types, they can be isolated based on the lack of 
expression of these “lineage markers” (Lin). Thus, immature ‘Lineage negative’ (Lin ) 
cells can be distinguished from the more abundant differentiated ‘Lineage positive’ 
(Lin+) cells (Wognum et a l, 2003).
In the search for a marker specific of human HSC, CD34 expression was identified as 
being restricted to HSC and early progenitors (Sutherland et a l, 1989). Combination of 
selection for CD34 expressing cells and injection into NOD/SCID mice led to the 
observation that CD34 is expressed on the majority of cells with in vivo repopulating 
potential, including the HSC and long term repopulating cells as well as early 
progenitors, but not on the majority of terminally differentiated cells. Thus, CD34+ cells 
are routinely considered as enriched for HSC in the clinics.
In an attempt to further refine the selection of HSC, the CD38 marker has also been used 
for isolating HSC. Indeed SRC have been phenotyped as Lin7CD34+/CD38' (Bhatia et 
a l , 1997). As a population highly enriched for multilineage repopulating cells, SRC are 
one of the most primitive populations of the haematopoietic hierarchy identified so far. 
This subset is generally considered to contain the HSC, although other studies have 
demonstrated that cells with long-term repopulating ability may additionally reside within 
a Lin'/CD34. population (Bhatia et a l, 1998). The further development of more 
permissive murine models and extensive work on further refinement and characterisation
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of specific markers on the surface of human HSC should allow for further refinement of 
the identity of human HSC.
Of note, an important body of work on HSC is carried out in inbred mice. Murine HSC 
display a different cell surface marker phenotype to human HSC. They are defined as 
KTLS (c-Kit+/Thyl7Lin'/Sca+) (Morrison and Weissman, 1994) and are studied using the 
same in vitro and in vivo assays than human HSC using murine cytokines and stromal 
cells in in vitro assays.
1.3 Evidence of dysregulated normal haematopoiesis leading to AML
1.3.1 AML is a stem cell disease
Once the identity of the normal HSC was somewhat clarified, it was attractive to define if 
they could be giving rise to AML. The hypothesis that leukaemic stem cells (LSC) could 
derive from HSC was based on the fact that the leukaemic bulk mostly consists of 
immature cells with limited proliferative capacity. A cell with an extensive degree of 
proliferative ability must have therefore existed to give rise to and maintain the entire 
leukaemic bulk. As mentioned previously, HSC are able to self-renew or differentiate 
into a variety of specialised cells but also to mobilise out of the bone marrow into 
circulating blood, undergo apoptosis or remain in a quiescent state. This variety of 
functions made them an attractive target for generation of the LSC.
Such a cell with long-term proliferative ability has been identified in AML using the 
same assay as for the identification of normal HSC, the SCID assay (Lapidot et al., 
1994). The evidence that these SCID-leukaemia initiating cells (SL-IC) are 
haematopoietic stem cell has been demonstrated by the fact that, as for normal 
haematopoiesis, the leukaemic stem cell is not only able to repopulate the SCID mice 
bone marrow but is also able to generate a transplantable AML in the NOD/SCID mice, 
which exhibits the same characteristics than the original AML sample (Bonnet and Dick, 
1997). Additionally both studies highlighted the fact that SL-IC share the same 
phenotype as SRC since they are Lin7CD34+/CD38\ Furthermore, it has also been
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demonstrated that, like normal HSC, the majority of LSC exist in a quiescent state (Guan 
et al., 2003), thereby allowing them to escape therapies which are usually directed 
towards rapidly dividing cells. The fact that LSC are not eliminated by chemotherapy 
would therefore explain the frequent relapses seen in AML patients.
However, recent publications have suggested that LSC could also reside within the Lin' 
/CD34+/CD38+ fraction (Taussig et a l , 2008). Although this fraction of cells was initially 
thought to not contain any engrafting cells, pre-treatment of the recipient mice with 
immunosuppressive anti-CD 122 antibodies was shown to allow for their engraftment 
(McKenzie et a l, 2005). In normal haematopoiesis, the Lin7CD34 /CD38+ fraction 
contains a long-term engrafting population that cannot give rise to secondary transplant 
(Hogan et al., 2002). In AML, some patient samples present long-term engrafting cells in 
the Lin'/CD34+/CD38" fraction, in the Lin7CD34+/CD38+ or in both fractions. It is not yet 
known if the Lin7CD34+/CD38+ fraction from AML samples can give rise to secondary 
transplants. This finding suggests that LSC could originate from a progenitor having 
acquired HSC properties or that cell surface marker expression is modified upon AML 
onset and cannot be readily compared to normal haematopoiesis. This last point still 
remains to be clarified.
Of note, identification of SL-IC pioneered the search for cancer stem cells in solid 
tumours. Since then breast, brain, prostate, colon and pancreatic cancers, as well as head 
and neck squamous cell carcinoma, multiple myeloma and melanoma have been shown 
to contain a cancer initiating cell (Al-Hajj et a l , 2003; Collins et a l , 2005; Dalerba et a l , 
2007; Fang et a l, 2005; Li et a l, 2007; Matsui et a l, 2004; O’Brien et a l, 2007; Prince et 
a l, 2007; Ricci-Vitiani et a l, 2007; Singh et a l, 2004).
1.3.2 Leukaemic cells present chromosomal aberrations and gene specific mutations
It is now commonly acknowledged that cancer arises from an accumulation of genetic 
and epigenetic changes in oncogenes and tumour suppressor genes that free cells from the 
mechanisms that control normal cell proliferation. The idea that cancer is caused by a 
series of successive somatic mutations has been originally supported by the study of
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cancers such as retinoblastoma, in which the age of incidence is consistent with the 
requirement of two mutations to completely remove the function of the Rb gene. Such 
studies have given rise to the ‘two hits’ model for cancer development (Hethcote and 
Knudson, 1978; Knudson, 2001). The fact that AML is a disease that primarily affects the 
elderly also supports the idea of damage accumulating over time. In AML such damage 
occurs in the form of chromosomal aberrations as well as gene specific mutations but 
rarely, unlike in solid tumours, as chromosomal amplification due to chromosome 
instability.
1.3.2.1 Chromosomal aberrations
Chromosomal aberrations encountered in AML can be deletion, gain of chromosomes or 
translocations, which are routinely identified by FISH. Gene and chromosomal deletions 
may involve a small part of the chromosome, such as the short or long arm (eg 5q") or the 
loss of an entire chromosome (monosomy 7). Losses most commonly affect 
chromosomes 5, 6, 7, 11, 20 and Y. Gains are common in chromosomes 8, 12, 19, 21 and 
Y. While numerical changes in AML are not unusual, balanced translocations of 
chromosomes, where no material is gained or lost, are the most common chromosomal 
aberrations observed. To date, there have been approximately 300 balanced translocations 
described in AML (Mitelman et al., 2008). In cancer in general, balanced translocations 
contributing to malignant change can arise via two main mechanisms: either by 
overexpression of a normal cellular gene due to the fusion of the promoter region from 
one gene to the protein coding region of another, or by the fusion of two genes to 
generate a chimeric gene that encodes a novel ‘fusion protein’. In AML, balanced 
translocations exclusively result in fusion proteins (Table 1.4). Of note, one given fusion 
protein can arise due to several different breakpoints usually located in the same region of 
the respective genes.
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Aberration Fusion protein Frequency (%)
t(8;21)(q22;q22)
RUNX1-
RUNX1T1 4.3
t( 15; 17)(q22;q21) PML-RARA 4.1
der(l lq23) MLL fusions 2.4
inv(16)(pl3q22) CBFB-MYH11 2.3
t(9;22)(q34;ql 1) BCR-ABL1 0.7
inv(3)(q21q26) RPN1-EVI1 0.6
t(6;9)(p22;q34) DEK-NUP214 0.3
t( 1 ;22)(p 13 ;q 13) RBM15-MKL1 0.2
t(8;16)(pll;pl3) MYST3-CREBBP 0.1
t(7; 11 )(p 15 ;p 15) NUP98-HOXA9 <0.1
Table 1.4: The 10 most common balanced chromosomal aberrations in AML 
(Mitelman et al, 2007).
Not all fusion protein partners have been characterised for all the different translocations 
identified in leukaemia, this is usually depending on the rarity of the translocation and the 
availability of chromosomal material to go beyond FISH and identify gene loci by PCR. 
Moreover, even if the identity and cellular function of the fusion partners are known, the 
role of the new chimeric protein is not always known. Fusion proteins can indeed act by a 
variety of mechanisms in AML.
Two well studied translocations are the t(9;22)(q34;ql 1) translocation in CML and the 
t(15;17)(q22;q21) translocation in FAB AML M3. As mentioned earlier, the 
t(9;22)(q34;ql 1) chromosomal rearrangement, also known as Philadelphia chromosome, 
was the first translocation to be characterised and results in the fusion of the genes BCR 
and ABL. This chimeric protein causes the tyrosine kinase activity of ABL to not be 
regulated anymore and the resulting constitutively active kinase provokes a deregulation 
of cell cycle control and resistance to apoptosis (Skorski, 2008). The t(l 5; 17) 
translocation fuses the promyelocytic leukaemia gene PML on chromosome 15 to the 
retinoic acid receptor a  gene, RARa, on chromosome 17. The resultant PML-RARa
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fusion protein functions as a transcriptional repressor whereas the wild type RARa is an 
activator (Pandolfi, 2001). Additionally llq23 aberrations involving MLL 
rearrangement, which represents one class of the WHO classification by themselves, are 
also quite well studied. More than 30 different fusion partners have been identified for 
this transcription factor. These partners cam be cytoplasmic proteins (MLL-SEPT6; MLL- 
AF1Q) but are mostly transcription factors as well (MLL-GAS7, MLL-ENL, MLL-AF9 
etc.). The resulting chimeric protein causes abnormal dimerisation of MLL, leading to 
aberrant maintenance of target gene expression, often resulting in a block in 
differentiation of haematopoietic cells (Mitterbauer-Hohendanner and Mannhalter, 2004; 
So and Cleary, 2004).
Although balanced translocations are often found in leukaemia, it is uncertain whether 
these translocations alone are sufficient to cause overt leukaemia. For instance, in CML, 
low levels of the BCR-ABL transcript are detectable in normal individuals indicating that 
while the translocation is important, it is not the only factor responsible for causing CML 
(Melo, 1996). Furthermore, two studies on identical twins harbouring the same 
TEL(ETV6)-AML translocation in-utero showed the twins to develop childhood ALL with 
variable latency periods before the onset of overt disease in one study (Ford et al., 1998) 
and a twin being pre-leukaemic and the other twin developing B-ALL in the other study 
(Hong et al., 2008). Such reports indicate that additional genetic events to the 
translocation are needed before the development of overt leukaemia.
1.3.2.2 Normal karyotype AML and gene specific mutations
As mentioned previously, the 10 most common balanced translocations occur in 
approximately 15% of AMLs, the other rare recurrent balanced translocations are 
observed in only 5% of cases and numerical changes in chromosome number and 
complex abnormalities each contribute to approximately 10% of AMLs respectively 
{Figure /. 7). Screening for mutations responsible for the development of the remaining 
50% of AMLs with no detectable cytogenetic abnormalities has therefore been of great 
interest for the past few years. Trying to understand if these mutations are linked in any
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sequential way is also essential since prognosis o f patients with normal karyotype is 
greatly variable.
Cytogenetic abnormalities in AML
normal karyotype 
50%
10 most common 
balanced translocations 
15%
rare recurrent balanced 
translocations 
5%
unique structural 
— changes 
10%
numerical changes 
10%
complex abnormalities 
10%
Fieure /. 7: Karyotype breakdown o f AML.
Approximately 50% of AML have no cytogenetic abnormalities. The ten most common 
balanced translocations observed in AML are detectable in approximately 15% of cases. 
Rare recurrent balanced translocations, unique structural changes, numerical changes 
and complex abnormalities account for approximately 35% of AMLs.
The completion of the human genome sequence has made every gene accessible to 
mutation analysis. Characterisation and study o f gene specific mutations in AML 
revealed that they can alter both normal proliferation and differentiation of 
haematopoietic cells. Some mutations result in constitutive activation o f tyrosine kinases
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and their subsequent pathways while other mutations alter the function of transcription 
factors. Genes commonly mutated in AML include FMS-like tyrosine kinase 3 (FLT3), 
nucleophosmin (NPM ll), mixed lineage leukaemia (MLL), CCAAT enhancer binding 
protein alpha (CEBPA), Runt related transcription factor 1 (RUNX1/CBFA2/AMLI/ 
EVI1), kit oncogene (cKIT) and v-Ha-ras Harvey rat sarcoma viral oncogene homologue 
(RAS).
1.4 Identifying ways of AML stratification to understand it better
1.4.1 Gene specific mutation in prognosis of normal karyotype AML
As discussed in section 1.1.5, the genetic aberrations causing AML can provide valuable 
information in regards to prognosis and treatment of the disease. AMLs with 
translocations involving the core binding factors (CBF) - typically t(8;21) and inv(16) - 
tend to do well overall with therapy whereas AMLs with complex karyotypes and 
deletions in chromosomes 5 and 7 have poor overall outcome.
Similar stratification of normal karyotype AML has been attempted and correlation of 
gene specific mutation pattern and clinical outcome has proven rather successful in 
segregating patients into good and poor prognostic groups within the intermediate group 
(Figure 1.8 and (Mrozek et a l, 2007a)).
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Fisure 1.8: Gene specific mutations pattern in normal karyotype AML as a prognostic 
tool (Mrozek et al., 2007b).
Despite having the same normal karyotype, adults with de novo NK AML are diverse in 
respect to their acquired gene mutations and gene expression changes. The presence of  
FLT3-ITD indicate poor prognosis. In the absence o f FLT3-ITD, the presence o f  NPM ll 
mutations and CEBPA mutations are indications o f favourable prognosis, while the 
presence ofMLL-PTDs and high BAALC expression are indicators o f  poor prognosis.
Indeed, FLT3 has been found to be mutated in approximately one third o f AML patients 
and has also been reported as mutated in ALL and MDS, making it one o f the most 
frequently mutated genes in haematological malignancies. The FMS-like tyrosine kinase 
3 (FLT3), encodes a membrane bound receptor tyrosine kinase, which is important in 
haematopoietic stem/progenitor cell survival and proliferation by signalling through the 
RAS pathway. FLT3 mutations are either internal tandem duplications (ITD) o f the 
juxtamembrane domain (30%) or point mutations usually involving the tyrosine kinase 
domain (TKD) (7%). Both types o f mutation constitutively activate FLT3 (Small, 2006; 
Stirewalt and Radich, 2003) therefore specific inhibitors o f FLT3 are being developed to 
be used as therapy for patients presenting such mutations (Hiddemann et al., 2005).
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FLT3 ITD mutation in the heterozygous state has been recognized as a poor prognostic 
risk factor for AML. Additionally, the loss of the wild type FLT3 allele that occurs in 
10% of patients with normal karyotype AML is associated with a worse outcome 
(Whitman et al., 2001). Recent studies have also shown that the size of the internal 
duplication of FLT3 may affect prognosis, with ITD of over 40bp in length having poorer 
outcome than those with shorter ITD (Stirewalt et al., 2006).
Heterozygous mutations in the nucleophosmin gene (NPMll), observed primarily within 
the normal karyotype subgroup, have recently been described as the most frequent 
genetic abnormality in AML, occurring in approximately 50 to 60% of normal karyotype 
adult AMLs (Chen et al., 2006). Various studies have demonstrated that patients with 
NPM ll mutation, in the absence of FLT3 ITD, have a complete remission (CR) rate 
similar to, or significantly higher than, patients with wild type NPM ll. These studies 
have shown a statistical trend towards favourable outcome in event free survival and 
overall survival in patients with N PM ll mutations (Boissel et al., 2005; Dohner et al., 
2005; Schnittger et al., 2005; Suzuki et a l , 2005).
In addition to being involved in numerous chromosomal translocations, MLL can also be 
found mutated in AML: partial tandem duplication in the MLL gene {MLL PTD) was the 
first molecular alteration shown to impact on the clinical outcome of NK AML. MLL 
PTD is detected in approximately 5 to 10% of cytogenetically normal adults with de novo 
AML and is associated with FLT3 ITD (Dohner et a l , 2005). Patients with MLL PTDs 
have significantly shorter complete remission durations than patients without the 
mutation (Caligiuri et a l, 1998; Dohner et a l, 2002).
CCAAT enhancer binding protein alpha {CEBPA) is a transcription factor involved in 
myeloid differentiation and proliferation control. Mutations in CEBPA occur in 
approximately 15 to 20% of NK AMLs and are also associated with favourable prognosis 
(Bienz et a l,  2005; Frohling et a l, 2004). Mutations in this gene are an example that 
gene specific mutation can occur in normal karyotype AML as well as in addition to a 
chromosomal aberration. Indeed, favourable prognosis conferred by mutations in CEBPA
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was initially demonstrated in patients in the intermediate cytogenetic risk category 
(Barjesteh van Waalwijk van Doom-Khosrovani et a l , 2003; Preudhomme et a l , 2002) 
and later confirmed in patients with normal karyotype (Bienz et a l , 2005; Boissel et a l , 
2005). Patients with mutations in CEBPA are also less likely to have concurrent poor 
prognostic mutations in FLT3 and MLL PTDs (Frohling et a l, 2004).
The overexpression of specific genes in normal karyotype AML can also be used in 
prognosis, with overexpression of BAALC, ERG, and WT1 all conferring poor prognosis 
(Bergmann et a l, 1997; Marcucci et a l , 2005a; Mrozek et a l, 2007b). Moreover, 
mutations in c-KIT and TP53, each occuring in 5 to 10% of cases of AML overall, have 
also been noticed preferably in one given prognosis cytogenetic group and predominate 
in patients with ‘favourable’ and ‘poor risk’ cytogenetics respectively (Beghini et a l, 
2000; Stirewalt et a l, 2001). Similarly, mutations in RUNX1 occur with higher incidence 
in patients with FAB type M0 or patients presenting with additional copies of 
chromosome 21 (Preudhomme et a l, 2000). Further studies on identification of mutations 
and correlation with chromosome abnormalities will help decipher any specific sequence 
of events required for the full onset of leukaemia.
1.4.2 Class I and class II mutations
Although AML appears to be a genetically heterogeneous disease, grouping mutations 
and chromosomal aberrations into broad categories based on their functional 
consequences is one way of simplifying the system. Frequently genetically heterogeneous 
mutations do target the same signal transduction and transcriptional pathways and 
therefore can be divided into groups. In an attempt to provide a more unified molecular 
way to explain how different mutations can generate essentially similar phenotypes, 
Gililland proposed a ‘two-hit’ model for leukaemogenesis (Dash and Gilliland, 2001; 
Gilliland, 2001). This is not to be confused with Knudson’s two-hit model of cancer 
development mentioned earlier (Knudson, 2001).
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myeloid disease such as activated RAS, FLT3 and c-KIT. Although there are differe 
between individual tyrosine kinases, Class I mutation functions result in similarity 
activation of downstream effectors such as STAT, PI3K and RAS signalling pathwa> 
murine models, many of these mutations cause expansion of the stem cell pool r< 
than overt leukaemia (McCormack et al., 2008).
Class I mutations Class II mutations
BCR-ABL CBFP-MYH11
N-RAS AML1-ETO
K-RAS TEL(ETV 6)-AML 1
c-KIT (exon 8 and Asp 816) PML-RARa
FLT3 (ITD and Asp 835) NUP98-HOXA9
PTPN11 PU.l
NF1 C/EBPa
TEL(ETV6)-PDGFRp AML1
AML 1-AMP 19
Table 1.5: Class I and class II mutations in AML
Gilliland's “two hit hypothesis" postulates that the development o f overt AML requir 
least one mutation from each class. Class I  mutations offer a survival or prolifer 
advantage to the cell whereas Class II mutations are involved in blocking differentia
Class II mutations comprise chromosomal translocations and point mutations targ 
transcription factors and transcriptional co-activators, often involving the core bir 
factor complex (CBF complex). In many cases, Class II mutations result in a blo< 
differentiation pathways or apoptotic mechanisms, causing impaired haematopc 
differentiation. In murine models these genes cause myeloproliferation rather than
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leukaemia (McCormack et a l, 2008). Evidence of two concomitant mutations coming 
each from one class has been reported in numerous studies (e.g FLT3 associates with 
PML-RARa but not with c-KIT or K-RAS; (Renneville et al., 2008)) corroborating 
Gililland’s two hit model where both a block in differentiation and a proliferative and/or 
survival advantage are necessary to result in leukaemic transformation.
Trying to fit each chromosomal aberration and gene specific mutation discovered in one 
of these two classes could help on with designing therapies based on the signalling 
pathway most likely to be dysregulated. FLT3 inhibitors, RAS pathway inhibitors and 
HDAC inhibitors are already being tested in clinical trials based on this rationale 
(Renneville et a l , 2008). Additionally routine screening for the presence of such well 
characterised mutations would help in monitoring the disease in patients with normal 
karyotype. Based on current large studies, the majority of AMLs have at least one genetic 
lesion described, however a proportion still remain with unknown genetic background. 
Also some mutations, such as NPM11, are well established as recurrent in leukaemia but 
are not known to be particularly involved in haematopoietic proliferation or 
differentiation. In such cases, a transgenic mouse model study can prove helpful. Indeed, 
transgenic mice heterozygous for NPM ll are shown to develop a haematological 
syndrome with features of a human myelodysplastic syndrome (Grisendi et a l , 2005) 
which, according to what has been found with other mouse models would classify 
NPM ll as a class II mutation and would indicate a role for NPM ll in haematopoietic 
differentiation. The fact that NPM11 associates with FLT3-ITD but not with CEBPA, 
would also support this hypothesis (Renneville et al., 2008).
Finally, determining a sequence of genetic events would potentially help to prevent 
progression of AML. This can be done by comparing samples from patients diagnosed 
with MDS which progress into AML, comparing progression from chronic phase to blast 
crisis in CML or examining variation in type of mutations between presentation and 
relapse samples from the same AML patient. In each case, a mutation that is maintained 
throughout the course of the disease is likely to have occurred early in the leukaemogenic
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process. Studying rare cases of familial AML can also help understanding 
leukaemogenesis.
Observation that acquisition of the AML-ETO translocation followed by the FLT3-ITD 
mutation led to the progression of MDS to AML (Pinheiro et a l, 2007) and that, in 
mouse models, the co-expression of pairs of genetic events such as the BCR-ABL and 
AMLI-EVII fusion proteins (Cuenco and Ren, 2004), or the PML-RARA translocation 
and an FLT3 mutation (Kelly et al., 2002) are necessary for the development of AML, 
indicate that class II mutations might precede class I mutations in the onset of 
leukaemogenesis.
1.5 Trying to generate leukaemic stem cells to understand their origin
Having identified AML as being organised as a hierarchy, thanks to the NOD/SCID 
model, and having acknowledged that chromosomal aberrations and mutations are causes 
or consequences of the disease, the exact way AML is generated still remains to be 
elucidated.
The fact that HSC remain in a quiescent state for a period of time, possibly as long as the 
lifetime of an individual, make them more likely to accumulate multiple mutations 
required for transformation to a malignant state. Alternatively, it could be possible that 
the LSC arises from a more restricted progenitor, or even a differentiated mature cell, 
which would first need to reacquire the ability to self-renew before becoming 
tumourigenic (.Figure 1.9). The later hypothesis requires many genetic abnormalities to 
occur, it is therefore more likely that AML represents aberrant haematopoiesis with the 
target cell for transformation lying within the HSC repertoire.
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Figure /. 9: The origin o f the LSC.
The HSC is an attractive cell for the transformation into LSC, already having the ability 
to self-renew and having longevity, allowing enough time for the accumulation o f genetic 
events required for transformation. However, the LSC could also arise from an early 
progenitor or mature cell that regains the ability to self-renew. Regardless o f the site o f  
origin, the bulk o f the blast cells resulting would be the same.
Although HSC and LSC are both quiescent, share the same surface marker phenotype and 
are capable to engraft NOD/SCID mice, LSC exhibit a dramatic increase in self-renewal 
ability over normal HSC while showing a block in differentiation. As mentioned earlier, 
this observation points out a major dysregulation o f the balance between self-renewal and 
differentiation in HSC as an essential feature of leukaemogenesis. Thus, gaining 
understanding on how these processes are regulated in normal haematopoiesis is 
important for the understanding o f how AML and other haematological malignancies are 
generated. Many studies have therefore been directed towards deciphering which genes 
regulate the decision o f the HSC to follow either route during normal haematopoiesis. 
Various techniques such as knock-out and knock-in mice or overexpression and
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downregulation of genes in HSC or other subsets of cells using viral vectors have been 
used for such studies.
Moreover, testing of the potential of known mutations in AML to dysregulate the self­
renewal versus differentiation balance is also an interesting approach in understanding 
leukaemogenesis. Additionally, examining the effect of introducing a fusion protein 
corresponding to translocations identified in AML patients into normal HSC is another 
way to understand the generation of leukaemia (Drynan et al., 2005; McCormack et a l , 
2008; Rabbitts et a l,  2001; So et a l, 2003). In this study, we have decided to try to 
identify potential genes involved in leukaemogenesis by a preliminary screening 
approach based on microarrays comparing gene expression levels between Lin' 
/CD34+/CD38‘ HSC and LSC, as described in Chapter III. The candidate gene chosen to 
pursue the study was Haematopoietic cell kinase (HCK), a non receptor tyrosine kinase 
from the Src kinase family (SFK) . Non exclusive literature review on what is known 
about SFK, cancer, haematopoiesis and leukaemogenesis will follow.
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2. Src Family Kinases 
2.1 SFK and cancer
2.1.1 v-src: the first oncogene from a big family
v-src was first discovered by Rous as a mutated gene captured in the genome of a 
retrovirus capable of causing sarcoma in chicken (Rous, 1911a; Rous, 1911b). Seven 
decades later the cellular homologue of v-Src, c-Src, was isolated (Stehelin et a l , 1976; 
Takeya et a l, 1982) and it was established that the gene encoded in the Rous sarcoma 
virus (RSV) genome, was coding for a protein with phosphorylation activity specifically 
directed towards tyrosine residues (Hunter and Sefton, 1980). It was then confirmed that 
this tyrosine kinase activity was required for RSV transformation (Sefton et a l, 1980; 
Shalloway et a l, 1981). Src was therefore not only ascertained as the first proto­
oncogene but also as the first protein tyrosine kinase.
Three of the nine members of the Src kinase family were isolated as oncogenes before 
being identified as cellular genes. v-Yes is able to induce sarcoma in chicken (Hunter and 
Sefton, 1980) while v-Fgr induces sarcoma in cats (Naharro et a l, 1983). Fyn, Lyn, Hck, 
Lck and Blk were later cloned and classified as Src family kinases (SFK) based on 
sequence homology. Their implication in cancer is becoming more and more evident. Yrk 
is the most recently found member of the family and is only expressed in chicken (Sudol 
eta!., 1993).
2.1.2 SFK tissue specific expression
One or more SFK are expressed in one given cell type and tissue specific splice variants 
as well as alternative translation initiation products result in the existence of at least 16 
Src-related gene products. Src, Fyn and Yes are ubiquitously expressed with increased
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expression in specific tissues (Brown and Cooper, 1996). Src exists as three splice 
variants, c-Src and two n-Src, alternative splice variants with an additional exon 
exclusively expressed in neurons (Modafferi and Black, 1999). Fyn also exists as three 
splice variants: Fyn, FynT and FynB. FynT and FynB contain two different extra seventh 
exons in comparison to Fyn and are found exclusively in T-cells and in neurons 
respectively (Davidson et a l, 1992; Picard et a l , 2002). The other members of the family 
are solely found in the haematopoietic system with specific expression between the 
different cell types constituting the system (Varmus and Lowell, 1994). Lyn exists as two 
alternatively spliced isoforms that are co-expressed together and primarily found in B 
cells and monocytes (Yi et al., 1991). The two isoforms from HCK are produced by the 
use of two different translation start codons and are found co-expressed in monocytes, 
neutrophils and immature B-cells (Lock et a l, 1991; Taguchi et a l, 2000). Lck is 
expressed in T-cells and Fgr in monocytes, natural killer cells and neutrophils; they both 
exist as one protein originating from one single transcript. Figure 1.10 shows the specific 
combination of SFK expressed at a definite level of expression by the different 
haematopoietic lineages (Corey and Anderson, 1999).
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Fie lire 1.10: Expression o f src family kinases in haematopoietic cells.
Expression of SFK increases as cells differentiate into one particular lineage. Adapted 
from Cooper et al. (Cooper and Howell, 1993; Varmus and Lowell, 1994).
It also has to be kept in mind, that SFK expression varies during haematopoiesis and cell 
differentiation. Evidence came first from differentiation studies o f the HL-60 AML FAB 
M2 cell line: indeed monocytic differentiation induced by treatment with 12-0- 
tetradecanoyl-phorbol-13-acetate (TPA) leads to expression o f Fyn and Lyn while 
treatment with 1,25-dihydroxyvitamin D3 leads to expression o f Fgr and Lyn. On the 
other hand, granulocytic differentiation following treatment with retinoic acid (RA) leads 
to strong expression o f Fgr and weak expression o f Fyn and Lyn (Katagiri et al., 1991). 
HCK appears only following terminal differentiation of FIL60 to monocytes and is even 
more abundant in HL-60 terminally differentiated into granulocytes using DMSO 
(Quintrell et al., 1987). This was further confirmed using other leukaemic cell lines 
(Willman et al., 1991).
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2.1.3 SFK implication in cancer
Since Src was identified as an oncogene in chicken, searching for a role of SFK in 
carcinogenesis seems to be obvious. Surprisingly mutations, rearrangements or 
amplifications of any SFK gene has been rarely observed in human cancer. Only a point 
mutation in Src leading to the formation of a truncated protein has been found to occur in 
12% of advanced colon carcinoma (Irby et a l, 1999). However, an increase in protein 
expression or activity of SFK has been found in colorectal carcinoma, breast, pancreatic, 
ovarian, bladder, gastric and lung cancers as well as in brain tumours and haematopoietic 
malignancies (Table 1.6 and(Benati and Baldari, 2008; Irby and Yeatman, 2000; Summy 
and Gallick, 2003).
D b e u t Src family k laasc 1 Defect
Colon cancer * Src | T Expression and activity, truncated form
\ Lck | Ectopic expression
y « | t  Kinase activity
Dr cast cancer
i
Src ! t  Activity
i Yes i T Expression and activity
1 F*n | T Expression and activity
Small cell lung cancer Src t  Expression
Lck 1 Ectopic expression
PET Lck \ Ectopic expression
Src ! T Expression
CML lick T Activity
Lyn l T Activity
AML I Lck ; t  Expression
ALL ; uk ! T Expression
B-CLL Lck ! Ectopic expression
i
Table 1.6: Variation in SFK expression and activity related to cancers adapted 
/r 0M(Benati and Baldari, 2008).
67
Chapter 1
2.2 Src / SFK structure and folding
SFK are proteins o f 52-60 kDa which share a conserved structural organisation consisting 
of six distinct functional domains: 1) The N-terminal Src homology 4 (SH4) domain, 2) 
the unique domain, 3) the SH3 domain, 4) the SH2 domain, 5) the catalytic domain, or 
SHI domain, and 6) the C-terminal tail. Figure 1.11 shows the crystal structure o f Src as 
a model for the general structure o f SFK. Each domain has a specific role either in the 
membrane localisation or in the kinase activity regulation that will be described in the 
following paragraphs.
Y-kmase
Fie ure 1.11: Src family tyrosine kinase structure (Schindler et al., 1999).
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2.2.1 The SH4 domain is directing membrane localisation of SFK
SFK are cytoplasmic tyrosine kinases associated with either the plasma membrane or 
intracellular membranes such as the endoplasmic reticulum or the endosomes. 
Localisation to either compartment is dependent on the type of acyl modification 
undergone by the 10 to 15 amino acids SH4 domain. The first 7 to 10 amino acid residues 
serve as a recognition signal for an N-myristoyl transferase (Kaplan et al., 1988; Pellman 
et al., 1985) which catalyses the attachment of myristic acid to an invariant amino- 
terminal glycine residue following cleavage of the N-terminal methionine. Myristoylation 
occurs during translation of SFK on free polyribosomes in the cytoplasm and is 
irreversible (Buss et al., 1984). This modification is necessary but not sufficient for SFK 
to be associated with the inner leaflet of the plasma membrane since myristoylated SFK 
can be also found in the cytoplasm (Levinson et a l, 1981). The presence of a lysine motif 
within the SH4 domain of most SFK contributes to their membrane targeting. Moreover 
the fact that several SFK share a common mechanism for membrane binding could also 
explain their functional redundancy (Silverman et al., 1993).
Additionally to myristoylation, the SH4 domain of any SFK, except Src and Blk, can 
undergo posttranslational palmitoylation on conserved cystein residues at position 3 
and/or 5. This reversible acylation occurs at the membrane on SFK already myristoylated 
and is required for targeting the proteins to lipid rafts (Robbins et al., 1995; Shenoy- 
Scaria et al., 1994). These specialised microenvironments within the plasma membrane, 
also known as calveolae, are enriched in glycosphingolipids, phosphoinositides and 
cholesterol as well as in distinctive integral membrane proteins and serve as signalling 
centres for the efficient integration of specific signals (Zajchowski and Robbins, 2002). 
Palmitoylation being reversible thanks to the action of palmitoylthioesterases (Linder and 
Deschenes, 2003), SFK might be relocalised to and from lipid rafts upon specific stimuli, 
thus establishing a mean of spacio-temporal regulation of SFK activation. Trimethylation 
subsequent to acylations has also been described for Fyn and is important for its function 
in cell adhesion and spreading (Liang et al., 2004).
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2.2.2 The unique domain confers specificity in cellular functions
The 50 to 70 amino acid long unique domain is highly divergent between the different 
SFK and is thought to confer specificity to each kinase by mediating interactions with 
specific receptors or cytoplasmic proteins. For instance the Lck unique domain mediates 
its interaction with CD4 and CD8a (Shaw et al., 1989). Fyn and Lyn unique domains 
allow their association to T and B cell receptors (TCR and BCR) (Rudd et al., 1993; 
Timson Gauen et a l , 1992).
2.2.3 Ligands with polyproline regions specifically bind to the SH3 domain
Src homology 3 domains (SH3 domains) are non-catalytic conserved domains that have 
been identified in many protein structures outside and including the SFK. The SF13 
domain is approximately 50 amino acids long and confers specificity in protein-protein 
interactions through the recognition of short contiguous proline rich motifs that fold into 
a left-handed polyproline type II (PPII) helical conformation (Musacchio, 2002). The 
sequence requirements for SH3 ligands have been figured out by use of phage display 
and chemical combinatorial peptide libraries and the signature sequence of SH3 ligands 
has been found to be a PxxP motif (in which x represents any amino-acid) nestled into 
two conserved hydrophobic binding pockets (Cheadle et a l,  1994; Rickies et al., 1994; 
Rickies et al., 1995; Yu et a l, 1994). Flexibility in the amino acid composition outside of 
the proline rich motif allows for binding to different SH3 domains of specific proteins 
(Mongiovi et a l, 1999). Another mechanism that might govern ligand binding to SFK is 
phosphorylation of certain residues within the SH3 domain. This phenomenon has been 
reported for Src where, following PDGF receptor stimulation, SH3 domain 
phosphorylation occurs on its peptide binding surface and reduces its binding affinity for 
peptide ligands in vitro (Broome and Hunter, 1997). On the other hand, phosphorylation 
of the SH3 domain binding ligands themselves within the proline rich recognition site has 
also been reported and can affect the intensity of the protein-protein interaction (Wu et 
a l, 1998). It can be noticed that the two neuronal splice variants of Src, n-Src, differs
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from c-Src by an insert of six or eleven amino acids in the SH3 domain (Brugge et a l , 
1985; Martinez et a l , 1987). This insertion might biase their binding affinity towards a 
distinct set of substrates and render them more active than c-Src, probably because of a 
destabilisation of the inactive conformation (Levy and Brugge, 1989). Additionally to 
binding PxxP motif containing signalling proteins, in order to position SFK in a certain 
molecular environment, the SH3 domain plays an important role in the regulation of SFK 
activity via protein-protein interactions as well as via intramolecular contact. This point 
will be discussed in section 2.2.6. HIV-1 Nef (Saksela et a l , 1995), Ras GTPase 
activating protein (RasGAP), (Briggs et a l , 1995), a disintegrin and metallopeptidase 
domain 15 (ADAM 15) (Poghosyan et a l , 2002), Wiskott-Aldrich syndrome protein 
(WASP), WASP-interacting protein (WIP), and engulfment and cell motility 1 (ELMOl) 
(Scott et a l, 2002), signal transducer and activator of transcription 3 (STAT3) (Schreiner 
et a l, 2002), activated Cdc42-associated kinase 1 (ACK1) (Yokoyama and Miller, 2003), 
the guanine nucleotide exchange factor C3G (Shivakrupa et a l, 2003) and p73 (Paliwal 
et a l, 2007) have been shown to be direct ligands for HCK SH3 domain, mostly by 
overexpression and interaction studies in Sf9 or COS cells.
2.2.4 Ligands with a specific phosphorylated tyrosine motif bind to the SH2 domain
Src homology 2 domains (SH2 domains) are also non-catalytic conserved domains that 
can be found in many protein structures outside and including the SFK and can be 
divided in four groups depending on the constitution of their consensus binding sequence 
(Pawson et a l, 2001; Songyang et a l, 1993). Figure 1.12 shows the main protein families 
containing SH2 domains, most of which are known to be direct interactors of SFK.
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Figure 1.12: Protein families containing SH2 a ltd SH3 domains (Pawson et al., 2001).
While SH3 domain interaction with a ligand is independent o f posttranslational 
modification, interactions with the SH2 domain are phosphorylation dependent. The SFK 
SH2 domain belongs to group I SH2 domains and its consensus binding sequence has 
been identified as pYEEI. Group II to IV SH2 domains from other proteins select for 
different sequences with binding specifity being based on residues positioned C-terminal 
of the phosphorylated tyrosine, i.e . +1 through +6 (Songyang et al., 1993). Mutation of a 
single critical residue can change the binding specificity o f a SH2 domain from one group 
to the binding specificity of a SH2 domain from a different group, implicating a major 
change in ligand type and subsequent signal transduction cascade (Songyang et al., 
1995b). However, amino acids N-terminal to the phosphotyrosine are also involved in
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binding and adds up to the interactions specificity (Bibbins et al., 1993), Although the 
reliance on phosphorylation for ligand recognition makes the interaction inducible and 
reversible, providing a switch to recruit proteins into activated complexes, exceptions 
have been noticed where SH2 ligands could bind in a phosphorylation independent 
manner (Dutartre et al., 1998; Joung et al., 1996; Park et al., 1995). Phosphorylation of 
specific residues within the SH2 domain itself have also been reported and might be 
involved in modulating the SH2 domain accessibility as well as the kinase activity of 
SFK. In addition to binding pYEEI motif containing signalling protein in order to 
position SFK in a certain molecular environment, the SH2 domain also plays a role in the 
regulation of SFK activity via protein-protein interactions as well as via intramolecular 
contact, as will be discussed in section 2.2.6. Granulocyte colony-stimulating factor 
receptor (G-CSFR) (Ward et al., 1998), RA70 (Kouroku et al., 1998), paxillin (Achuthan 
et al., 2006) and FLT3 (Mitina et a l , 2007) have been shown to be direct ligands for the 
HCK SH2 domain, mostly by overexpression and interaction studies in 293T-HEK or 
TPA differentiated U937 cells. Additionally, pl20Cbl (Howlett et a l , 1999) and BCR- 
ABL (Stanglmaier et al., 2003) interacts with HCK via both SH2 and SH3 domains.
2.2.5 The SHI domain catalyses protein tyrosine phosphorylation
The SHI domain is the catalytic domain of the SFK and like for all eukaryotic protein 
kinases is shaped into a bilobal structure (Taylor et al., 1993). The classic protein kinase 
conformation comprises a smaller N-terminal lobe connected by a flexible hinge region 
to a larger C-terminal lobe, with the active site located in the cleft inbetween the two 
lobes. The N-lobe is responsible for binding metal associated nucleotides. SFK being 
tyrosine kinases prefer Mn2+ over Mg2+ ions as co-factors in vitro (Hunter, 1989; Hunter 
and Cooper, 1985). A conserved lysine residue, K295 in c-Src and K290 in HCK, is 
present in the nucleotide binding pocket in the small lobe and co-ordinates the a - and (3- 
phosphate groups of ATP. Mutation of this critical lysine residue results in the generation 
of an enzymatically inactive, or kinase dead, protein. The C-lobe is principally 
responsible for substrate binding and catalysis. The activation loop connecting the two
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lobes contains an autophosphorylation site corresponding to Y416 in c-Src and to Y411 
in HCK. Phosphorylation of this critical tyrosine, while not absolutely required for 
enzymatic activity, ensures maximal catalytic potential of SFK (Ferracini and Brugge, 
1990). Affinity of substrate binding is dependent on recognition of certain tyrosines in a 
sequence specific context by certain residues in the activation loop itself (Laham et a l, 
2000). The use of synthetic combinatorial peptide and phage display libraries have shown 
that different classes of tyrosine kinases preferentially bind to distinct sequences in their 
substrates (Nair et al., 1995; Schmitz et al., 1996; Songyang and Cantley, 1995; 
Songyang et a l, 1995a). It has actually been reported that distinct groups of protein 
tyrosine kinases phosphorylate peptidic motifs recognised by distinct groups of SH2 
domain or can even phosphorylate motifs recognised by their own SH2 domain 
(Songyang et a l, 1995a). Catalytic domains are, however, autonomous from regulatory 
domains in terms of substrate/ligand specificity since fusion of the regulatory domains of 
EGF receptor ErbB to the catalytic domain of Src results in a chimeric protein inducing 
sarcoma formation (a Src property) without the leukaemogenic potential of ErbB (Chang 
et a l, 1995).
2.2.6 SFK folding and ligand interaction: a complex regulation of activity
Protein kinases are important molecular switches involved in the transmission of 
numerous cellular signals. As such, they must possess the inherent ability to alternate 
between catalytically active and catalytically inactive states. Point mutations and deletion 
studies suggested that such regulation was made possible by intramolecular interactions 
involving the SH2 and SH3 domains (Erpel et a l, 1995; Hirai and Varmus, 1990a; Hirai 
and Varmus, 1990b; O'Brien et a l, 1990; Reynolds et a l, 1992; Seidel-Dugan et a l, 
1992; Veillette et a l, 1992). The C-terminal tail was also long known to have an 
influence on Src activity since the main difference between v-Src and c-Src resides in the 
fact that the C-terminal part of c-Src is replaced by a viral sequence in v-Src, rendering it 
sarcomagenic (Takeya et a l, 1981). Mutation studies revealed that tyrosine Y527 was a 
critical residue in restricting Src activity since its phosphorylation by the kinase Csk led
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to suppression o f fibroblast transformation by activated c-Src but not by v-Src or mutant 
Y527F (Sabe et al., 1992). Additional mutations studies also suggested a link between 
Y527 regulatory phosphorylation and SH2 and/or SH3 domains presence since mutations 
in, or deletion of, either domain led to SFK activity even when Y527 was phosphorylated 
(C)kada et al., 1993; Superti-Furga et al., 1993). Crystal structures o f inactive c-Src and 
HCK confirmed that phosphorylated Y527 (Y522 in HCK) was physically interacting 
with the SH2 domain - reminding that SH2 domain typically interact with a 
phosphotyrosyl m otif (Sicheri and Kuriyan, 1997; Sicheri et al., 1997). However, this 
interaction is not obstructing the catalytic site directly, but rather positioning the SH2 
domain on the other side o f the molecule making contact with the C-terminal lobe o f the 
kinase domain (as best visible on Figure I.1J).
Comparing crystal structures o f inactive SFK to the crystal structure o f active Lck 
(Yamaguchi and Hendrickson, 1996) revealed that the intramolecular interactions within 
inactive SFK were actually more complicated than expected. As shown on the schematic 
representation o f the close inactive conformation o f SFK {Figure 1.13 B), a linker region 
connecting the SH2 domain and the kinase domain adopts a left-handed polyproline type 
II conformation, typical m otif recognised by the SH3 domain, providing the basis for a 
tripartite interaction between the SH3 domain, the linker and the back o f the N-terminal 
lobe of the kinase domain {Figure 1.13 C).
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Fisure 1.13: Crystal structure o f HCK (Chong et al., 2005).
(A) Schematic representation o f the hypothetical unfolded SFK. (B) Schematic 
representation o f the close inactive conformation o f SFK. (C) Crystal structure o f HCK.
Thus, the SH2 domain:C-terminal tail interaction and the SH3 domain:PPII linker 
interaction maintain the two lobes of the kinase domain in a distorting position 
incompatible with enzymatic activity. Interestingly, neither of the two internal ligand 
sequences represents an optimal binding sequence, allowing for disruption o f the 
constraints by binding an SH2 ligand or an SH3 ligand thanks to the flexibility of the 
connector between these two domains (Young et al., 2001). Binding o f either allosteric 
effector, which exert higher binding affinity than the intramolecular sequences, or 
dephosphorylation of Y527 in the C-terminal tail allow for ultimate autophosphorylation 
o f Y416 in the activation loop and adoption of a fully catalytically active conformation. It 
was first thought that dephosphorylation o f Y527 was necessary for phosphorylation of 
Y416 to happen but a multitude o f recent studies have proven that several intermediate
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active states could lead to the ultimate fully active state as illustrated in Figure 1.14 
(Banavali and Roux, 2008; Briggs et al., 1997; Lerner and Smithgall, 2002; Moarefi et 
al., 1997; Porter et al., 2000).
IMMI l in k e r
SH2 ; Q  K inase
‘C lo se d ’
I n u c th e
Y Ya autophosphorylation
Fully activeActive
Active Fully active
Active
Ya autophosphorylation
Fisure 1.14: Possible interactions leading to change o f conformation from  a dosed 
inactive state to an open fu lly  active state o f SFK (Chong et al,, 2005).
Fully active
Of note, none of the crystal structures resolved to date include the SH4 and unique 
domains (Sicheri et al., 1997; Xu et al., 1997). Since the unique domain is divergent for 
each SFK, resolution of full length protein crystal structures might reveal that the 
regulations described previously may slightly differ inbetween SFK depending on the 
extent to which the N-terminal regions folding influences the reported conformation of 
the SHI, SH2 and SH3 domains.
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2.3 Functions of SFK in the mature haematopoietic system
SFK are activated downstream of several cell surface receptors and have been implicated 
in mediating a variety of signals leading to changes in proliferation, differentiation, 
survival, cellular architecture, adhesion and migration (Bjorge et a l , 2000; Brown and 
Cooper, 1996; Thomas and Brugge, 1997). The description of their implication in such 
cellular events will be restricted to the haematopoietic system with emphasis on myeloid 
SFK, Hck, Fgr and Lyn.
2.3.1 SFK downstream of immune receptors
Immune responses against pathogens rely on immune recognition receptors such as T-cell 
receptor (TCR), B-cell receptor (BCR), receptors for the Fc portion of immunoglobulin 
antibodies (FcR) and activating natural killer (NK) cell receptors (Figure 1.15). These 
immunoreceptors are multimeric complexes comprising ligand binding and signal 
transducing subunits. Unlike growth factor receptors, immunoreceptors are devoid of 
intrinsic kinase activity and depend on cytoplasmic kinases for transduction of their 
signal. Their signalling capacity is based on the presence of several conserved bipartite 
‘immunoreceptor tyrosine-based activation motif(s)’ (ITAM) in their cytoplasmic chains 
or in receptor-associated adaptor molecules (Hamerman and Lanier, 2006; Ravetch and 
Lanier, 2000).
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Fieure I. IS: ITAM-bearing adaptors and immunoreceptors (Hamerman and Lanier, 
2006).
The a  and fi chains o f the T cell receptor (TCR) associate with the CD3 family o f ITAM- 
containing adaptors. CD36, y, and e each contain one cytoplasmic IT AM and one 
extracellular Ig domain and are found exclusively in T-cells. CD3E, displays three IT AMs 
and forms a disulphide-bonded homodimer. CD3 C is also found in T-cells as well as in 
NK cells, where it associates with several activating NK receptors. The B cell receptor 
(BCR) is composed of surface immunoglobulin (slg) associated with a disulphide-bonded 
heterodimer o f Iga and Igfi, each o f which contains one IT AM and one extracellular Ig 
domain similar to CD3S, y, and e. Iga and Igf) are exclusively expressed in B-cells. The 
FceRIy (FcRy) ITAM-containing adaptor is expressed in myeloid cells, B-cells, and NK 
cells and in some T-cells. FceRIy consists o f a minimal extracellular domain with one 
cytoplasmic ITAM and forms a disulphide-bonded homodimer (of note, in some cells 
FceRIy forms a disulphide-bonded heterodimer with CD3L). FceRIy can associate with 
various receptors, including FcaRI (also known as CD89) depicted here. DAP 12 has a 
structure and expression pattern similar to that o f FcRy. In myeloid cells and NK cells, 
DAP 12 associates with various receptors, including TREM-2 depicted here.
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SFK have been found to be associated with the inner-leaflet of the plasma membrane in 
the vicinity of the cytoplasmic tails of the immunoreceptors and adaptors organised as 
lipid rafts (Abram and Lowell, 2007b; Ilangumaran et a l 2000; Resh, 1996; Xavier and 
Seed, 1999). Upon antigen binding to the immunoreceptors, SFK are responsible for the 
phosphorylation of the IT AM motifs, turning them into a tandem SH2 ligand docking site 
for the Syk/ZAP70 family of cytoplasmic kinases and other SH2 domain containing 
signalling proteins (Latour and Veillette, 2001). For example, Lck and FynT signal 
downstream of TCR immunoreceptors (Gassmann et a l , 1992; Veillette et a l , 1988), 
Lyn signals downstream of BCR (Takata et a l, 1994) as well as FcR. Fgr and Hck signal 
downstream of FcyR (Fitzer-Attas et a l, 2000).
Activated Syk and ZAP70 kinases trigger a phosphorylation cascade implicating proteins 
such as SLP-76, phosphatidylinositol 3-kinase (PI3K), and Vav family members, leading 
to activation of MAPKs and actin cytoskeletal reorganisation. Specific cellular responses 
follow, e.g. proliferation and cytokine production for T-cells, proliferation and antibody 
secretion for B-cells and degranulation and respiratory burst for granulocytic cells.
SFK are also implicated in regulation of the immune response by phosphorylating 
Tmmunoreceptor tyrosine-based inhibitory motif(s)’ (ITIM) within the cytoplasmic tails 
of negative regulatory receptors such as CD22 in B-cells, killer inhibitory receptors 
(KIR) in NK and cytotoxic T-cells, FcyRIIB, PIR-B or SHPS-l/SIRPa in myeloid cells 
(Abram and Lowell, 2007a). Phosphorylated ITIM motifs serve as SH2 ligand docking 
site for phosphatases SHP1 and SHP2 (SH2-domain-containing phosphatase 1 and 2) or 
lipid phosphatase SHIP1 (SH2-domain-containing inositol phosphatase 1) depending on 
the cellular context. In turn, these phosphatases dephosphorylate phospho-ITAM and 
autophosphorylated SFK leading to immune signal attenuation (Abram and Lowell, 
2007b).
Thus, immune signal transmission and immune response regulation are dependant on the 
specific composition of lipid rafts at the surface of a given haematopoietic cell bringing 
together immunoreceptors, ITAM-containing adaptors, SFK and ITIM-containing 
inhibitory receptors which would recruit Syk/ZAP70 kinases as transducers and 
phosphatases as inhibitors (Table 1.7). The mechanism by which SFK and subsequently
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ITIM-containing inhibitory receptors are clustered to lipid rafts is currently poorly 
understood.
Cell type Immunoreceptor ITAMadaptor SFK
Syk or
ZAP70
kinase
ITIM containing
inhibitory
receptors
T-cells TCR CD3£ Lck ZAP70 CTLA4 (CD 152), PD1(CD279)
B-cells BCR
Ig a  and p 
(CD79 a 
and b)
Lyn Syk FcyRIIB, CD22
Myeloid
cells FcR
FcRy
chain
Hck/Fgr/
Lyn Syk
PIR-B, SIRPa, 
FcyRIIB (CD32)
NK cells NK-activatingreceptors DAP 12 Lck ZAP70/Syk KIR (CD158)
Table 1.7: Composition of lipid rafts for signalling downstream of immunoreceptors 
(Abram and Lowell, 2007a).
Differential composition o f lipid rafts downstream o f T-cells, B-cells, myeloid cells and 
natural killer (NK) cells immunoreceptors.
2.3.2 SFK downstream of cytokine receptors
Haematopoietic cells possess the particularity of proliferating or differentiating strictly 
upon external stimulation by soluble cytokines or upon cell-to-cell interaction with bone 
marrow stromal cells, or would, by default, undergo apoptosis. This dependence on 
inducible cytokine secretion or vicinity to stromal cells allow for homeostasis of the 
blood cell composition. In response to leukaemia inhibitory factor (LIF), bone marrow 
stromal cells produce interleukins, IL-3 and IL-6, as well as granulocyte-macrophage 
colony-stimulating factor (GM-CSF), macrophage colony-stimulating factor (M-CSF) 
and granulocyte colony-stimulating factor (G-CSF) (Szilvassy et al., 1996). Subsequently 
early haematopoietic progenitor cells stimulated with IL-3 and GM-CSF secrete IL-6, 
LIF and oncostatin M (OSM) (Yoshimura et a l , 1996). Multipotential progenitors can be 
stimulated by IL-3 and thrombopoietin (TPO) (Kaushansky, 1998) while IL7, IL-5, G- 
CSF, M-CSF and erythropoietin (EPO) stimulates lymphoid progenitors, eosinophils,
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granulocytes, monocytes/macrophages and erythroblasts respectively. TPO also 
stimulates megakaryocyte proliferation and differentiation. Additionally, cytokines are 
produced by macrophages, mast cells and activated T-cells as part of the inflammatory 
response. Thl helper T-cells secrete IL-2, tumor necrosis factor-13 (TNF(3) and interferon- 
Y (IFNy) while Th2 helper cells secrete IL-4, IL-5 and IL-10. Both Thl and Th2 helper T- 
cells secrete IL-3 and GM-CSF and their own development is regulated by IL-12 and IL- 
4 respectively (Manetti et al., 1993; Mosmann et a l , 2005; Takeda et al., 1996; 
Thierfelder et a l , 1996). Cytokines appear to be pleiotropic and redundant therefore a 
considerable amount of studies have tried to decipher how they can initiate different 
signals.
Cytokines bind to their cognate receptor that are classified in five different subclasses. 
Most cytokine receptors consist of a specific ligand binding extracellular subunit and an 
intracellular signal transducing subunit that is common to the receptor of a given subclass 
(Taniguchi, 1995). They are devoid of intrinsic kinase activity and, like 
immunoreceptors, are dependant on cytoplasmic kinases for transduction of their signal 
(.Figure.116).
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PTK receptor family HP 130 family IL-2 receptor family
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Fieure.1.16: Five subclasses o f cytokine receptors (adapted from  (Reddy et a l, 2000).
Protein tyrosine kinase (PTK) receptor family is given as a counter example. The gp!30 
family signal through a common gpl30 (3-subunit and display a specific ligand binding 
a-subunit. The IL-2 receptor family signal through a common IL-2Ry and a specific 13- 
subunit; their ligand binds to a specific a-subunit. The GH family is structurally similar 
with a single subunit that homodimerises upon ligand binding. The IFN family is 
composed o f paired signal transducing subunits that are structurally similar but distinct 
between the different members o f the family. The gpl 40 family signal through a common 
gpl4Q (3-subunit and possess a specific ligand binding a-subunit.
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2.3.2.1 The JAK-SFK-STAT pathway
Janus kinases (JAK) are commonly thought to be responsible for signal transduction from 
the cytokines receptor to the signal transducers and activators of transcription (STAT) 
factors (Darnell et a l , 1994; Ihle et a l, 1995; Pellegrini and Dusanter-Fourt, 1997; Shuai 
and Liu, 2003; Ward et a l, 2000), but recent evidence implicate SFK in this axis of 
transduction as well {Figure 1.17;(Rane and Reddy, 2002). Upon ligand binding, cytokine 
receptors dimerise and JAK, which are constitutively bound to them, get activated and 
phosphorylate them (Watowich et a l , 1994). The kinase/receptor interaction is thought to 
occur via an N-terminal SH2-like domain in the Janus kinases (Haan et a l , 2006), 
however, the mechanism of JAK activation is not completely understood (Cacalano et a l , 
1999; Chen et a l, 1997; Frank et a l, 1995). Phosphorylated receptors then serve as a 
docking site for an SH2 domain containing protein such as STAT and SFK. Two models 
exist regarding the subsequent phosphorylation of STAT: either by JAK or by SFK. Both 
possibilities have been reported to happen, depending on the cell type and the STAT 
considered. Consequently, specificity of action of a given cytokine seems to be dependent 
on which of the two transduction pathways they employ. Once phosphorylated, STAT 
homo- or heterodimerise via SH2 domain interaction and translocate to the nucleus where 
they induce expression of specific genes such as JunB, j3-casein, Piml, p21, cyclin Dl, 
SOCS3, Bc1xl , IFN-y or FCyRI (Darnell, 1997; Ward et a l, 2000). In cells stimulated 
with G-CSF, STAT3 leads to PU.l or C/EBPa expression, transcription factors that are 
essential for granulopoiesis (Numata et al., 2005; Panopoulos et a l, 2002).
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Figure 1.17: The JAK-Src-STATpathway (adaptedfrom (Reddy et al., 2000).
Upon ligands binding, SFK are recruited to the cytokine receptors and phosphorylate the 
receptor in a JAK dependent or independent fashion, leading to STAT recruitment, 
phosphorylation and translocation into the nucleus.
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Since the Janus kinase family is composed of four members, JAK1, JAK2, JAK3 and 
TYK2 and STAT exist as 10 different proteins, the possibilities o f transduction 
downstream of the many cytokine receptors seems infinite. Table 1.8 shows the 
combination o f JAK and/or SFK and /or STAT pathway that have been reported to exist 
for each cytokine receptor.
Subclasses CD Expressed on Associate with JAK
Recruit
SFK
Recruit
STAT
gp!30 family
IL-6R CD 130/ CD 126
Activated B-cells, 
plasma cells, 
endothelial cells, 
low on most 
leukocytes
JAK I*9’32, 
JAK2*9’32, 
TYK2*32
Hck*30
STAT1,
STAT3*31’
32
IL-11R
j a k i *9,
JAK2*9,
TYK2
Src, Yes STAT3
Cardiotropin-1
(CT)R
JAK1*9,
JAK2*9,
TYK2
ND STAT3
Ciliary 
neurotrophic 
factor (CNTF)R
JAK l ’9, 
JAK2*9, 
TYK2
ND STAT3
Oncostatin M 
(OSM) R
JAK1*9,
JAK2*9,
TYK2
Src
kinases STAT3
Leukaemia 
inhibitory factor 
(LIF)R
CD118 Epithelial cells in embryo and adult
JAKI*9,32,
JAK2*9’32,
TYK2*32
Hck*30 STAT3*31’32
IL-2 receptor family
IL2R CD 132/ CD122
T-cells, B-cells, 
NK cells, 
monocytes
JAKI*1-2,
JAK2,
JAK3*1’2
Fyn, Lck, 
Hck
STAT5-a,
STAT5-
b*17,
STAT3
IL-4R CD 132/ CD 124
Monocytes, 
haematopoietic 
precursors, 
epithelial cells, 
low on 
lymphocytes
JAKI*1,2,
JAK3*1’2 Lck STAT6*17
IL-7R CD 132/ T-cells, pro B- JAKI*1*2, Lyn STAT5-a,
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CD127 cells JAK3 1 " STAT5-b,
STAT3
IL-9R CD 132/ JAK3*1’2 ND
STATS-a,
STAT5-b,
STAT3
IL-15R CD 132/ Activatedmonocytes
JAKI*2,
JAK3*2 Lck
STAT5-a,
STAT5-b,
STAT3
Growth hormone family
Growth 
hormone (GH)R JAK2*4’9
Src
kinases
STAT5-a,
STAT5-b,
STAT3
Prolactin
(PRL)R JAK2*10 Src*28
STAT6,
STAT5-a,
STAT5-b,
STAT3
Erythropoietin
(EPO)R
JAK2*6,7,8,
9,24
Src*29,
Lyn*27’33
STAT5-a,
STAT5-
^*14,17,24,29,
33
G-CSFR CD114
Myeloid 
progenitors, 
endothelial cells
JAK2,
JAK3
Lyn,
Hck*32
STAT3,
STAT5
Thrombopoietin
(TPO)R CD110
Megakaryocytes, 
platelets, some 
CD341ow stem 
cells
TYK2,
JAK2 ND
STATS-a, 
STAT5-b
Interferon family
Interferon a  
receptor 
(IFNAR)
CD120a or 
b
Haematopoietic 
and non 
haematopoietic 
cells
JAKI,
TYK2 Lck
STAT1,
STAT2
Interferon y 
receptor 
(IFNGR)
CDwl 19
Macrophage, 
monocytes, 13- 
cells, T-cells, NK 
cells neutrophils, 
endothelial cells
JAKI*5,
JAK2*5 Hck, Lyn
STAT I*15’ 
16
IL-10R CDw210
T-cells, B-cells, 
NK cells, 
monocytes, 
macrophages
JAKI,
TYK2 ND
STAT1,
STAT3
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gpl40 family
IL-3R CD131/CDwl23
Lymphoid subset, 
basophils, 
haematopoietic 
progenitors, 
macrophages, DC 
cells, 
megakaryocytes
JAK2*11
Lyn,
Hck*25,
Fyn
STAT5-a,
STAT5-k* 17,18,23
STAT3’
STAT6*17
IL-5R CD131/CDwl25
Eosinophils,
basophils JAK2*13,19 (Btk)
STAT I*22 
, STAT5-
a,
STAT5-
b*19’23,
STAT3*21
GM-CSFR CD131/CD116
Monocytes, 
granulocytes, 
DCs, endothelial 
cells
JAK2*3,12’20 Lyn,Hck*26
STAT5-a,
STAT5-b*20,23
Table 1.8: JAK, SFK and STAT known to interact with each member o f the five
subclasses o f cytokine receptors (adapted from (Rane and Reddy, 2002).
Compilation of references mentioning interactions between one or more o f the JAK, SFK, 
STAT and/or cytokine receptors. *1 (Russell et al., 1994) *2(Russell et al., 1995) *3 
(Zhao et al., 1995) *4(Frank et al., 1995) *5(Kohlhuber et al., 1997) *6(Watowich et al.,
1994) *7(Witthuhn et al., 1993) *8(Miura et al., 1994) *9 (Tanner et al.,
1995)*10(DaSilva et al., 1994) *11(Silvennoinen et al., 1993) *12(Quelle et al., 1994) 
*13(Takaki et al., 1994) *14(Barber et al., 2001) *15(Kovarik et al., 2001) *16(Kotenko 
et al., 1996) *17(Quelle et al., 1995) *18(Azam et al, 1995) *19(Kouro et al., 1996) 
*20(Matsuguchi et al., 1997) *21 (Caldenhoven et al., 1995) *22(van der Bruggen et al.,
1995) *23(Mui et al., 1995) *24(Wakao et al, 1995) *25(English, 1996) *26(Linnekin et 
al., 1994) *27(Chin et al., 1998) *28(Kazansky et al, 1999) *29(Okutani et al, 2001) 
*30(Ernst et al., 1999) *31 (Meyn et a l, 2005) *32(Ernst et a l, 1996) *32 (Ward et al, 
1998) *33 (Ingley et al, 2005)
When looking at JAK association per cytokine receptor subfamily, gpl30 subfamily and 
gpl40 subfamily each associates with a specific group of JAK. This selection is 
determined by motifs within the cytokine receptors (Jiang et al., 1996; Narazaki et al., 
1994). Similarly, the type o f STAT getting phosphorylated in a system is dependent on
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binding sequences on the cytokine receptor and not on the type of JAK bound to the 
receptor, therefore the gpl30 and IFN subfamilies never phosphorylate STATS isoforms, 
while the GH-R and IL-2R subfamilies never phosphorylate STAT1 {Table 1.8). On the 
other hand, while most members of these two subclasses phosphorylate STAT3 and 
STATS, the GH-R subclass uses JAK2 while the IL-2R subclass barely does. Differences 
in pattern of association between gpl40 and GH-R subclasses are a priori more subtle to 
figure out. Activation pattern is probably also dependent on JAK availability since JAK3 
expression is restricted to the haematopoietic system, while other JAK are ubiquitous. 
Transphosphorylation of JAK has been reported where stimulation and aggregation of 
one type of cytokine receptor triggers the activation of several JAK that are necessary for 
further signal transduction (Oakes et a l, 1996; Rodig et al., 1998).
Most of the work linking SFK to the JAK-STAT pathway has been done in the IL-3 
dependent murine 32Dcl3 cell line. This cell line undergoes apoptosis in the absence of 
IL-3, a phenomenon bypassed by overexpression of transforming v-Src (Kruger and 
Anderson, 1991). Furthermore, the v-Src infected cells lose their capacity to differentiate 
into mature granulocytes upon G-CSF stimulation, implicating an action of Src 
downstream of both the IL3 receptor and the G-CSF receptor in this model. Examination 
of the JAK phosphorylation status showed that they were not activated by v-Src while 
STAT1, STAT3 and STAT5 were. However, direct interaction could only be proven 
between v-Src and STAT3; STAT1 and STAT5 did not immunoprecipitate with Src 
(Chaturvedi et a l, 1997). Interdependence of the JAK and SFK is proven in IL-3 
stimulated 32Dcl3 cells: in these cells, JAKI, JAK2 and Src are phosphorylated but a 
dominant negative mutant of JAK2 does not influence STAT3 phosphorylation, while a 
dominant negative mutant of Src prevents STAT3 phosphorylation (Chaturvedi et a l, 
1998). Of note, v-Fgr does not abrogate 32Dcl3 cells’ IL-3 dependence or capacity to 
terminally differentiate following G-CSF stimulation (Chaturvedi et a l, 1997). However, 
HCK overexpression lengthens 32Dcl3 cells’ viability in absence of IL-3, without leading 
to independence and, surprisingly, blocks G-CSF induced granulocytic differentiation 
(English, 1996). Of note, another murine IL-3 dependent cell line, NFS-60, which 
proliferates rather than differentiates in the presence of G-CSF, shows activation of HCK
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following G-CSF stimulation (32Dcl3 cell line does not express HCK) where HCK 
directly interacts and phosphorylates G-CSFR. In these two cell lines, activation of 
JAKI, JAK2, Tyk2, STAT1 and STAT3 is observed while it is not the case in terminally 
differentiated neutrophils also stimulated with G-CSF (Avalos et al., 1997). In 
neutrophils, Lyn has been implicated in transmitting the G-CSF signal (Corey et a l , 
1994). Thus, in overexpression systems, SFK differentially mediate the signal of a given 
cytokine receptor, probably via a SH2 and SH3 domains interaction based STAT 
recruitment and phosphorylation (Chaturvedi et a l , 1997).
Implication of HCK in the GM-CSF transduction pathway has been shown in neutrophils 
(Wei et a l , 1996) and in the AML FAB M2 HL-60 cell line, however HL60 cells 
required differentiating pretreatment with DMSO, retinoic acid (RA) or 1,25 
dihydroxy vitamin D3 (Linnekin et a l , 1994). In G-CSF and GM-CSF studies, Lyn 
seemed to be constitutively associated with the cytokine receptor while HCK was only 
recruited upon cytokine stimulation.
Another example of linking SFK to STAT activation without requirement of JAK is 
found in BCR-ABL transduced cells. Indeed, Lyn and HCK have been shown to be 
phosphorylated in BCR-ABL transduced 32D cells (Danhauser-Riedl et a l, 1996) and 
HCK has been implicated in BCR-ABL induced IL-3 independence of the DAGM cell 
line. In these BCR-ABL transduced cells, cytokine independence was abolished by co­
expression of a kinase dead mutant of HCK while co-expression of wild-type HCK only 
partially restrained the independence, suggesting the activation of several SFK for IL-3 
independence (Lionberger et a l , 2000). In BCR-ABL expressing 32Dcl3 cells, HCK has 
been shown to directly interact with STAT5 and phosphorylate it while BCR-ABL itself 
is present in the immunocomplex but does not directly bind to STAT5 (Klejman et a l, 
2002).
It is important to notice that all these studies implicating HCK have been done in BCR- 
ABL transduced cells and are also independent of any cytokine receptor stimulation. In 
cell lines derived from CML patients such as K562, STAT-5, JAKI, JAK2 (Chai et a l, 
1997) and Lyn are constitutively phosphorylated while HCK is not (Donato et a l, 2003), 
(Danhauser-Riedl et a l, 1996). Other evidence of possible interaction of SFK with STAT 
comes from overexpression studies in insect cells (Schreiner et a l, 2002). In such studies,
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proven direct interaction between SFK and STAT3 implicates the SFK SH3 domain but 
is not exactly physiological. Studies in murine embryonic stem cells (ES cells) indicate a 
direct interaction between HCK and the gpl30 subunit which mediate LIF dependence 
for maintenance of self-renewal property (Ernst et a l , 1994). Further studies have also 
implicated JAKI, JAK2, TYK2 and STAT3 in this process, though JAK and SFK did not 
act through the same pathway (Ernst et a l, 1999; Ernst et a l, 1996; Meyn et a l, 2005). 
Moreover, overexpression of constitutively active HCK led to LIF independence for 
maintenance of undifferentiation, a phenotype shared by activated v-Ras (Ernst et al,
1996). Studies in IL-3 dependent Baf-B03 cell lines transduced with an EpoR-gpl30 
chimaera confirmed interaction between HCK and the gpl30 subunit that transduced a 
proliferation signal (Schaeffer et a l, 2001). Physiological interaction of SFK and gpl30 
has also been confirmed in multiple myeloma cell lines (Hallek et a l, 1997; Hausherr et 
a l, 2007). Of importance, studies using SFK inhibitors revealed that maintenance of an 
undifferentiated state was a matter of balance between different SFK expression and 
activation. It was observed that differentiating cells, following LIF withdrawal, naturally 
downregulated HCK and Lck, while, paradoxically, complete inhibition of all SFK led to 
LIF independence for maintenance of pluripotency (which is consistent with the previous 
HCK overexpression experiments). On the other hand, partial inhibition of some SFK led 
to ES cells differentiation despite the presence of LIF (Meyn et al., 2005).
2.3.2.2 Regulation of the JAK-Src-STAT pathway
Various phosphatases such as PTPeC, SH-PTP1, PTP1B and SHP-1, SHP-2 and CD45 
have been shown to dephosphorylate at least one member of the JAK family in a cytokine 
receptor dependent fashion (Rane and Reddy, 2002), SHP-1 can also dephosphorylate 
cytokine receptors directly. Of note SHP-1, SHP-2 and CD45 have also been implicated 
in dephosphorylating SFK downstream of immunoreceptors (as described previously) but 
not yet downstream of cytokine receptors. The family of supressors of cytokine signalling 
(SOCS) is also involved in the JAK-STAT pathway regulation by either binding directly 
to JAK in their catalytic domain or by binding to cytokine receptors, where they compete 
with STAT, therefore inducing a downregulation of the signal transduction {Figure 1.18).
91
Chapter I
Action o f SOCS can also imply ubiquitination o f JAK bound to cytokine receptors. Since 
STAT3 has been shown to induce gene transcription o f at least SOCS3, SOCS regulation 
acts as an inducible feedback loop (Brender et al., 2001; He et al., 2003).
SHP-2
cytoplasm
cytokine G
activation
d im eriza t io n
transloca t ion
nucleus
c-myc, cyclins, 
Bcl-xL,Mcl 1, survivin, 
VEGF, SOCS, MMPs
PIAS3
t a r g e t  g e n e s
Fisure 1.18: Regulation o f the JAK-STAT pathway (adapted from  (Desrivieres et al., 
2006).
The JAK-STAT pathway is regulated at different levels by phosphatases, SOCS and PIAS.
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Additionally, the family of protein inhibitors of activated STAT (PIAS) offer further 
inhibition by directly binding specific phosphorylated STAT preventing them to bind 
DNA by SUMOylation (Wormald and Hilton, 2004). Of note, SOCS ubiquitination 
properties and half-life are negatively regulated by its phosphorylation, an event observed 
shortly after Epo, IL-2, IL-3 or IL-6 stimulation. SOCS3 phosphorylation following IL-6 
stimulation of murine embryonic fibroblast (MEF) has been shown to be independent of 
JAK and dependent on Lck. This study therefore postulates a role of SFK in potentiation 
of cytokine signal by negative regulation of its inhibition (Sommer et a l , 2005).
2.3.2.3 Additional pathways downstream of cytokine receptors implicating SFK
In addition to the JAK-SFK-STAT pathway, the Shc-Ras-Raf-MEK-ERK pathway, as 
well as the PI3K-PTEN-AKT-mTOR pathway, are triggered downstream of cytokine 
receptor signalling (Figure 1.19 and (Steelman et a l, 2008). These pathways are known 
to transduce signals relative to apoptosis, proliferation via cell cycle progression and cell 
growth, and cell migration. So far, SFK have been implicated in c-Raf phosphorylation, 
interaction with Akt and triggering of the mTOR pathway independently of Akt. 
However, most components of these 3 pathways are involved in leukaemia either via 
mutations, over-activations, deletions or involvement as a partner of an aberrant fusion 
protein.
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Figure 1.19: The JAK-SFK-STATpathway, the Shc-Ras-Raf-MEK-ERK pathway and 
the PI3K-PTEN-AKT-mTOR pathway are triggered downstream o f cytokine receptor 
signalling. (McCubrey et al., 2008).
Red arrows indicate phosphorylation. Blue arrows indicate inhibition. Black arrows 
indicate interaction. Diamonds indicate transcription factors. Circles indicate proteins. 
Boxes indicate action.
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2.3.3 SFK downstream of integrins: involvement in adhesion and migration
SFK have also been found to be activated downstream of adhesion receptors such as 
integrins. Integrins are heterodimers of a  and |3 subunits involved in cell-cell and cell- 
extracellular matrix interactions implicated in cell adhesion, spreading and migration 
(Miranti and Brugge, 2002; Schwartz and Ginsberg, 2002; Webb et al., 2002). Such 
cellular events are required in inflammatory responses, tissue repair and regeneration as 
well as in morphogenesis and can also be implicated in tumour cells invasion. At least 25 
different integrins exists, composed of one of the 19 possible a  subunits associated with 
one of the 8 p subunits, and each type is expressed on a subset of haematopoietic cells 
{Figure /.20)(Takagi and Springer, 2002).
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Fieure 1.20: The integrin family (http://imst.cities, fr).
The integrin family is composed o f 3 subfamilies: VLA, cytoadhesins and Leu-cam 
consisting o f a specific mix and match o f 19 possible a  subunits associated with one o f 
the 8 possible (3 subunits.
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In a non-adherent cell, the extracellular domain of integrin receptors is folded in a way 
that restricts ligand binding. Signalling occurring upon binding of a cytokine or a 
chemokine to its cognate receptor induces the separation of integrin receptor cytoplasmic 
tails leading to the unfolding of the extracellular domain. This phenomenon known as 
inside-out signalling activates the integrins to be able to bind to their ligands with high 
affinity and to cluster together to amplify the following outside-in signal. SFK have been 
identified as acting downstream of the inside-out signalling of some of these integrins in 
a cell type specific manner (Adachi and Suzuki, 2007; Evangelista et a l , 2007; Frame et 
al., 2002; Giagulli et a l, 2006; Piccardoni et a l, 2004; Samayawardhena et a l, 2007; 
Tang et al, 2006; Totani et a l, 2006). One given integrin heterodimer can bind to several 
ligands without specificity but with a certain selectivity. Similarly, the different 
component of the extracellular matrix - collagen, laminin, fibronectin, vitronectin or 
fibrinogen - can be recognised by several type of integrins (Hynes, 1992). However, 
cooperation with distinct immunoreceptors, cytokine receptors, chemokine receptors or 
growth factor receptors delineate interactions with distinct intracellular proteins 
specifying the subsequent type of cellular responses. Following integrins engagement, 
signals can be transduced via several pathways implying either FAK, Syk, She or 
tetraspanin (Giancotti and Tarone, 2003; Miranti et a l, 1998). Either pathway triggers 
signals of cellular adhesion and migration which influence cell proliferation or apoptosis 
in a cell type dependent manner. Most, if not all integrins, propagate signals via FAK and 
recruit SFK in a talin and paxillin dependent fashion {Figure 1.21). Specific subsets of 
integrins use caveolin-1 instead of talin as an adaptor protein (a lp l ,  a5 p l, avP3) or no 
adaptor protein at all (a6p4) and trigger the Shc/Grb2/Ras/ERK pathway independently 
of FAK. Both the FAK and the She pathway can be brought into cross-talk and synergy 
via growth factor signalling. SFK have a central role in any of these three scenarios.
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Fisure 1.21: Common outside-in fi-subunit mediated integrin signalling (Giancotti and 
Tarone, 2003).
Most integrins (except a l  pi, a5fil, av(33 and a6[34) propagate signals via FAK and 
recruit SFK in a talin and paxillin dependent fashion.
Integrin signalling pathways implicating Syk are seen in haematopoietic cells such as 
leukocytes and platelets and transduce signals via the same intracytoplasmic proteins as 
the immunoreceptors (Figure 1.22).
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Fisure 1.22: Syk mediated outside-in integrin signalling (Abram and Lowell, 2007a).
Integrin signalling pathways implicating Syk are seen in haematopoietic cells such as 
leukocytes and platelets and transduce signals via the same intracytoplasmic proteins as 
the immunoreceptors.
SFK involvement in integrin signalling and propagation of signals leading to cell 
adhesion and migration has clearly been established via phenotyping studies o f various 
single, double and triple knock-out mice (Table 1.9). However, detailed signalling 
distinguishing between each SFK needs further investigation.
HCK itself has not been reported to signal downstream o f integrins via FAK or She. Its 
only known interaction with She is downstream o f gpl30 (Ernst et al., 1996). HCK has 
been reported to specifically co-cap with M acl/CD l lb/CD18 but is not known to directly 
interact with any other integrin (Tang et al., 2006). In a model of thrombohemorrhagic 
vasculitis, HCK has recently been reported to signal via Syk downstream of Mac-1 in 
neutrophils (Hirahashi et al., 2006; Ley and Zarbock, 2006). The lack of knowledge 
about any other specific signalling pathway involving HCK is essentialy due to its high 
redundancy with Fgr and Lyn necessitating double or triple knock-out mice to reveal a 
phenotype
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Knock-out Phenotype References
Src •/' Ostoeopetrosis (Soriano et a l , 1991)
Src'THck^
Severe osteopetrosis; associated 
haematopoietic deficiences
(Lowell e ta l , 1996b)
Src^’/Fgr'7" similar to Src-/- phenotype (Lowell e ta l, 1996a)
Fyn’/_ or FynT7'
Neuronal abnormalities; increased 
ethanol sensitivity and susceptibility to 
drug-induced seizures; myelination 
defects; TCR signalling defects in 
thymocytes; delayed spreading of 
platelets on fibrinogen-coated surfaces
(Appleby et a l , 1992; 
Grant et a l, 1992; 
Miyakawa et a l , 
1997; Miyakawa et 
a l, 1996; Reddy et 
a l, 2008; Stein et al., 
1992)
Yes"7' No phenotype (Stein et a l, 1994)
Src '^/Yes*7' Die perinatally (Stein e ta l , 1994)
Src^'/Fyn"7" Die perinatally (Stein et a l , 1994)
Fyn‘/7Yes‘/‘ Autoimmune disease; renal malfunction (Stein et a l, 1994)
Lck’7'
Defective TCR signalling and thymocyte 
maturation (low CD4+CD8+ T-cells); 
immune defects; retinal dysplasia
(Molina ef al, 1993; 
Molina et a l, 1992; 
Molina et a l , 1998)
Lck'77Fyn'7'
No T-cells (Groves et a l, 1996; 
van Oers et a l, 1996)
Lyn'7'
Defective BCR signalling and B-cell 
maturation; high level of serum IgM; 
autoimmune disease; age related 
splenomegaly and macrophage tumor, 
(mild myeloproliferative disease); 
defective FcR signalling and allergic 
response; neutrophils with enhanced 
respiratory burst and secondary granule 
release; hyperadhesive neutrophils and
(Harder et a l , 2001; 
Hibbs et a l, 1995; 
Nishizumi et a l, 
1995; Pereira and 
Lowell, 2003)
1 0 0
Chapter I
macrophages
Lyn'^'/Fyn'7' Severe autoimmune kidney disease (Yu et a l, 2001)
Lyn'7VHck'7'
Myeloproliferative disease (MPD), 
severe lung inflammation with extensive 
macrophage infiltration
(Xiao et a l , 2008)
Hck'7'
No obvious overall phenotype; slight 
delay in FcR mediated phagocytosis; do 
not develop thrombohemorrhagic 
vasculitis; reduced degranulation and 
cytokine production in FceRI-stimulated 
hck(-/-) mast cells
(Hirahashi et al., 
2006; Hong et a l, 
2007; Lowell et al, 
1994)
Fgr'7'
No obvious overall phenotype; decreased 
lung eosinophilia in allergic lung 
inflammation
(Lowell e ta l, 1994; 
Vicentini et a l , 2002)
Hck'7TFgr'7'
Extreme sensitivity to Listeria infection; 
resistant to LPS endotoxemia; defects in 
PML and macrophage responses 
(degranulation, respiratory burst); 
migration/adhesion defects; reduced 
neutrophils (32-integrin mediated 
spreading and adhesion; impaired 
polymorphonuclear leukocyte (PMN) 
capacity to adhere with activated platelets 
in suspension
(Evangelista et a l, 
2007; Giagulli et a l, 
2006; Lowell and 
Berton, 1998; Lowell 
et a l, 1996a; Lowell 
et a l, 1994; Mocsai et 
a l, 1999; Suen et a l, 
1999)
Hck'7'/Fgr'77Lyn‘7' 
(also named SFK'7' 
or HLF)
Impaired FcR induced signalling and 
phagocytosis; impaired 
polymorphonuclear leukocyte (PMN) 
capacity to adhere with activated platelets 
in suspension
(Evangelista et a l , 
2007; Fitzer-Attas et 
a l, 2000)
Table L9: Non-exhaustivephenotype of SFKsingle, double and triple available knock­
out mice.
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Although knock-out mice did not allow to elucidate specific roles for HCK, 
overexpression studies of constitutively active HCK confirmed a role for HCK in 
adhesion/migration, phagocytosis and inflammation. Indeed, these mice showed a 
spontaneous lung inflammation with infiltration of macrophages and eosinophils and an 
excessive immune response to stimulating agents (Ernst et al., 2002). An important body 
of work by Maridonneau-Parini’s team, also using overexpression of constitutively active 
HCK but in fibroblasts (which do not express endogenous HCK), implicates p59HCK in 
the formation of membrane protusion in a Rac and Cdc42 dependent manner (Carreno et 
a l , 2002) and p61HCK in the formation of podosome rosettes in a Rac, Cdc42 and Rho 
dependent manner (Cougoule et al., 2005). The formation of such structures has been 
confirmed to naturally occur in stimulated macrophages and in BCR-ABL positive CML 
cells, further stating a role for HCK in cellular adhesion (Poincloux et a l , 2006).
2.3.4 Role of SFK in primitive haematopoietic cells
Until recently, the role of SFK in primitive haematopoietic cells had not been examined. 
Using the background observation that patients with severe congenital neutropenia 
acquiring a G-CSFR truncating mutation have a high risk of developing AML, Mermel et 
al. examined the role of myeloid SFK in early granulopoiesis (Mermel et a l , 2006). This 
study revealed that even if single or triple myeloid SFK knock-out mice have a normal 
resting haematopoiesis, HCK specifically plays a role in regulating the G-CSF induced 
proliferation of granulocytic precursors, while Lyn controls the overall production of 
myeloid progenitors. None of these two SFK were shown to regulate the terminal 
granulocytic differentiation. Borneo J. et al. confirm an essential role of myeloid SFK 
following G-CSF stimulation by demonstrating their influence on HSC mobilisation both 
in an extrinsic and an instrinsic way (Borneo et a l , 2007). Although this study proposes a 
potential mechanism of action of myeloid SFK on the bone marrow environment in the 
context of HSC mobilisation, the influence of SFK on HSC intrinsic pathways in this 
same context remains to be fully explored. Additionally, SFK were shown to have a role 
in HSC self-renewal since triple knockout mice displayed a higher number of HSC in 
their bone marrow which have a decreased repopulating capacity. This HSC phenotype
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was eventually attributed to the sole Lyn deficiency, confirming its role in both the HSC 
and myeloid progenitor production (Orschell et al., 2008). While haematopoiesis in triple 
myeloid SFK knock-out mice proceed quite normally, surprisingly, double knock-out 
mice for both Lyn and HCK display a dramatic phenotype partially resembling Lyn 
single knock-out mice (developing mild MPD) and constitutively active Hck knock-in 
mice (developing severe lung inflammation) phenotypes (Xiao et a l , 2008). This 
phenotype is transplantable and has been shown to be STAT5 and SHIP dependent. Since 
all studies on SFK in HSC and haematopoietic progenitors have been done in mice and 
reveal intricate compensations between myeloid SFK, it remains to be established if the 
individual SFK play the same roles in human HSC.
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3. Aim of this study
Acute myeloid leukaemia (AML) is characterised by an accumulation of immature blasts 
that fail to fully differentiate. Leukaemia is organised as a hierarchy, which is maintained 
by leukaemic stem cells (LSC). To identify molecular differences between normal 
haematopoietic stem cells (HSC) and LSC, we performed microarray analyses and found 
that haematopoietic cell kinase (HCK) is overexpressed in LSC in comparison to normal 
bone marrow and umbilical cord blood HSC.
By analysing various fractions of AML samples, we first assessed whether we could 
distinguish a specific pattern of HCK expression inbetween AML samples and in 
comparison to umbilical cord blood (UCB).
Then, in order to evaluate a potential role for HCK in leukaemogenesis, we used two 
different lentivirus based approaches to either (1) knock-down HCK in leukaemic cell 
lines (with the aim to ultimately work with patient sample fractions) or (2) to overexpress 
HCK in UCB stem cell enriched fractions.
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II Materials and methods
1. Molecular biology
1.1 Quantitative real time PCR
1.1.1 RNA extraction
RNA was extracted from sorted AML, normal bone marrow and umbilical cord blood
samples using Trizol (Invitrogen). The RNeasy microkit (Qiagen) was used for extraction
of RNA from cell lines according to manufacturer’s instructions.
1.1.2 RNA reverse transcription into cDNA
One hundred nanograms of RNA were added to the appropriate amount of RNAse and 
DNAse free water (Sigma) containing 1.2 pL of 10 pM oligoTi4.i6 (Sigma) in a final 
volume of 13 pL. RNA was allowed to hybridise to oligodT by incubating the mix for 10 
min at 65 °C then on ice for 5 min. Seven microlitres of a master mix corresponding to 2 
pL of lOx buffer, 2 pL of 10 pM dNTPs, 2 pL of 0.1 M DTT, 0.5 pL of RNase inhibitor 
and 0.5 pL of Superscript III were added to each RNA sample and incubated at 50°C for 
lh then at 70°C for 15min. If necessary, cDNA samples were stored at -20°C until ready 
to use for quantitative real time PCR.
1.1.3 Quantitative real time PCR
A cDNA master mix of 20 pL of RNAse and DNAse free water and 2 pL of cDNA 
(corresponding to 5 ng of equivalent RNA for a duplicate reaction) was prepared for each
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sample. Aliquots of 11 pL were pipetteted into a PCR 96 well plate. Aliquots of 11 pL of 
RNAse and DNAse free water only were also pipetteted as non-template controls (NTC). 
A master mix, corresponding to 25 pL of 2x SYBR® green PCR mix (Applied 
Biosystems), 1.5 pL of the appropriate 10 pM forward primer and 1.5 pL of the 
appropriate 10 pM reverse primer was prepared for each primer pair and 14 pL of the 
mix were added to each well of the PCR 96 well plate. The final volume of each 
duplicate reaction was 25 pL. Real-time PCR was performed using the ABI Prism 7700 
Sequence Detector System (ABI/Perkin Elmer, Foster City, CA, USA). All the reactions 
were carried out in duplicate under the following conditions: an initial step at 50°C for 2 
minutes and 95°C for 10 minutes, followed by 40 cycles of a two stage PCR, consisting 
of 95°C for 15 seconds and 60°C for one minute. GAPDH was used as an endogenous 
reference gene. Analysis was carried out using the software SDS provided with the ABI 
Prism 7700.
1.2 Cloning
1.2.1 shRNA cloning
1.2.1.1 Hybridisation of shHCK4 oligonucleotides
Forward 5 ’ -GAT CCCCGCTT GCT GG ACTTT CT G AATT C A AG AG ATT C AG AAAGT 
CAGCAAGCTTTTTGGAAA- 3 ’ and reverse 5 ’ -AGCTTTTCCAAAAAGCTTGCTGGA 
CTTTCT G AAT CT CTT G AATT C AG AAAGT CC AGC AAGCGGG-3 ’ shHCK4 encoding 
oligonucleotides were resuspended in RNAse and DNAse free water at a final 
concentration of 40 pM. 20 pL of each long oligonucletide were added to 10 pL of 
annealing buffer 5x (500 mM potassium acetate, 150 mM HEPES-KOH, pH 7.4, 10 mM 
magnesium acetate) and hybridised by incubating the 50 pL mix for 1 min at 95°C, 15 
min at 37°C and overnight at RT.
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1.2.1.2 Verification of the integrity of the pHl-Xho shuttle vector
Two hundred nanograms of pHl-Xho plasmid DNA was digested in a mix of 2 pL of lOx 
EcoRl digestion buffer, 1 pL of EcoRl restriction enzyme and 1 pL of BgHI restriction 
enzyme, topped up with water to a final volume of 20 pL (E/B digest) or in a mix of 2 pL 
of 1 Ox buffer 2 digestion buffer, 1 pL of Xhol restriction enzyme and 2 pL of 1 Ox BSA, 
topped up with water to a final volume of 20 pL (X digest). Digestion mixes were 
incubated for 4h30 at 37°C and loaded on an agarose gel to assess for successful 
digestion (See ‘Agarose gel electrophoresis and visualisation’ section). All reagents for 
restriction digests were from New England Biolabs, Hitchen, UK.
1.2.1.3 Restriction digest of the pHl-Xho shuttle vector
Two hundred nanograms of pHl-Xho plasmid DNA was digested in a mix of 2 pL of lOx 
buffer 2 digestion buffer, 1 pL of EcoRl restriction enzyme and 1 pL of Hindlll 
restriction enzyme, topped up with water to a final volume of 20 pL. Digestion mixes 
were incubated for 4h30 at 37°C and loaded on an agarose gel to assess for successful 
digestion and subsequent gel purification (See ‘Agarose gel electrophoresis and 
visualisation’ section). All reagents for restriction digests were from New England 
Biolabs, Hitchen, UK.
1.2.1.4 Ligation of the hybridised shHCK4 oligonucleotides to the pHl-Xho shuttle 
vector
A ligation mix of 14 pL of hybridised oligonucleotides, 2 pL of EcoRl I Hindlll restricted 
pHl-Xho plasmid DNA, 1 pL of T4 DNA ligase, 2 pL of lOx ligase buffer and 1 pL of 
RNAse and DNAse free water were left to incubate overnight at 16°C. DH5a bacteria 
were transformed with 2 pL of the ligation mix using Ampicillin as a selection antibiotic 
(see ‘Bacterial transformation’ section).
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1.2.1.5 Restriction of the shHCK4-pHl-Xho shuttle vector and the pRLL-SIN-cPPT- 
PGK-eGFP-WPRE lentiviral backbone/ Verification of cloning of pHl- 
shHCK4 into the lentiviral backbone
One microgram of lentiviral plasmid DNA or pHl-Xho plasmid DNA were digested in a 
mix of 5 pL of lOx buffer 2 digestion buffer, 1.5 pL of X ho lrestriction enzyme and 5 pL 
of lOx BSA, topped up with water to a final volume of 50 pL. Digestion mixes were 
incubated for 4h at 37°C and loaded on an agarose gel to assess for successful digestion 
and subsequent gel purification. All reagents for restriction digests were from New 
England Biolabs, Hitchen, UK.
1.2.1.6 Ligation of the pHl-shHCK4 fragment into the pRLL-SIN-cPPT-PGK-eGFP- 
WPRE lentiviral backbone
The Xhol restricted and gel purified pHl-shHCK4 fragment was serially diluted in 
RNAse and DNAse free water at dilution ratios 1:2, 1:10, 1:100 and 1:1000. One 
microlitre of either dilution was mixed to 1 pL of Xhol restricted, gel purified and 
dephosphorylated lentiviral plasmid DNA and the ligation mix was completed by adding 
1 pL of T4 DNA ligase, 2 pL of lOx ligase buffer and 15 pL of RNAse and DNAse free 
water before being incubated overnight at 16°C. XL-Gold bacteria were transformed with 
3 pL of the ligation mix using Ampicillin as a selection antibiotic (see ‘Bacterial 
transformation’ section).
1.2.2 miRNA cloning
1.2.2.1 Hybridisation and dilution of miRNA oligonucleotides
Top strand of miRNA 604 (5’ -TGCT GAT C ACTT C AGGGTTT G AC AT CGTTTT GGCC 
ACTGACTGACGATGTCAACCTGAAGTGAT-39), miRNA 605 (5’-TGCTGTGTAGA 
AGT CAT CC AGC AC ACGTTTT GGCC ACT G ACTG ACGT GT GCT GT G ACTT CT AC A 
-3’), miRNA 606 (59 -T GCT GAT AC AGGGC A ACC ACGAT GAT GTTTTGGCC ACT G
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ACT G AC ATC AT CGTTT GCCCT GT AT-3 ’) and miRNA 607 (5 ’ -T GCT GAAG AGT AG 
CTT CCTTT AGT GGGTTTT GGCC ACT G ACT G ACCC ACT AAA A AGCT ACTCTT- 3 ’) 
and bottom strands (complementary sequence of the top strand) were resuspended as 200 
pM solutions in RNAse and DNAse free water. Five microlitres of each given top strand 
were hybridised to 5 pL of their respective bottom strand by adding 2 pL of lOx Oligo 
Annealing Buffer (Invitrogen) and 8 pL of RNAse and DNAse free water. Each 
hybridisation mix was incubated for 4 min at 95°C then allowed to cool down at RT for 
10 min. Each 50mM hybridised miRNA solution obtained was further serially diluted to a 
500mM and a 10 nM solution in order to proceed to their ligation into the 
pcDNA™6.2GW/EmGFP-miR vector. Fifty micromolar stock solution and intermediate 
dilution solutions were frozen at -20°C.
1.2.2.2 Ligation of the hybridised miRNA oligonucleotides to the pcDNA™6.2GW 
/EmGFP-miR vector
A ligation mix of 4 pL of hybridised miRNA oligonucleotides (miRNA 604, 605, 606 
and 607), 2 pL of the linear pcDNA™6.2GW/EmGFP-miR vector plasmid, 1 pL of T4 
DNA ligase (Invitrogen), 4 pL of 5x Ligation buffer (Invitrogen) and 9 pL of RNAse and 
DNAse free water was incubated 5 min at RT, then kept on ice until ready for 
transformation. TOP 10 bacteria were transformed with 2 pL of the ligation mix using 
Spectinomycin as a selection antibiotic (see ‘Bacterial transformation’ section).
1.2.2.3 Restriction digest of the pcDNA™6.2GW/EmGFP-miR-miRNA 604, 605, 
606, 607 plasmids
One microgram of pcDNA™6.2GW /EmGFP-miR-miRNA 604, pcDNA™6.2GW 
/EmGFP-miR-miRNA 605, pcDNA™6.2GW /EmGFP-miR-miRNA 606 and 
pcDNA™6.2GW /EmGFP-miR-miRNA 607, to be used as ‘backbone’, were digested in 
a mix of 2 pL of lOx buffer 3 digestion buffer, 1 pL of BglH restriction enzyme, 1 pL of 
Xhol restriction enzyme and 2 pL of 1 Ox BS A, topped up with water to a final volume of 
20 pL. Three times 2 pg of pcDNA™6.2GW /EmGFP-miR-miRNA 604,
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pcDNA™6.2GW /EmGFP-miR-miRNA 605, pcDNA™6.2GW /EmGFP-miR-miRNA 
606 and pcDNA™6.2GW /EmGFP-miR-miRNA 607, to be used as ‘insert’, were 
digested in a mix of 2 pL of lOx buffer 3 digestion buffer, 1 pL of BamHI restriction 
enzyme, 1 pL of Xhol restriction enzyme and 2 pL of lOx BSA, topped up with water to 
a final volume of 20 pL. Digestion mixes were incubated for 4h at 37°C and loaded on an 
agarose gel to assess for successful digestion and subsequent gel purification. All 
reagents for restriction digests were from New England Biolabs, Hitchen, UK.
1.2.2.4 Ligation of the pcDNA™6.2GW/EmGFP-miR-miRNA60.x ‘backbones’ to the
miRNA60.x ‘inserts’
‘Backbone’ pcDNA™6,2GW /EmGFP-miR-miRNA60.x was ligated to BamHIlXhoI 
digested miRNA604, 605, 606 and 607 inserts in a 1:3 ratio (where x represents the last 
digit of the miRNA name, 4, 5, 6 or 7). A ligation mix of 50 ng of the 5849 bp backbone, 
3.94 pL of the 150 bp insert, 1 pL of T4 DNA ligase, 10 pL of 2x Ligation buffer, topped 
up to 20 pL with RNAse and DNAse free water, was incubated 5 min at RT then kept on 
ice until ready for transformation. TOP 10 bacteria were transformed with 2 pL of either 
of the 12 ligation mixes using Spectinomycin as a selection antibiotic (see ‘Bacterial 
transformation’ section). pcDNA™6.2GW /EmGFP-miR-miRNA604 ligated to 
miRNA605 will be called mi45, pcDNA™6.2GW /EmGFP-miR-miRNA604 ligated to
miRNA606 will be called mi46, pcDNA™6.2GW /EmGFP-miR-miRNA604 ligated to
miRNA607 will be called mi47, pcDNA™6.2GW /EmGFP-miR-miRNA605 ligated to
miRNA604 will be called mi54, pcDNA™6.2GW /EmGFP-miR-miRNA605 ligated to
miRNA606 will be called mi56, etc.
1.2.2.5 Restriction digest of the 12 pcDNA™6.2GW/EmGFP-miR-miRNA plasmids 
containing two miRNA sequences
One microgram of each of the 12 pcDNA™6.2GW /EmGFP-miR-miRNA 604-605, 604- 
606, 604-607 etc, generated previously, were digested in a mix of 2 pL of lOx buffer 3 
digestion buffer, 1 pL of BgUI restriction enzyme, 1 pL of Xhol restriction enzyme and 2
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\iL of lOx BSA, topped up with water to a final volume of 20 pL, to be used as 
‘backbone’. Digestion mixes were incubated for 4h at 37°C and loaded on an agarose gel 
to assess for successful digestion and subsequent gel purification. All reagents for 
restriction digests were from New England Biolabs, Hitchen, UK.
1.2.2.6 Ligation of the pcDNA™6.2GW/EmGFP-miR-miRNA60.x-60.x ‘backbones’ 
to the miRNA60.x ‘inserts’
Each of the 12 ‘backbone’ pcDNA™6.2GW /EmGFP-miR-miRNA60.x-60.x was ligated 
to miRNA604, 605, 606 and 607 inserts in a 1:3 ratio. A ligation mix of 50 ng of the 6 kb 
backbone, 3.75 pL of the 150 bp insert, 1 pL of T4 DNA ligase, 10 pL of 2x Ligation 
buffer, topped up to 20 pL with RNAse and DNAse free water, was incubated 5 min at 
RT then kept on ice until ready for transformation. TOP 10 bacteria were transformed 
with 2 pL of either of the 24 ligation mixes using Spectinomycin as a selection antibiotic 
(see ‘Bacterial transformation’ section). pcDNA™6.2GW /EmGFP-miR-miRNA604-605 
ligated to miRNA606 will be called mi456, pcDNA™6.2GW /EmGFP-miR-miRNA604- 
605 ligated to miRNA607 will be called mi457, pcDNA™6.2GW /EmGFP-miR- 
miRNA604-606 ligated to miRNA605 will be called mi465, pcDNA™6.2GW /EmGFP- 
miR-miRNA604-606 ligated to miRNA607 will be called mi467, pcDNA™6.2GW 
/EmGFP-miR-miRNA604-607 ligated to miRNA605 will be called mi475, etc.
1.2.3 p59HCK cDNA cloning
1.2.3.1 Amplification of p59HCK cDNA
p59HCK cDNA was amplified from Mono-mac-6 cells’ total cDNA using the forward 
primer 5’-ATGGGGTGCATGAAGTCCAAGT-3’ and the reverse primer 5’-TCATGGC 
TGCTGTTGGTACTG-3’. Ideal annealing temperature was determined using a 
temperature gradient ranging from 57 to 63 °C. A master mix corresponding to 5 pL of 
lOx Takara buffer, 8 pL of Takara dNTPs, 0.1 pL of 100 pM forward primer, 0.1 pL of
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100 pM reverse primer, 0.5 pL of Takara polymerase, 100 ng of equivalent RNA and 
34.76 pL of RNAse and DNAse free water was prepared and 50 pL PCR mix was 
pipetteted into a PCR 96 well plate. PCR reactions were carried out in duplicate under the 
following conditions: an initial hot start step at 95°C for 1 minute, followed by 35 cycles 
of a four stage PCR, consisting of 100°C for 5 seconds, 98°C for 5 seconds, 1 min 
annealing at 57, 57.3, 57.9, 58.7, 59.8, 61.3 or 63°C and 2 min elongation at 68°C. A 
final elongation step at 72°C for 10 min completed the PCR, which was kept at 4°C until 
ready to run on an agarose gel. Ten microlitres of the PCR products were run on a 1% 
agarose gel {Figure II. 1).
Fisure II. 1: p59HCK PCR products.
p59HCK cDNA was amplified by PCR from Mono-mac-6 cells total cDNA using an 
annealing temperature gradient ranging from 57 to 63 °C.
The 1.5 kb PCR product amplified at 63°C was cloned into the pCR® 2.1-TOPO vector 
by TA ligation.
1.2.3.2 TA ligation
The amplified p59HCK cDNA was cloned into the pCR® 2.1-TOPO vector by TA 
ligation (Invitrogen). This type of ligation takes advantage of the fact that the final PCR
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extension step of 10 minutes at 72°C adds an A base overhang on PCR products. The 
linear pCR® 2.1-TOPO vector, provided by Invitrogen, contains T overhangs. Three or 
four microlitres of PCR product were ligated to 1 pL of pCR® 2.1-TOPO vector in saline 
conditions for 5 minutes at room temperature, according to the manufacturer’s 
instructions (Invitrogen TOP bacteria were transformed with 1 pL of either ligation mix 
using Ampicillin as a selection antibiotic (see ‘Bacterial transformation’ section).
1.2.3.3 Verification of cloning of p59HCK cDNA into the pCR® 2.1 -TOPO vector
Two microlitres of each p59HCK-pCR® 2.1-TOPO vector were digested in a mix of 2 pL 
of lOx buffer 2 digestion buffer, 1 pL of Kpnl restriction enzyme, 1 pL of Not I  restriction 
enzyme and 2 pL of lOx BSA, topped up with water to a final volume of 20 pL. 
Digestion mixes were incubated for 2h at 37°C and loaded on an agarose gel to assess for 
successful digestion and subsequent gel purification. All reagents for restriction digests 
were from New England Biolabs, Hitchen, UK.
1.2.3.4 Restriction of the pENTRlA-IRES-GFP shuttle vector and the p59HCK-pCR® 
2.1-TOPO cloning vector
One microgram of pENTRlA-IRES-GFP plasmid or 1 pg of p59HCK-pCR® 2.1-TOPO 
was digested in a mix of 5 pL of lOx buffer Eco digestion buffer and 1.5 pL of EcoRl 
restriction enzyme, topped up with water to a final volume of 50 pL. Digestion mixes 
were incubated for 2h at 37°C and loaded on an agarose gel to assess for successful 
digestion and subsequent gel purification. All reagents for restriction digests were from 
New England Biolabs, Hitchen, UK.
1.2.3.5 Ligation of the p59HCK fragment to the pENTRlA-IRES-GFP or pENTRlA- 
IRES-YFP shuttle vector
pENTRlA-IRES-GFP or pENTRlA-IRES-YFP shuttle vectors were ligated to the EcoRl 
restricted p59HCK fragment in a 1:1 and 1:2 molecular ratio. Ligation mixes of 50 ng of
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the 3846 bp backbone, 50 ng or 100 ng of the 1580 bp insert, 1 pL of T4 DNA ligase, 10 
pL of 2x Ligation buffer, topped up to 20 pL with RNAse and DNAse free water were 
incubated 5 min at RT then kept on ice until ready for transformation. DH5a bacteria 
were transformed with 2 pL of either ligation mix using Kanamycin as a selection 
antibiotic (see ‘Bacterial transformation’ section).
1.2.3.6 Verification of cloning of p59HCK cDNA into the pENTRl A-IRES-GFP or 
the pENTRl A-IRES-YFP shuttle vectors
Two microlitres of each p59HCK-pENTRl A-IRES-GFP plasmid were digested in a mix 
of 2 pL of 1 Ox buffer 4 digestion buffer, 1 pL of Xmal restriction enzyme and 2 pL of 
lOx BSA, topped up with water to a final volume of 20 pL. Digestion mixes were 
incubated for 2h at 37°C and loaded on an agarose gel to assess for successful digestion 
and subsequent gel purification. Two microlitres of each p59HCK-pENTRl A-IRES-YFP 
plasmid were digested in a mix of 2 pL of 1 Ox buffer 3 digestion buffer and 1 pL of 
BstXI restriction enzyme, topped up with water to a final volume of 20 pL. Digestion 
mixes were incubated for 2h at 55°C and loaded on an agarose gel to assess for 
successful digestion and subsequent gel purification. All reagents for restriction digests 
were from New England Biolabs, Hitchen, UK.
1.2.3.7 Gateway recombination of the pENTRl A-IRES-GFP or the pENTRl A-IRES- 
YFP plasmid with the LNT-Sffv-cddB-MCS lentiviral vector
p59HCK cDNA was transferred into the lentivirus vector LNT-SffV-cddB-MCS, a kind 
gift from Dr Adrian Thrasher (Demaison et al., 2002), by the Gateway cloning system 
(Invitrogen) which uses site-specific recombination properties of the bacteriophage 
lambda. One hundred and fifty nanograms of destination vector (lentiviral vector) and 
300 ng of the pENTRl A-HCK-IRES-GFP vector (or the pENTRl A-IRES-YFP vector) 
were incubated with 4 pL of 5x LR Clonase Reaction Buffer and 4 pL of LR Clonase 
Enzyme Mix in a final reaction volume of 20 pL. Reactions were incubated at 25°C for 1 
hour. 2 pL of Proteinase K solution were added to terminate the reaction and incubated at
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37°C for 10 min. XL-Gold bacteria were transformed with 2 pL of the recombination 
reaction using Ampicillin as a selection antibiotic (see ‘Bacterial transformation’ 
section).
1.2.3.8 Verification of cloning of p59HCK cDNA into the LNT-Sffv-cddB-MCS
lentiviral vector
One microgram of LNT-Sffv-p59HCK-IRES-GFP plasmid was digested in a mix of 2 pL 
of lOx buffer 4 digestion buffer, 1 pL of SacII restriction enzyme and 1 pL of Age I  
restriction enzyme, topped up with water to a final volume of 20 pL. Digestion mixes 
were incubated for 2h at 37°C and loaded on an agarose gel to assess for successful 
digestion and subsequent gel purification. All reagents for restriction digests were from 
New England Biolabs, Hitchen, UK.
1.2.4 Agarose gel electrophoresis and visualisation
DNA fragments were separated by agarose gel electrophoresis, using Flowgen or Horizon 
58 (Gibco) gel electrophoresis apparatus tank apparatus. Agarose gels were prepared by 
mixing 1 g - if looking at medium fragments (cloning into intermediary vectors) - or 2 g - 
if looking at small DNA fragments (cloning into lentiviral vectors) - of agarose powder 
(Life Technologies) to IX Tris-Acetate-EDTA (TAE) buffer. The 1 or 2 % Agarose 
solution was brought to the boil by microwaving and allowed to cool down. Upon 
cooling, ethidium bromide solution was added at a final concentration of 0.5 pg/mL to 
allow for the subsequent visualisation of DNA fragment. The warm agarose solution was 
poured into an electrophoresis chamber and an appropriately sized comb was inserted to 
shape the loading wells prior to letting the agarose gel solidify. DNA samples diluted in 
5x loading buffer and appropriate DNA size ladder (HyperLadder (Bioline) or lkb 
ladder- Invitrogen) were loaded into the wells and gels were electrophoresed at 100V for 
the appropriate length of time. DNA was visualised by transillumination with ultraviolet 
light and photographed as a permanent record.
116
Chapter II
1.2.5 DNA fragment purification
1.2.5.1 Agarose gel purification
Following agarose gel electrophoresis, restriction enzyme digest products of the 
appropriate size were excised using a clean scalpel with all efforts to keep exposure to 
UV light minimal. Qiagen Gel Purification Kit (Qiagen) was used to recover the digested 
DNA following manufacturer’s protocol. Final elution volume was 30 pL of RNAse and 
DNAse free water.
1.2.5.2 Column purification
One microgram of EcoRl restricted pENTRl A-IRES-GFP plasmid or the total volume of 
each dephosphorylation reaction was column purified according to manufacturer’s 
instructions to remove enzymes {EcoRl or CIP) from the reaction mixes. The purified 
DNA fragments were eluted in 30 pL of RNAse and DNAse free water.
1.2.6 Calf intestinal phosphatase (CIP) treatment
To prevent vectors cut with a single restriction enzyme from self-ligating, the restricted 
and gel purified vector was treated with CIP enzyme (New England Biolabs, Hitchen, 
UK) to remove the phosphate group from the 5’ overhangs. One unit of CIP/ pg of DNA 
was incubated with 1 pg of lentiviral vector DNA or 1 pg of pENTRl A-IRES-GFP for 
lh30 at 25°C in lx NEB buffer 3 in a final volume of 50 pL. CIP was inactivated by 
heating the mix to 70°C for 10 min. The dephosphoiylated lentiviral backbone was 
subsequently column purified according to manufacturer’s instructions.
1.2.7 Plasmid DNA sequencing
Each sequencing reaction was prepared by mixing 8 pL of BDT buffer containing
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labelled dNTPs, 200 ng of DNA and 3.2 pg of primer topped up to a final volume of 20 
pL. Amplification PCR was carried out using the progam described at the end of this 
paragraph at annealing temperature indicated in section 1.2.8, Table II.l. PCR products 
were purified using DyeEx 2.0 Spin Columns (Qiagen, Crawley, UK). Columns were 
vortexed to resuspend the matrix and then spun for 3 minutes at 750g. The sequencing 
PCR mix was then applied to the compacted column and again spun for 3 minutes at 
750g. The purified samples were then dried using a vacuum centrifuge (DNA Speed Vac, 
DNA120; Savant). Samples were run on the Prism 3730 as a service provided by CRUK. 
Sequence analysis was carried out by using the 4Peaks program 
(http://mekentosi .com/4 peaks A and the BLAST online program, for verification of 
sequence identity and detection of false negative results. The CLUSTALW online 
program was used for sequence alignment. Ml 3 forward and reverse primers were 
separately used to ensure the successful cloning of shHCK4 at an annealing temperature 
of 60°C. EmGFP forward sequencing primer was used to ensure the successful cloning 
and chaining of various combinations of miRNA 604, 605, 606 and 607 at an annealing 
temperature of 51°C.
Amplification PCR program for sequencing:
Step 1. Ramping by 2.5°C/sec to 96°C 
Step 2. 96°C for lmin 
Step 3. 96°C for 10 sec
Step 4.Ramping by l°C/sec to annealing temperature
Step 5. Annealing temperature for 5 min
Step 6. Ramping by 1°C/sec to 60°C
Step 7. 60°C for 4 min
Go to step 3, 24 times
End step. 12°C for ever.
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1.2.8 Primers used in this study
Quantitative real-time PCR primers
HCK F RT CATCATCGTGGTTGCCCTGTA
HCK R RT GCGGGCG AC AT AGTT GCTT
FgrF RT GAGG AGCCC AT CT AC AT CGT G
Fgr R RT CAGGGGTTGTACTCATCGTCC
FynF RT TGTGACCTCCATCCCCAACT
Fyn R RT AACT C AGGT CAT CTTCT GT CCGT
Hck F2 RT CATCATCGTGGTTGCCCTGTA
Hck R2 RT GCGGGCG AC AT AGTT GCTT
LckF RT C ACG AAGGT GGCGGT G AAG A
LckR RT G AAGGGGT CTTGAGAAAAT CCA
Lyn F RT G AGGCTCT ACGCT GT GGTC A
Lyn R RT GACTCGGAGACCAGAACATTAGC
Src F RT C AGTGT CT GACTT CGAC AACGC
Src R RT CC AT CGGCGT GTTT GG AGT A
Yes F RT GCT GC ACT GT ATGGT CGGTT
Yes R RT AGGGCACGGC ATCCTGT AT C
Sequencing primers Annealing temperature
HCK-RTf2 CATCATCGTGGTTGCCCTGTA 61
HCK-RTr2 GCGGGCGAC AT AGTT GCTT 64
HCK CTG CT GGGGGGGCGCT C AAGC 69
hckGCbox F AGAGGCTT AGAGGCGAGT GG 69
HCKseq 1 F TGGCAGTGAAGACGATGAAG 61
HCKseq 2 R AAGT C AGC AAT CTTAC AC AC 51
HCKseq 3 F T GAT GGAGAT CGT C ACCT ACG 62
IRESseq 1 F T GGCT CTCCT C AAGCGT ATT 61
GFPseq 2 F G AACTT C AGGGT C AGCTT GC 61
HCK ATG AT GGGGT GC AT G AAGT CC AAGT 66
HCK TCA T CAT GGCT GCT GTT GGT ACT G 63
EmGFP forward GGC AT GG ACG AGCT GT AC AA 61
Table II. 1: Primers used fo r  real-time quantitative PCR and sequencing PCR.
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1.3 Bacterial cultures
1.3.1 Bacterial transformation
Two microlitres of plasmid or ligation mix were transformed into 50 pL of chemically 
competent DH5a (Stratagene), XL-blue (Stratagene), XL-Gold (Stratagene) or TOP 10 
(Invitrogen) bacteria, according to manufacturer’s protocol. Briefly, DNA was incubated 
with the bacteria on ice for lh30; when dealing with XL-Gold bacteria, 2 pL p- 
mercaptoethanol was added per vial of cells and vials were tilted every 10 min during this 
30 min incubation. Bacteria were then heat shocked at 42°C for 30 seconds and 
immediately put back on ice for 2 min. Three hundred microlitres of warm SOC media 
was added to the cells dropwise and mixed by tilting the vial. Bacterial solutions were 
incubated at 37°C for lh  at 220 rpm. Two hundred and fifty microlitres of bacteria 
solution were plated onto LB agar plates containing the appropriate antibiotic and 
incubated overnight at 37°C. If pCR® 2.1-TOPO vector plasmids, which contain the P- 
galactosidase reporter gene, were used, X -gal (20 mg/mL) was spread onto the LB agar 
plates lh prior to bacteria plating, to allow for blue/white selection (white colonies are 
positive for the gene of interest). The next day, 10 colonies were picked from the plates 
and processed for adequately sized plasmid DNA preparation and glycerol stock 
preparation.
1.3.2 Plasmid preparation
Individual bacterial colonies were picked from LB agar plates using a 200/20 pL Gilson 
pipette non-filtered plastic tip and put to grow in 5 mL of LB broth supplemented with 50 
pg/mL of either ampicillin, spectinomycin or kanamycin in a 37°C shaking incubator.
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1.3.2.1 Miniprep
Plasmid recovery from small amounts of bacterial culture (4 mL) was carried out using 
QIAprep Spin Miniprep Kit (Qiagen) following manufacturer’s instructions. Final elution 
volume was 30 pL of RNAse and DNAse free water (Sigma). Alternatively minipreps 
were carried out on the Qiagen robot (miRNA chaining screening).
1.3.2.2 Maxiprep
For purification of up to 500 pg of transfection grade plasmid DNA, Qiagen Plasmid 
Maxi Kit was used, following manufacturer’s instructions.
1.3.2.3 Megaprep -  endotoxin free
For purification of up to 2.5 mg advanced transfection grade plasmid used in lentivirus 
production, Qiagen EndoFree Plasmid Mega Kit was used, following manufacturer’s 
instructions.
1.3.3 Glycerol stocks
Bacteria were stored at -80°C in 15% glycerol.
2. Biochemistry
2.1 Western blotting
2.1.1 Protein isolation
Pelleted cells were resuspended in 100-200 pL of the appropriate cell lysis buffer and 
incubated on ice for 30 minutes (see below for composition of lysis buffers). The cell
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lysate was cleared of cellular debris by centrifuging for 20 minutes at 20,000 g at 4°C. 
The supernatant containing the total proteins was collected and either frozen at -80°C or 
directly processed to measure protein concentration. Total protein concentration was 
determined using the Precision Red Advanced Protein Assay (Universal Biologicals, 
Cambridge) according to the manufacturer’s instructions: a standard curve was made by 
serially diluting commercial lyophilised bovine serum albumin (BSA, NEB) to 
concentrations ranging from 0 to 50 pg/mL in PBS. Samples were appropriately diluted 
(usually 1:10) and 10 pL of the standard and unknown samples were pipetted into a flat- 
bottomed 96 well plate. After adding 300 pL of reagent to the 10 pL of samples, optical 
density was read at 600 nm and cell lysate protein concentrations were determined via 
reading against the BSA standard curve.
2.1.2 Immunoprecipitation
For each sample to be studied, 30 pL of 50% protein A-Sepharose bead slurry (Roche) 
were mixed with 0.5 mL ice cold PBS containing 1 pg of the appropriate antibody 
(mouse anti-HCK, rabbit anti-HCK, goat anti-phosphoHCK Y411 or isotype control 
antibodies) and left to bind for lh at 4°C by tumbling the Eppendorf tubes end over end 
in a tube rotator set up at 8-10 rpm. In the meantime, each sample cell lysate was 
precleared by adding 30 pL of 50% protein A-Sepharose bead slurry (Roche) to a volume 
of cell lysate corresponding to 450 pg of total protein. Eppendorf tubes were tumbled end 
over end for 30 min at 4°C in a tube rotator set up at 8-10 rpm. In the meantime antibody- 
bound beads were washed three times by centrifuging the mix for 10 sec at 4°C at 16,000 
g, aspirating the supernatant (containing unbound antibodies) using a P I000 tip 
connected to a vacuum aspirator, adding 1 mL of ice cold lysis buffer, inverting the 
Eppendorf tube three or four times and centrifuging the tubes again. When processing 
numerous samples, tubes were kept on ice all along the washing procedure. Eppendorf 
tubes containing the preclearing cell lysates were centrifuged for 5 min at 4°C at 16,000 g 
and supernatants were transferred to individual tubes containing antibody-bound beads 
and 20 pL of 5% BSA. The latter mixtures were allowed to immunoprecipitate overnight
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by tumbling the Eppendorf tubes end over end at 4°C in a tube rotator set up at 8-10 rpm. 
Finally, immunoprecipitates were washed four times by centrifuging the mix for 10 sec at 
4°C at 16,000 g, aspirating the supernatant (containing unbound proteins) using a P I000 
tip connected to a vacuum aspirator, adding 1 mL of ice cold wash buffer, tumbling the 
Eppendorf tubes end over end in a tube rotator set up at 8-10 rpm for 5 min at 4°C by and 
centrifuging the tubes again. When processing numerous samples, tubes were kept on ice 
inbet ween washing steps. The fourth wash was done in ice cold PBS instead of wash 
buffer and the final product of settled beads containing the bound antigen were boiled in 
15 pL of 2x Lammeli sample buffer. Alternatively, the fourth and a fifth wash were done 
in lx kinase buffer, keeping the beads in a final volume of 25 pL of kinase buffer to 
process into the in vitro non radioactive kinase assay.
2.1.3 SDS-PAGE
Thirty micrograms of total protein per sample were mixed with an equivalent volume of 
2x sample loading buffer (see below for composition of the buffer) and proteins were 
denatured by boiling for 5 minutes at 95°C and then kept on ice until ready to load. Two 
Novex® Tris-Glycine 4-12% gels, 1 mm thick (Invitrogen), were assembled on an XCell 
SureLock® Mini-Cell system (Invitrogen) filled with running buffer (see below for 
composition of the buffer) according to the manufacturer’s instructions. Once loaded, the 
gels were run at 125V and proteins were separated by electrophoresis for approximately
2.5 hours. Full-range Rainbow and Prestained broad range molecular weight markers 
(Amersham and New England Biolabs) were run alongside the samples, to allow for the 
identification of bands.
2.1.4 Western blotting
Proteins were transferred from the gel to a Hybond-C nitrocellulose membrane 
(Amersham) using a semi-dry transfer system (Biorad) in lx transfer buffer (see below
123
Chapter II
for composition of the buffer) for 1.5h at 100 mA and 10V. The membranes were 
blocked with 30 mL 5% Marvel dry powder milk in TBST (see below for composition of 
the buffer) or for 5% BSA, 50 NM NaF in TBST when blocking for phospho specific 
detection, for 2 hours at room temperature, on a rocking shaker. Primary antibody was 
added at optimised dilutions to 15 mL blocking buffer and membranes were incubated 
overnight at 4°C on a rotating shaker. Rabbit anti-HCK antibody (N-30 Santa Cruz 
Biotechnology, Santa Cruz USA) and mouse anti-HCK antibody (clone 18 BD 
Bioscience) were used at 1:4,000 dilution. Goat anti-phospho-HCK antibody (Y411 Santa 
Cruz Biotechnology, Santa Cruz USA), rabbit anti-phospho-STAT5 Tyr694 antibody 
(Cl 1C5 Cell Signalling Technology) and goat anti-phospho-STATS Tyr694 antibody (sc- 
11761 Santa Cruz Biotechnology, Santa Cruz USA) were used at 1:500 dilution. The 
membranes were washed 5 times for 5 minutes with fresh TBST. Secondary antibody 
(1:4,000 dilution; Pierce Biotechnology) conjugated to horse radish peroxidase was 
added to 15 mL blocking buffer and membranes were incubated for 2 hours at room 
temperature, on a rocking shaker. The membranes were washed 4 times for 5 minutes 
with fresh TBST, followed by a final wash in TBS buffer. Specific protein detection was 
achieved by incubating each membrane for 1 min with 5 mL of ECL Plus 
chemoluminescent substrate (Amersham) and exposing them to films (Kodak, 
Switzerland) for various lengths of time. Films were developed using a Hoeffman 
automatic developer.
2.2 Flow cytometry
2.2.1 Cell cycle analysis by DAPI internal staining
Half a million cells for cell lines or 0.25x106 cells of Lin"/CD34+/CD38' were 
resuspended in 500 pL of PBS in a polystyrene 5 mL FACS tube (Falcon). 500 pL of 4% 
Paraformaldehyde (PFA; Sigma) equilibrated at room temperature was added to the cell 
suspension and cells were incubated for 10 minutes at RT (final concentration 2% PFA). 
Cells were washed by adding 4 mL of PBS and centrifuging them at 300 g for 7 minutes
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(low brake speed). Supernatant was aspirated and cells were resuspended in 500 pL of 
PBS. 500 pL of 0.2% Triton-XlOO was added to the cell suspension and cells were 
incubated at RT for 10 minutes (final concentration 0.1% Triton-XlOO). Cells were 
washed as described above with PBS 2% FCS and resuspended in 300 pL of PBS 2% 
PCS containing 1 pg/mL DAPI. After 20 min incubation in the dark, samples were 
processed for cell cycle analysis on LSRII analyser.
2.2.2 Apoptosis analysis by Annexin V external staining
Half a million cells were stained for Annexin V according to manufacturer’s instructions 
(BD Biosciences). Briefly, cells were washed with ice cold PBS by centrifuging them at 
300 g for 7 minutes (low brake speed). Cells were resuspended at lxlO6 cells/mL in lx 
ice cold Binding Buffer provided by the manufacturer. Five microlitres of Annexin V- 
Alexa 647 conjugated antibody and 0.2 pg DAPI were added to each sample, which were 
then incubated in the dark for 15 min. Two hundred microlitres of ice cold Binding 
Buffer were added to each sample, which were analysed on an LSRII analyzer.
2.2.3 HgCh treatment
Half a million cells were washed with PBS by centrifuging them at 300 g for 7 minutes 
(low brake speed) and resuspended in 1 mL of 0.5 mM HgCL. Cells were incubated for 5 
min at 37°C in a 5% CO2 incubator in a 5 mL polystyrene FACS tube. Cells were washed 
in PBS by centrifuging them at 300 g for 7 minutes (low brake speed). Pelleted cells were 
resuspended in 0.5 mL PBS and fixed by adding 0.5 mL of 4% Paraformaldehyde (PFA) 
dropwise and processed for staining for flow cytometry as described below. If cells were 
being treated for subsequent Western blot analysis, 3 million cells were washed with PBS 
by centrifuging them at 300 g for 7 minutes (low brake speed) and resuspended in 0.5 mL 
of pre-warmed culture medium. PP2 or SU6656 inhibitors were added to a final 
concentration of 5 or 10 pM and the cells were incubated for lh at 37°C in a 5% CO2
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incubator in a 24 well plate (Falcon). Cells were pelleted by centrifuging them at 300 g 
for 7 minutes (low brake speed) and resuspended in 2x Lammeli sample buffer.
2.2.4 PP2 or SU6656 treatments
Half a million cells were washed with PBS by centrifuging them at 300 g for 7 minutes 
(low brake speed) and resuspended in 1 mL of pre-warmed culture medium. PP2 or 
SU6656 inhibitors were added at a final concentration of 5 or 10 pM and the cells were 
incubated for lh at 37°C in a 5% CO2 incubator in a 5 mL polystyrene FACS tube. Cells 
were fixed by adding 1 mL of 4% Paraformaldehyde (PFA) dropwise and processed for 
staining for flow cytometry as described below. If cells were being treated for subsequent 
Western blot analysis, 3 million cells were washed with PBS by centrifuging them at 300 
g for 7 minutes (low brake) and resuspended in 0.5 mL of pre-warmed culture medium. 
PP2 or SU6656 inhibitors were added at a final concentration of 5 or 10 pM and the cells 
were incubated for lh at 37°C in a 5% CO2 incubator in 24 well plate (Falcon). Cells 
were pelleted by centrifuging them at 300 g for 7 minutes (low brake) and resuspended in 
2x Lammeli sample buffer.
2.2.5 Intracellular staining for flow cytometry (non-phospho-speciflc)
Between 0.25 and lx l0 6 cells (depending on the experiment) were resuspended in 500 
pL of PBS in a polystyrene 5 mL FACS tube, 500 pL of 4% Paraformaldehyde (PFA) 
equilibrated at room temperature was added to the cell suspension and cells were 
incubated for 10 minutes at RT (final concentration 2% PFA). Cells were washed by 
adding 4 mL of PBS and centrifuging them at 300 g for 7 minutes (low brake). 
Supernatant was aspirated and cells were resuspended in 500 pL of PBS. 500 pL of 0.2% 
Triton-XlOO was added to the cell suspension and cells were incubated at RT for 10 
minutes (final concentration 0.1% Triton-XlOO). Cells were washed twice, as described 
above, with PBS 2% FCS and resuspended in PBS 2% FCS and aliquoted as 50 pL per
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FACS tube (one tube per primary antibody needed). Primary antibody from a master mix 
was added to the cells to a final concentration of 1 jig /tube and incubated for 1 hour at 
RT. Cells were washed with PBS 2% FCS and resuspended in 50 jiL 2% FCS. Secondary 
antibody conjugated to a fluorochrome diluted 1:50 was added the cells from a master 
mix (corresponding to 2 pL per tube) and incubated at RT for 45 minutes in the dark. 
Cells were washed with PBS 2% FCS, resuspended in 300 pL PBS 2% FCS 1 mg/mL 
DAPI and analysed by flow cytometry (LSRII, BD Biosciences).
2.2.6 Intracellular staining for flow cytometry (phospho-specific)
Cells were resuspended at a concentration of lx l06/mL of OptiMEM 0.25% BSA in a 
polystyrene 5 mL FACS tube 15 min to 24h prior to staining. 1 mL of 4% 
Paraformaldehyde (PFA) equilibrated at 37°C was added dropwise, while vortexing, to 
the cell suspension and cells were incubated for 10 minutes at 37°C in a 5% C02 
incubator (final concentration 2% PFA). Cells were washed twice, first by centrifuging 
them at 300 g for 7 minutes (low brake) then by resuspending them in 1 mL PBS topped 
up to 5 mL and centrifuging at 300 g for 7 minutes (low brake). Supernatant was 
aspirated and cells were resuspended in 1 mL ice cold methanol added dropwise while 
vortexing. After 30 min incubation at 4°C, cells were washed twice, as described above, 
with PBS 5% BSA and resuspended in an appropriate volume of PBS 5% BSA, so that 
exactly 50 pL of cell suspension could be aliquoted per antibody needed. Fifty microlitres 
of primary antibody was added to the cells from a master mix to a final concentration of 1 
pg/tube (or 3 pL of directly conjugated antibody/tube) and incubated for 1 hour at RT 
(protected from light for directly conjugated antibodies). Cells were washed with PBS 
5% BSA and resuspended in 50 pL 5% BSA. If required, 50 pL of secondary antibody 
conjugated to a fluorochrome diluted 1:50 was added the cells from a master mix 
(corresponding to 2pL per tube) and incubated at RT for 45 minutes in the dark. Cells 
were washed with PBS 5% BSA, resuspended in 300 pL PBS 2% FCS 1 mg/mL DAPI 
and analysed by flow cytometry (LSRII, BD Biosciences).
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2.2.7 PhosphoFACS: signal transduction by flow cytometry
Cells were resuspended at a concentration of lx l06/mL of OptiMEM 0.25% BSA in a 
polystyrene 5 mL FACS tube 24h prior to proceeding for staining. Cells were stimulated 
with G-CSF, GM-CSF or IL-6 at a final concentration of 100 ng/mL for 30 min or lh. 
Celles were fixed by adding 1 mL of 4% Paraformaldehyde (PFA) equilibrated at 37°C 
dropwise while vortexing and processed for intracellular staining for flow cytometry.
2.2.8 Extracellular staining for phenotyping
Half a million cells were washed with PBS and resuspended in 50 pL of PBS containing 
2% FCS. Five microlitres of the appropriate directly conjugated antibodies were added to 
the 5 mL FACS tubes and the samples were incubated for 30 min at 4°C in the dark. 
Unbound antibodies were washed by centrifugation for 7 min at 300g, cells were 
resuspended in 300 pL PBS 2% FCS 1 mg/mL DAPI and analysed by flow cytometry 
(LSRII, BD Biosciences). Alternatively, cells were washed and processed for internal 
staining for flow cytometry. Flow cytometry analysis was conducted on a BD LSR II 
(BD Bioscience) using the Diva software (BD Biosciences). Subsequent analysis was 
performed with FlowJo software (Ashland USA). Lasers and bandpass filters required for 
analysis are listed in Table II.2. During analysis, the photomultiplier gains were set so 
that the background signal from the combined isotype control gave 1-5% positive cells in 
each collection channel. Compensation amounts were set according to the detected 
spectral overlap.
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Laser Bandpass Filter Fluorochrome
488nm (blue) 440/40
530/30
575/26
660/20
695/40
780/60
660/20
DAPI
FTTC
PE
633nm (red)
Topro-3
PerCP
PE-Cy7
APC
Table IL2: Laser and bandpass filters  u sed fo rflo w  cytometry analysis.
2.2.9 Labelling of HCK antibody and mouse isotype control with Alexa 647 
fluorochrome
Before proceeding to antibody labelling according to the manufacturer’s instructions 
(Invitrogen), anti-HCK antibody was concentrated at 1 mg/mL using the iCON™ 
Concentrator 7 mL/20K column according to the manufacturer’s instructions (Pierce). 
Briefly, 4 mL of Millipore treated water were added to the upper sample chamber and the 
column was pre-rinsed by centrifugation for 15 min at 2,000 g. The water was discarded 
and 1 mL of the appropriate antibody (mouse HCK sold by Santa Cruz at 250 pL/mL or 
mouse isotype control sold by BD) was added to the upper sample chamber. The column 
was centrifuged for 15 min at 2,000 g and the concentrated antibody was collected from 
the upper chamber. Antibody concentration was measured using a Nanodrop device and, 
if the concentration was near 1 mg/mL in a final volume of 100 pL, it was processed for 
Alexa 647 labelling.
A solution of 1M sodium bicarbonate was prepared according to manufacturer’s 
instructions (Invitrogen) and 10 pL of this solution were added to the 100 pL of 
concentrated antibody solution. The latter mixture was transferred to a tube containing a 
reactive dye provided by the manufacturer and the dye was dissolved by inversion. The 
labelling reaction was allowed to occur by incubating the vial for lh at room temperature, 
inverting it every 15 min. In the meantime, a resin bed was prepared for elution of the 
labelled antibody, by adding 1 mL of homogenised resin onto a spin column and allowing
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it to settle. Resin was added until the volume bed reached 1.5 mL and the column was 
allowed to drain into a 5 mL FACS tube by gravity. The spin column was positioned onto 
a collection tube and centrifuged for 3 min at 1,100 g. The resin buffer was discarded and 
the 100 pL of labelling antibodies were loaded onto the resin bed dropwise. The antibody 
solution was allowed to absorb into the resin bed and the column was placed onto a fresh 
collection tube. The tube was centrifuged for 5 min at 1,100 g and the antibody 
concentration and degree o f labelling were determined using a Nanodrop device. 
Labelled antibodies were stored protected from light at 4°C and a volume of antibody 
corresponding to 4 moles o f Alexa 647 was used for subsequent FACS staining.
2.2.10 Absolute cell count using counting beads
Cells were washed with PBS and resuspended in 300 pL PBS 2% FCS 1 mg/mL DAPI. 
Fifty microlitres of counting beads were added to each tube shortly prior to analysis by 
flow cytometry (LSRII, BD Bioscienees). Absolute number of cells originally present in 
the tube was calculated taking into account the original beads concentration indicated by 
the manufacturer (Invitrogen).
2.2.11 Antibodies used in this study
The following antibodies were used in external staining or internal staining for flow 
cytometry and for Western blots (Table II. 3).
Directely conjugated antibodies
CD marker Clone Isotype Conjugate
CD13 WM15 IgGl K PE
CD13 WM15 IgGl K APC
CD14 M5E2 IgG2aK APC
CD14 M5E2 IgG2ax PE-Cy7
CD15 HI98 IgMK PE
CD15 HI98 IgMK APC
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CD33 WM53 IgG|  K PE
CD33 WM53 IgG |K APC
CD33 P67.6 IgGl K PE-Cy7
CD34 8G12 IgGl  K PE
CD34 8G12 IgGl K PE-Cy7
CD38 HIT2 IgCn K PE
CD38 HB7 IgGl K PE-Cy7
Lineage cocktail Multiple Multiple FITC
(includes CD3, CD 14, 
CD 16, CD 19, CD20, 
CD56)______________
Phospho-STAT5 Y694 
Phospho-STAT3 Y705 
Phospho-ERK 
Phospho-c-Raf_______
_____________ Non-conjugated antibodies
Mouse HCK__________________________
Rabbit HCK*_________________________
Phospho-HCK Y 411 *__________________
STAT5***___________________________
STAT5
________________ Secondary antibodies________________
Anti-mouse HRP* or Alexa 647**____________________
Anti-rabbit HRP* or Alexa 647**_____________________
Anti-goat HRP* or Alexa 647**______________________
Table II.3: Antibodies and fluorochromes used in this study.
All antibodies were purchased from Beckton Dickinson (BD) Biosciences, Cowley, 
Oxford except for antibodies marked with asterisks: . * Santa Cruz. ** Molecular probes, 
Invitrogen. *** Cell Signalling Technology. In addition, isotype controls were purchased 
from BD Biosciences. The fluorochromes used are FITC = fluorescein isothiocyanate, 
PE = phycoerythrin, APC = allophycocyanin, PE-Cy7 = phycoerythrin-cyanin 7.
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2.3 In vitro non-radioactive kinase assay
Final volume of each kinase assay reaction is 50 jaL pipetted into a 384 well black plate, 
all pipetting was done at 4°C. An Antibody Beacon detection complex/substrate mix was 
prepared by mixing multiples of 18 pL of lx kinase buffer (containing freshly added 
DTT at a final concentration of 2 pM), 0.5 pL of Oregon Green 488 ligand, 0.5 pL of 
anti-phosphotyrosine antibody P-Tyr-100 and 1 pL of tyrosine kinase substrate 1. ATP 
mix was prepared by mixing multiple of 15 pL of lx kinase buffer and 0.74 pL of 100 
mM ATP.
Duplicate control sample mixes consisted of (i): ligand only control: 1 pL of Oregon 
Green 488 ligand into 99 pL of lx  kinase buffer to split in two; (ii) phospho-peptide 
control: 1 pL of Oregon Green 488 ligand, 1 pL of anti-phosphotyrosine antibody P-Tyr- 
100, 5 pL of control phospho-peptide into 93 pL of kinase buffer to split in two; (iii) no 
kinase control: 40 pL of Antibody Beacon detection complex/substrate mix, 50 pL of 
kinase buffer to split in two replicates ultimately topped up by 5 pL 5 mM ATP; (iv) no 
ATP control: 1 pL recombinant HCK (25ng) into 60 pL kinase buffer and 40 pL of 
Antibody Beacon detection complex/substrate mix to split in two; (v) no substrate 
control: 1 pL recombinant HCK (25 ng), 1 pL of Oregon Green 488 ligand, 1 pL of anti- 
phosphotyrosine antibody P-Tyr-100 into 88 pL kinase buffer to split in two replicates, 
ultimately topped up by 5 pL 5 mM ATP. The recombinant kinase control scale was 
prepared by adding 1 pL of recombinant HCK (Active Motif) to 50 pL of kinase buffer 
and serially diluting it 5 times. Forty microlitres of Antibody Beacon detection 
complex/substrate mix were added to each well, which was split in two replicates 
ultimately topped up by 5 pL of 5 mM ATP. Twenty-five microlitres of each 
immunoprecipitate were pipetted into a well using a cut P20 tip, topped up with 20 pL of 
Antibody Beacon detection complex/substrate mix and 5 pL of 5 mM ATP. When 
appropriate, diluted Src kinase inhibitor or DMSO was added at room temperature prior 
to the addition of ATP. Plates were read in a microplate reader (Perkin Elmer), using a 
485/530 nm filter, after a 45 or 50 min incubation period at room temperature in the 
chamber of the reader.
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3. Cell biology
3.1 Cell culture
3.1.1 Maintenance of adherent cells
SW28, JAR, 293T-HEK and HeLa cells were maintained in Dulbecco’s Modified Eagle’s 
Medium (DMEM, Gibco Invitrogen) high glucose, supplemented with 10% fetal calf 
serum (FCS, Gibco Invitrogen) and 1% penicillin/streptomycin (CRUK) in cell culture 
treated flasks (Falcon) in a 37°C 5% CO2 incubator. Cells were passaged when reaching 
80% confluency or whenever needed for performing experiments. To passage the cells, 
the media was removed from the cells by aspiration and the cells were washed with PBS. 
Trypsin (CRUK) was added to the cells and the flask was incubated for 5 minutes at 
37°C. FCS was added to stop the trypsin activity and cells were centrifuged for 7 minutes 
at 300 g with high brake applied. Cells were resuspended in media and counted on a 
haemocytometer. An appropriate number of cells were perpetuated in fresh media.
3.1.2 Maintenance of suspension cells
HL-60, NB4, Fujioka/P31, U937, THP1, K562, Jurkat, J6A, Kasumi-1 and KGla cells 
were maintained in RPMI 1640 medium with Glutamax (Gibco Invitrogen), 
supplemented with 10% fetal calf serum (FCS, Gibco Invitrogen) and 1% 
penicillin/streptomycin (CRUK) in cell culture treated flasks (Falcon) in a 37°C 5% CO2 
incubator. Mono-mac-6 cells were maintained in the same medium additionally 
supplemented with 1% non-essential amino acids, 1 mM sodium pyruvate and 9 pg/ml 
human insulin. Cells were maintained as 300,000 cells/mL and numerated every 3 days 
using Trypan blue exclusion in order to generate their growth curve.
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3.2 Stem cell enriched fraction purification
Stem cells were extracted from human umbilical cord blood. Informed consent was 
obtained from mothers awaiting caesarean section at the obstetric units of the Royal 
London Hospital, Whitechapel, London and the University College Hospital, Camden, 
London. Blood was extracted from the placenta and umbilical cords with a 20 mL syringe 
and immediately supplemented with heparin (Sigma Aldrich, Dorset, UK) to a final 
concentration of 1 mg/mL in 50 mL tubes. Tubes were transferred to the laboratory and 
stored overnight on a rocker at room temperature for extraction of stem cells on the next 
day.
3.2.1 Mononuclear cells preparation from umbilical cord blood by density 
centrifugation.
Fifteen miiilitres of Ficoll-Paque Plus (Amersham Biosciences UK Ltd, Little Chalfont, 
Buckinghamshire) were distributed into 50 ml tubes (Coming). Umbilical cord blood was 
diluted with PBS (one volume of blood for three volumes of PBS) and 35 mL of diluted 
blood were slowly layered onto the Ficoll-Paque Plus. The tubes were centrifuged at 
20°C for 30 minutes at 400 g with no brake applied. Pasteur pipettes (Fisher Scientific) 
were used to aspirate the mononuclear cells which form a layer at the interphase of serum 
and ficoll and mononuclear cells were pooled into fresh 50 mL tubes. The cells were 
diluted further with PBS (one volume of MNC for one volume of PBS) and centrifuged at 
4°C for 7 minutes at 300 g to better wash off the Ficoll-Paque Plus. Recovered MNC 
were resuspended in 5 mL of PBS with 2% FCS and contaminating red cells were lysed 
by adding 40 mL of ammonium chloride (Stem Cell Technologies, Meylan, France) and 
incubated at 4°C for 5 minutes. Lysis was inactivated by addition of 5 mL of FCS. Cells 
were centrifuged at 4°C for 7 minutes at 300 g and MNC were numerated using a 
haematocytometer and the Trypan blue exclusion method for assessing their viability. If 
more than 2x108 MNC were obtained, the cord blood sample was further processed by 
lineage depletion.
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3.2.2 Lineage depletion of normal haematopoietic tissue
Mononuclear cells isolated from human cord blood were depleted of cells expressing 
mature lineage antigens using the StemSep column system from Stem Cell Technologies
*T
(Meylan, France). Mononuclear cells were resuspended in PBS with 2% FCS as 7x10 
cells/mL. StemSep Human Hematopoietic Progenitor Cell Enrichment Cocktail (Stem 
Cell Technologies, Vancouver, Canada) was added at a concentration of 100 uL of 
cocktail per mL of cells in solution. This antibody cocktail, consisting of anti-CD2. CD3, 
CD 14, CD16, CD 19, CD24, CD56, CD66b, and anti-glycophorin A antibodies, was 
supplemented with the anti-CD41 antibody at a concentration of 10 uL of CD41 per mL 
of cells in solution. After 30 minutes at 4°C, 60 p,L of Magnetic Colloid (Stem Cell 
Technologies) per mL of cell suspension was added to the cell suspension. Cells were 
incubated for 30 minutes at 4°C. During this incuabation period, a StemSep Negative 
Selection Column (Stem Cell Technologies) was positioned within a magnetic field, 
primed with PBS and equilibrated with PBS with 2% FCS according to the 
manufacturer’s instructions. The cell suspension labelled with colloid was pumped 
through the column and Lineage negative (Lin') cells were eluted into a fresh 50 mL tube 
by washing with PBS containing 2% FCS. Lineage marker expressing cells positively 
labelled with the colloid remain trapped within the column, as long as they stay within 
the magnetic field. Lin' cells were centrifuged at 4°C for 7 minutes at 300 g, counted and 
frozen in FCS supplemented with 10% dimethyl-sulphoxide (DMSO, Sigma). The 
column, containing the lineage positive cells, was washed with 2% FCS and the cells 
were either discarded, or frozen down and used as control cells in staining experiments.
3.3 siRNA electroporation
One millilitre of pre-warmed cell line culture medium was aliquoted in a 24 well plate 
and kept in a 37°C 5% CO2 incubator until ready to use. The appropriate cell line was 
washed in PBS, numerated by Trypan blue exclusion and resuspended as lxlO6 cells/mL 
in pre-warmed growth medium. The cell solution was aliquoted in the appropriate
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number of electroporation cuvette and 1 pg of the appropriate siRNA was added to the 
cell suspension. Electroporation was undergone at 300 millivolts and 125 millifarradays 
for 3.3 milliseconds and 500 pL of the pre-warmed culture medium previously aliquoted 
in the 24 well plate was added to the cuvette immediately after electroporation. The 
whole volume of electroporated cell suspension was transferred to one well of the 24 well 
plate (final volume 1.5 mL). Samples were incubated for the appropriate amount of time 
(as indicated in the text) at 37°C 5% CChthen assessed for HCK silencing.
3.4 siRNA or miRNA nucleofection
Half a millilitre of Supplement was mixed with 2.25 mL of Nucleofactor solution R, V or 
C according to the manufacturer’s instructions (Amaxa) and was pre-warmed to 37°C. 
One millilitre of pre-warmed cell line culture medium was aliquoted in a 24 well plate 
and kept in a 37°C 5% CO2 incubator until ready to use. The appropriate cell line was 
washed in PBS, numerated by Trypan blue exclusion and aliquoted as lx l0 6 cells in 5 
mL polystyrene FACS tubes. Each aliquot was centrifuged and processed one by one for 
nucleofection: one given aliquot of lxlO6 cells was resuspended in 100 pL of the 
appropriate Nucleofactor solution, 1 pg of the appropriate siRNA or miRNA encoding 
plasmid was added to the cell suspension and mixed by gently tilting the FACS tube. The 
whole volume of cell suspension was transferred to a fresh nucleofection cuvette. The 
appropriate Nucleofactor program was selected and the cuvette was positioned in the 
Nucleofector chamber. Immediately after nucleofection, 500 pL of pre-warmed culture 
medium was added to the cuvette and the whole volume of nucleofected cell suspension 
was transferred to one well of the 24 well plate using the thin plastic Pasteur pipette 
provided by the manufacturer. The Nucleofactor device was reset to start position and the 
next sample was processed for nucleofection. Samples were incubated for 48h at 37°C 
5% CCbthen assessed for HCK silencing (siRNA) or GFP expression (miRNA).
136
Chapter II
3.5 Transient transfection of 293T-HEK cells
700,000 293T-HEK cells per well were plated into a 6 well plate. Twenty-four hours later 
cells were transfected with either 3 pg of lentiviral mock plasmid encoding GFP or 3 pg 
of lentiviral mock plasmid encoding YFP or 3 pg of lentiviral plasmid encoding either 
p59HCK-GFP or p59HCK-YFP. PEI was used as a transfection agent at a 1:2 ratio (6 pg 
of PEI for 3 pg of DNA). Cells from one well were left as a non-transfected sample, but 
still incubated with PEI as a control for PEI toxicity and basal endogenous level of HCK. 
PEI was first mixed into Opti-MEM medium by vortexing, as a master mix for all 
reactions, and allowed to sit for 5 min at room temperature. Appropriate amount of DNA 
was mixed into Opti-MEM for each construct. 75 pL of PEI solution and 75 pL of DNA 
solution were mixed together by vortexing and allowed to sit for 20 min at room 
temperature. 150 pL of PEI-DNA complex solution was then added dropwise to 293T- 
HEK cells acclimatised into 3 mL of Opti-MEM medium. After 5h incubation at 37°C 
5% CO2, transfection reaction medium was changed for fresh culture medium and cells 
were incubated for 48h. GFP expression could be detected 24h post transduction under a 
fluorescence microscope. Forty-eight hours post transduction cells were trypsinised, fixed 
with 2% PFA and processed for HCK and phospho-HCK Y411 internal staining.
3.6 Overexpression/ silencing of HCK in 293T-HEK cells
The experimental design of this experiment is summarised in Table 11.4. 700,000 293T- 
HEK cells per well were plated into a 6 well plate. Twenty-four hours later cells from 3 
wells were transfected with 3 pg of lentiviral plasmid encoding p59HCK-YFP and cells 
from 2 wells were transfected with 3 pg of lentiviral mock plasmid encoding YFP. PEI 
was used as a transfection agent at a 1:2 ratio (6 pg of PEI for 3 pg of DNA). Cells from 
one well were left as a non-transfected sample, but still incubated with PEI as a control 
for PEI toxicity and basal endogenous level of HCK. PEI was first mixed with Opti- 
MEM medium by vortexing, as a master mix for all reactions, and allowed to sit for 5 
min at room temperature. Appropriate amount of DNA was mixed with Opti-MEM, as
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two master mixes for transfection, with either p59HCK-YFP or YFP. 75 pL of PEI 
solution and 75 pL o f DNA solution were mixed together by vortexing and allowed to sit 
for 20 min at room temperature. 150 pL o f PEI-DNA complex solution was then added 
dropwise to 293T-HEK cells acclimatised into 3 mL of Opti-MEM medium. After 5h 
incubation at 37°C 5% CO2 , transfection reaction medium was changed for fresh culture 
medium and cells were incubated overnight. For HCK silencing to occur, one of the 3 
wells transfected with p59HCK-YFP was transduced with the pRLL-SIN-cPPT-shHCK4- 
PGK-eGFP-WPRE silencing lentivirus at MOI 10 (this combination will be called ‘HCK 
sh’), one of the 3 wells was transduced with the pRLL-SIN-cPPT-PGK-eGFP-WPRE 
mock lentivirus at MOI 10 (this combination will be called ‘HCK mock’) and the last of 
the 3 wells transfected with p59HCK-YFP was left as a non-transduced control (this 
combination will be called ‘HCK alone’). One o f the 2 wells transfected with YFP was 
transduced with the pRLL-SIN-cPPT-PGK-eGFP-WPRE mock lentivirus at MOI 10 (this 
combination will be called ‘YFP mock’). The other well was left as a non-transduced 
control (this combination will be called ‘YFP alone’). Appropriate amount o f virus was 
added to the 293T-HEK cells in 1 mL o f fresh culture medium. GFP expression could be 
observed 24h post transduction under a fluorescence microscope. Forty-eight hours post 
transduction (i.e. 72h post-transfection) cells were numerated and 150,000 293T-HEK 
cells were lysed with 350 pL of RLT buffer and frozen at -80°C for further RNA 
extraction. Left over cells were lysed with RIPA buffer and cell lysates were frozen at - 
80°C for subsequent analysis by Western-blot.
Well 1 W ell 2 Well 3 Well 4 Well 5 Well 6
Transfection p59HCK-YFP p59HCK-YFP p59HCK-YFP YFP YFP PEI only
Transduction shHCK4-GFP Mock GFP — Mock GFP — —
Name o f  the 
combination
HCK sh HCK mock HCK alone YFP mock
YFP
alone
293T
Table II. 4: Design o f the transient HCK overexpression/stable shHCK4 transduction 
experiment in 293T-HEK cells.
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3.7 Lentivirus production
3.7.1 293T-HEK cells transfection and lentivirus production
Lentiviruses used to transduce leukaemic cell lines or lineage depleted umbilical cord 
blood cells were produced by transient transfection of three plasmids into 293T cells. 
These three plasmids were the self-inactivating transfer vector plasmid containing the 
gene or shRNA of interest, a multi-deleted packaging plasmid and pMD.G, which 
provides the viral envelope 139. Each plasmid was produced in an endotoxin free system 
(Qiagen EndoFree Plasmid Mega Kit for the self-inactivating transfer vector plasmid 
containing the gene or shRNA of interest, Plasmid Factory for the pMD.G and the multi­
deleted packaging plasmid).
Two million 293T-HEK cells per flask were seeded in twenty-four 175cm2 flasks 4 days 
prior to transfection. A master mix corresponding to 100 pg of PEI per 5 mL of 
OptiMEM per flask was prepared, briefly vortexed and incubated for 5 min at RT. A 
master mix corresponding to 17.5 pg of the envelope plasmid, 32.5 pg of the packaging 
plasmid and 50 pg of the transfer vector plasmid in 5 mL OptiMEM per flask was 
prepared, added to the PEI suspension (final ratio 1:1), vortexed and incubated at room 
temperature for 20 minutes. Ten millilitres of the DNA plus PEI complexes were added 
to the cells, which were previously acclimatised in 15 mL of OptiMEM, resulting in a 
final volume of 25 mL. The cells were incubated at 37°C for 4 hours, after which the 
media was replaced with fresh supplemented DMEM culture medium. After 24 hours, the 
media was replaced with fresh media. Forty-eight hours post-transfection the medium 
was harvested and cleared of unattached cells and cellular debris by filtering through a 
0.45 run filter. Virus was concentrated by centrifuging for 4 hours at 19,000 g at 4°C in a 
Beckman ultracentrifuge. After centrifugation, the supernatant was removed and 100 pL 
StemSpan media (Stem Cell Technologies) was added to the pellet, which was left to 
dissolve on ice for 1 hour. The undissolved pellet was gently resuspended, taking great 
not to produce air bubbles, and the virus was aliquoted into 50 pL fractions, with 30 pL 
being saved for titration purposes. This harvesting and concentrating procedure was
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repeated the next two days (72h and 96h post transfection).
3.7.2 Lentivirus titration
To titre the virus, 50,000 HeLa cells were plated into each well of a 12 well tissue culture 
treated plate (Falcon) in a volume of 1 mL normal growth media. Serial dilutions of the 
virus ranging from 1/100 to 1/100,000 for each day were prepared and added to the cells. 
Seventy two hours post-transduction the cells were trypsinised, resuspended in 300 pL 
PBS 2% FCS and analysed for GFP expression by flow cytometry on a FACSCalibur 
(BD Bioscience, San Jose USA) using TOPRO-3 as a live/dead cells discriminatory dye 
(2 pL/tube). Virus titre was calculated based on percentage of GFP positive HeLa cells.
3.8 Viral transduction
3.8.1 Transduction of leukaemic cell lines
Fujioka/P31, U937 and Mono-mac-6 cells were aliquoted into 12 well flat bottom tissue 
culture plates at a final concentration of 0.3x106/mL (once the virus will be added) in 
their respective culture medium. Cells were transduced at multiplicity of infection (MOI) 
80, meaning that 80 virus particles were added for every cell. Cells were left to transduce 
overnight in a 37°C 5% CO2 incubator. The next day cells were washed by resuspending 
them in a final volume of 15 mL of growth medium and then resuspended in the same 
volume of fresh culture medium they were previously in.
3.8.2 Transduction of Lin'cells
Three wells of a flat bottom tissue culture 96 well plate were coated with 100 pL of 
retronectin (100 ng/mL, Takara) by incubating the plate lh at 37°C. After washing the
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wells twice with PBS, Lineage depleted cord blood mononuclear cells resuspended in 
StemSpan media (Stem Cell Technologies) supplemented with cytokines (50 ng/mL SCF, 
50 ng/mL FLT3-L, 10 ng/mL IL -6, 20 ng/mL TPO; PeproTech) were aliquoted into the 
wells at a final concentration of lx l0 6/mL (once the virus will be added). Lin' cells were 
aliquoted in triplicate for subsequent transduction with either (i) mock or (ii) 
silencing/overexpression lentivirus and for use as (iii) non-transduced control. Lin' cells 
were first left to activate at 37°C, 5% CO2 for 4 hours then transduced at multiplicity of 
infection (MOI) 80, meaning that 80 virus particles were added for every Lin' cell, by 
simple addition of the appropriate volume of virus already resuspended in StemSpan. 
Cells were left to transduce overnight in a 37°C 5% CO2 incubator. The next day cells 
were washed in PBS 2% FCS (washing each well with 5 volumes of 100 pL), counted 
and used immediately for in vitro assays.
3.9 XTT assay
Cells were plated at a density of 50,000 cells/100 pL in triplicate in four flat bottom 96 
well plates and incubated at 37°C, 5% CO2 for 24h, 48h or 96h. Fifty microlitres freshly 
mixed tetrazolium salt (XTT labelling reagent) and electron-coupling reagent were added 
to the wells of one plate 24h, 48h, 96h or immediately, after cell plating. XTT reagents 
containing plates were incubated for 2h at 37°C, 5% CO2 and formazan salt production 
was determined by measuring absorbance at 450 and 650 nm. Cell proliferation was 
represented as absorbance at 450 nm corrected by absorbance at 650 nm overtime.
3.10 Lin' ex vivo expansion
Equal numbers of mock transduced, shHCK4 transduced/ovHCK transduced or non- 
transduced Lin cells were resuspended in a final volume of 100 pL of StemSpan 
containing either 300 ng/mL SCF, 300 ng/mL Flt3-L and 20 ng/mL TPO (mediuml) or 
100 ng/mL SCF, 100 ng/mL Flt3-L and 20 ng/mL IL-6 (medium 3). Lin' cells were 
numerated every 3 days on an LSRII analyser using counting beads, an appropriate 
number of cells were used for various in vitro assay and unused equal number of cells
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were replated for each condition, adding fresh cytokines each time.
3.11 Myeloid differentiation culture
Lin" cells were resuspended in restricting myeloid differentiation medium (IMDM, 15% 
FCS, 20 ng/mL IL-3 and 20 ng/mL SCF (Barabe et al., 2007)) or in terminal granulocytic 
differentiation medium (IMDM, 20% FCS, 50 ng/mL G-CSF and 50 ng/mL SCF 
(Edvardsson et al., 2004)) at a final concentration of 20,000 cells/mL and seeded in 
triplicate. Lin" cells were maintained for 12 days, adding fresh cytokines every 3 days.
3.12 Erythroid differentiation culture
Lin" cells were resuspended in erythroid differentiation medium (100 ng/mL SCF, 5 
ng/mL IL-3, 3 IU/mL EPO, 1% BSA, 120 pg/mL iron-saturated human transferrin, 900 
ng/mL FeSCU, 90 ng/mL Fe(NC>3)3, 10 pg/mL insulin, 10"6 M hydrocortisone) 
(Giarratana et al., 2005) at a final concentration of 10,000 cells/mL and seeded in 
triplicate. Lin" cells were split 1:5 after 4 days in culture and cell differentiation was 
assessed by flow cytometry after 8 days in culture.
3.13 CFC assay
3.13.1 CFC for leukaemic cell lines with and without cytokines
Four thousand virally transduced and mock Fujioka/P31, U937 or Mono-mac-6 cells 
were added to 4 mL of H4330 MethoCult media (Stem Cell Technologies) supplemented 
with 1% penicillin/streptomycin. Cells and media were vortexed gently to ensure even 
distribution of cells throughout the viscous media. 1 mL of methylcellulose and cells 
mixture was dispersed into a 35 mm cell culture plate (Falcon) using a 1 mL syringe and
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blunt end needle. All samples were plated in triplicate and maintained in high humidity 
conditions. Plates were left for 14 days under normal growth conditions and then colonies 
were scored by visualisation under an inverted fluorescence microscope.
3.13.2 CFC for Lin'cells
Four thousand lentivirally transduced and control Lin' cells were added to 4 mL of H4434 
MethoCult media (Stem Cell Technologies) supplemented with 1% 
penicillin/streptomycin. Cells and media were vortexed gently to ensure even distribution 
of cells throughout the viscous media. 1 mL of methylcellulose and cells mixture was 
dispersed into a 35 mm cell culture plate (Falcon) using a 1 mL syringe and blunt end 
needle. All samples were plated in triplicate and maintained in high humidity conditions. 
Plates were left for 14 days under normal growth conditions and then colonies were 
scored by visualisation under an inverted fluorescence microscope.
Methylcellulose assays only allow us to infer the cell of origin and are therefore 
retrospective in nature. By observing the type of colony present, the cell of origin can be 
determined. More primitive cells are able to give rise to larger colonies of mixed cell 
types. Colonies are categorised based on the morphology of the cells. They can be 
assembled into the following 6 categories, BFU-E, CFU-E, CFU-GEMM, CFU-GM, 
CFU-G and CFU-M.
3.14 Transwell migration assay
3.14.1 Migration towards FCS
An appropriate number of 8 pm inserts for 24 well plate (Thinsert, Greiner Bio One) 
were coated with 100 pL fibronectin (20 pg/mL) overnight at 4°C. The next day, each 
insert was washed 3 times with PBS and kept in PBS until ready to use. An appropriate 
number of wells from a 24 well plate were filled with 600 pL of pre-warmed IMDM
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(Gibco) 0.25% BSA, adding 5% FCS (Gibco) when necessary. Triplicate wells were 
prepared for each sample and the plate was kept at 37°C, 5% CO2 in an incubator until 
ready to use. Fujioka/P31, U937 or Mono-mac-6 cells transduced with mock or shHCK4 
lentivirus or non-transduced were numerated and resuspended in pre-warmed serum free 
IMDM medium at a density of 6x105 cells/mL. One millilitre of each cell solution was 
then kept at 37°C, 5% CO2 in an incubator until ready to aliquot. One hundred and fifty 
microlitres of each cell solution were aliquoted in triplicate into an empty insert and the 
insert was transferred to a well containing serum free or serum supplemented IMDM, 
prepared previously. Plates were incubated for 4h30 at 37°C, 5% CO2 and cell migration 
was determined by counting the number of cells at the bottom of the well using counting 
beads (Invitrogen). To do so, after the 4h30 incubation, the total volume of each well was 
transferred to a 5 mL polystyrene FACS tube (Falcon) and the well was washed with 1 
mL PBS, also added to the tube. After centrifugation, the cells were resuspended in 300 
pL of PBS containing DAPI and 50 pL of counting beads were added just before 
proceeding with reading on an LSRII analyser.
3.14.2 Cytokine pre-stimulation prior to migration assay towards FCS
Transmigration inserts were coated and 24 well plates were prepared as described above. 
Mono-mac-6 cells transduced with mock or shHCK4 lentivirus or non-transduced were 
numerated and resuspended in pre-warmed IMDM medium at a density of 6x105 
cells/mL. One millilitre of each cell solution was then aliquoted in triplicate and 1 pL of 
G-CSF or GM-CSF (PeproTech; final concentration 100 ng/mL) was added to two of the 
aliquots. Cells were incubated at 37°C, 5% CO2 in the incubator for 15 min. The tubes 
were topped up with 4 mL PBS, centrifuged at room temperature for 7 minutes at 300g 
and pelleted cells were resuspended in pre-warmed serum free IMDM medium at a 
density of 6xl05 cells/mL. One hundred and fifty microlitres of each cell solution was 
aliquoted in triplicate into an empty insert and the insert was transferred to a well 
containing serum supplemented IMDM, prepared previously. Plates were incubated for 
4h30 at 37°C, 5% CO2 and cell migration was determined by counting the number of
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cells at the bottom of the well using counting beads (Invitrogen).
3.14.3 Chemotaxis assay
Transmigration inserts were coated as described above. . An appropriate number of wells 
from a 24 well plate were filled with 600 pL of pre-warmed IMDM (Gibco) 0.25% BSA, 
containing G-CSF, GM-CSF or both cytokines at a final concentration of 100 ng/mL. 
IMDM containing 5% FCS (Gibco) was used as a control. Triplicate wells were prepared 
for each sample and the plate was kept at 37°C, 5% CO2 in the incubator until ready to 
use. Mono-mac-6 cells were added in the upper part of the transwell, allowed to migrate 
and numerated as described above.
4. Storage of patient samples
Blood patient samples obtained by leukapheresis or venepuncture were collected with 
informed consent and stored in the Centre for Medical Oncology, John Vane Science 
Centre, Charterhouse Square, London. Samples arrived at the centre either in a solution 
of RPMI medium with heparin or in a solution of EDTA, to prevent clotting. Samples in 
EDTA were diluted with RPMI prior to processing. Whole mononuclear cells were 
enriched from the patient sample by density centrifugation. To this end, 5 mL of 
Lymphoprep (Axis-Shield PoC, Oslo, Norway) were added to 15 mL tubes (Coming, 
Sigma-Aldrich, Dorset, UK) and 10 mL of the patient blood sample were layered on top 
of the Lymphoprep with a plastic pipette. Tubes were then centrifuged at room 
temperature for 25 minutes at 400 g with no brake (using a Beckman GS6R centrifuge, 
Beckman Coulter, Fullerton, USA). The differentially centrifuged central layer of white 
blood cells was separated from the plasma and red blood cells by aspiration with a plastic 
Pasteur pipette. The collected white blood cells were further diluted with 10 mL of RPMI 
and the 15 mL collection tubes (Coming) were then centrifuged at 300 g for 10 minutes 
with high brake. The supernatant was discarded and the cells were resuspended in an 
appropriate amount of ice cold solution of RPMI and 10% DMSO added dropwise. Cells
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suspension was aliquoted in cryovials and stored in liquid nitrogen.
5. Solutions and recipes
Analytical or equivalent grade chemicals were obtained from Sigma,
UK or BDH, UK. All buffers and solutions used de -ionised water as the diluent and were 
sterilised by autoclaving or filtration as appropriate.
5.1 Electrophoresis
5.1.1 1 Ox TBE electrophoresis buffer (1L)
108g Tris base
55g boric acid
40mL 0.5 M EDTA, pH 8.0
Working stock = lx
5.1.2 Agarose gel electrophoresis loading buffer (1 Ox)
25mM EDTA 
50% glycerol (v/v)
0.25% bromophenol blue (w/v).
5.2 Western Blotting
5.2.1 Modified RIPA buffer (200 mL)
50 mM TrisHCl buffer pH 7.5 
150mM NaCl 
1% Nonidet P40 
1 mM EDTA
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0.3 mM activated sodium orthovanadate (Na3V0 4 ) 
50 mM sodium fluoride (NaF)
Protease inhibitors (Sigma)
5.2.2 Buffer A (100 mL)
50 mM Tris buffer pH 7.5 
1 mM EDTA 
1 mM EGTA
0.5 mM activated sodium orthovanadate (Na3V0 4 ) 
10 mM sodium P-glycerophosphate 
50 mM sodium fluoride (NaF)
5 mM sodium pyrophosphate 
1% Triton X-100
0.1% |3-mercaptoethanol 
Protease inhibitors (Sigma)
5.2.3 1 Ox Running Buffer (1L)
30g Trizma base 
144g Glycine 
lOg SDS 
120
pH to 8.5
Working stock = lx
5.2.4 Transfer Buffer (2L)
22.5 g glycine 
4.84 g Trizma base 
400 mL methanol
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5.2.5 IOx TBS(IL)
24.2g Trizma base 
80g sodium chloride 
pH to 7.6
Working stock = lx
5.2.6 TBST (2L)
200 mL lOx TBS 
10 mL 10% Tween
5.2.7 Blocking Solution for non-phospho Western Blot 
5% Marvel milk in TBST
5.2.8 Blocking Solution for phospho Western Blot 
5% BSA, 50 mM NaF in TBST
5.3 Bacteria Culture
5.3.1 LB -Broth 1 litre (CRUK)
15 g bacto -agar
Melt then cool to 50°C prior to addition of antibiotics. Pour into petri dishes 
and leave to set at room temperature in a laminar airflow hood. Dry plates in 
37°C incubator 2-3 hours before use.
5.3.2 X -gal
Stock solution 20 mg/ml. 0.2 g dissolved in 10 ml of N,N -Dimethylformamide. 
Filter, sterilise through a 0.4 pm filter and store at -20 °C.
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5.3.3 Ampicillin, Kanamycin and Spectinomycin
Stock solution 50 mg/ml. Filter, sterilise through a 0.4 pm filter and store at 
-20°C. Use at a final concentration of 0.05 mg/ml in media.
5.4 Miscellaneous
TE buffer pH 7.4 or pH 8.0
10 mM Tris -HC1 (pH titrated with 10 M NaOH)
1 mM EDTA pH 8.0
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III Microarrays LSC vs HSC
1. Preliminary work
1.1 Microarray set up
To try to understand what makes SCID-leukaemia initiating cells (SL-IC) different from 
SCID-repopulating cells (SRC) at the molecular level, a gene profiling study comparing 
Lin7CD347CD38‘ leukaemic/normal stem cell fractions and Lin'/CD34+/CD38+ 
leukaemic blast/early progenitor fractions using Affymetrix U133A oligonucleotide 
arrays was started. Fractions were sorted from (i) seven AML patient peripheral blood 
samples, (ii) three independent commercial normal bone marrow samples and (iii) two 
pooled umbilical cord blood (UCB) samples. Patients with a variety of karyotypes and 
FAB classes were intentionally chosen since the starting point of interest was to identify 
AML ‘leukaemic stem cell features’ regardless of the AML type {Figure III. I). Lin' 
/CD34+/CD38" and Lin'/CD34+/CD38+ fractions from patients and commercial bone 
marrow were isolated by three way fluorescence activated cell sorting (FACS) using anti- 
Lineage cocktail, anti-CD34 and anti-CD38 antibodies. An additional Ficoll-Paque™ 
gradient isolation step was performed before FACS for UCB. mRNA was extracted using 
Trizol® and cDNA was generated following Affymetrix recommendations.
Chapter III
Sample (MNC) FAB Karyotype
1 Ml Normal karyotype
2 M2 Normal karyotype
3 M4 3+, 10+
4 M4 Normal karyotype
5 M2 Normal karyotype
6 M2-tAML Complex
7 M2 t (8,21)
Controls:
* 2 (pooled) cord blood samples
• 3 independent commercial normal bone marrow samples 
Fieure I IL1: Samples used in microarray analysis.
FAB classification and karyotype o f the AML patient samples used in the microarray 
study. Pooled umbilical cord blood and bone marrow samples were used as controls.
After application of different statistical tests (t-test, etc...) and normalisations, microarray 
data could be studied in two different directions. Either by looking exclusively at AML 
data first, extracting genes differentially expressed between the available fractions and 
then comparing the expression of the identified genes to normal samples, or by 
comparing AML samples to normal samples fraction to fraction and then in between 
fractions.
1.2 First approach to microarray analysis
The first approach, taking into account only AML data (the ‘normal sample data’ were 
not available at that time), allowed the identification of 15 genes common to all 
leukaemic patients that were either up- or downregulated when comparing the leukaemic 
stem cell (Lin CD34f CD38') to both the leukaemic blast (Lin CD34+CD38+) and the bulk
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leukaemic mononuclear cell transcriptomes (Table 7/7.7). The expression of these 
selected genes was not varying between leukaemic blasts and MNC, suggesting that their 
level of expression was specific to LSC. However, when the expression of these genes 
was checked on microarrays of normal stem cell and progenitor fraction (cord blood 
and/or bone marrow), it was not significantly different between normal and leukaemic 
stem cells.
Genes exclusively upregulated in Lin'/CD34+/CD38' cells in comparison to MNC and 
Lin'/CD34+/CD38+ cells in all patient samples
TBC1D16
DRD2
NFKBIA
Patient 3 Patient 4 Patient 5 Patient 6 Patient 7
1.340
1.212
1.649
1.455
1.297
1.520
1.222
1.196
1.346
1.377
1.174
1.301
1.503
1.149
2.098
Genes exclusively downregulatec in Lin'/CD34+/CD38' cells in comparison to MNC and
Lin'/CD34+/CD38+cells in all patient samples
Patient 3 Patient 4 Patient 5 Patient 6 Patient 7
RACGAP1 -5.236 -1.715 -3.559 -3.344 -1.567
FLJ20485 -1.587 -1.988 -1.675 -2.028 -2.262
NUSAP1 -32.258 -5.556 -2.262 -2.688 -4.854
DLEU2 -1.828 -1.267 -2.141 -1.751 -1.351
FLJ10719 -2.732 -2.101 -2.183 -1.543 -1.890
MAC30 -4.132 -2.793 -1.527 -1.299 -1.553
RRM2 -5.076 -1.786 -3.774 -1.996 -2.770
TXNDC7 -3.425 -2.232 -1,610 -1.748 -1.876
ANP32E -1.905 -2.336 -1.692 -2.433 -2.451
RRM2 -5.102 -3.984 -6.098 -2.584 -6.024
PCNA -3.704 -3.650 -2.801 -2.070 -2.532
FABP5 -7.299 -2.132 -2.558 -2.045 -1.185
PRC1 -14.368 -2.445 -2.404 -1.555 -2.315
Table IIL1: Genes differentially expressed in Lin/CD34 /CD381 in comparison to 
MNC and Lin/CD34+/CD38+ in all patient samples.
Genes exclusively upregulated or downregulated in Lin/CD34/CD38' cells in 
comparison to MNC and Lin/CD34 VCD38+ cells in all patient samples.
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2. Fraction to fraction microarray analysis
Lists o f genes o f interest were generated using the Genespring software by applying two 
different statistical strategies. In each strategy five lists were generated: List 1 comparing 
Lin7CD34+/CD38' fraction from normal bone marrow (HSC) to Lin7CD34+/CD38‘ 
fraction from AML patients (LSC); List 2 comparing Lin'/CD34+/CD38+ fraction from 
normal bone marrow (early progenitors) to Lin'/CD34+/CD38+ fraction from AML 
patients (leukaemic blasts). Each list contains genes differentially expressed between the 
two given populations by at least two fold up or down using t-test statistics (Figure III. 2 
a). Using Venn diagram analysis Lists 3, 4 and 5 were obtained. List 3 corresponds to 
genes common to List 1 and 2, List 4 to genes unique to List 1 (differentially expressed 
only at the stem cell level) and List 5 to genes unique to List 2 (differentially expressed 
only in the Lin7CD34+/CD38+ compartment).
In strategy 1, the Lin7CD34+/CD38' fraction of either of the two bone marrow samples 
(BM1 and BM2) or the mean value o f the two bone marrow samples (mean BM) was 
compared pairwise to each o f the seven Lin /CD34+/CD38' AML fractions. The genes 
common to each o f these pairwise comparisons correspond to List 1. List 2 was obtained 
in the same way comparing Lin7CD34+/CD38t fractions (Figure III. 2 b, Strategy \). This 
strategy takes into account the variability introduced by the heterogeneity of the AML 
samples, 
a
List (T)
HSC
CD34+CD38-
2 fold
or LSC
CD34+CD38-
List (2)
Early C1 
progenitors 
CD34+CD38+ -
2 fold
or
Leukaemic
blasts
CD34+CD38+
List List
List
154
Chapter III
Strategy 1: comparing BM to each AML sample individually
2CB Mean BM 1 2 3 4 5 6 7
t  1 I t  t  t  t  t  t  t
2C B  B M  1 1 2  3 4  5 6  7 Y Common genes
t  1 i t  t  t  t  t  t  t 2 fold up or down
2C B  B M  2 1 2  3 4  5 6 7
t  1 i t  t  t  t  t  t  t
Strategy 2: comparing the mean value of BM to the mean value of 
the AML samples
Mean BM Mean AML samples => senes
4_________________ f  2 fold up
or down
c
Top 12, List 4, Strategy 1 Top 12, List 4, Strategy 2
HCK 2.649 to 47.71
CHS1 2.42 to 30.34
AKAP13 6.226 to 27,3
KYNU 3.05 to 24.31
MGC5395 4.278 to 16.77
FYB 2.206 to 17.78
AKAP13 4.36 to 12.51
ADD3 3.805 to 12.05
GAS7 2.3 to 11.85
ANKRD12 4.608 to 10.99
CAP350 3.567 to 10.90
TRIM38 2.32 to 9.816
HCK 23.95
GAS7 13.8
TYROBP 12.5
NBS1 9.89
unknown 6.00
NKTR 5.59
HIST2H2AA 5.49
SLC03A1 5.43
ZNF216 5.36
UCP2 5.31
ADD3 5.27
BRD2 5.17
Figure III.2: Two d ifferen t strategies to analyse the microarray data and identify genes 
differentially expressed between L S C  and  HSC,
(a) Generation o f lists o f  genes differentially expressed using the Genespring software: 
List 1: genes differentially expressed by two fo ld  up or down between Lin/CD34 VCD3S'
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fraction from normal bone marrow (HSC) and Lin/CD34+/CD38~ fraction from AML 
patients (LSC); List 2: genes differentially expressed by two fold up or down between Lin 
/CD34+/CD38+fraction from normal bone marrow and LinZCD34+/CD38+ fraction from 
AML patients; List 3: genes common to List I and 2; List 4: genes unique to List 1; List 
5: genes unique to List 2. (b) Two different statistical strategies to analyse the 
microarray data: Strategy 1, fraction (e.g. Lin'/CD34+/CD38') o f either o f the two bone 
marrow samples (BM1 and BM2) or the mean value o f  the two bone marrow samples 
(mean BM) was compared pairwise to each o f the seven AML fractions using t-test 
statistics. Strategy 2, fraction (e.g. Lin/CD34 /CD38' ) o f  the mean o f the two bone 
marrow samples (mean BM) was compared to the mean value o f the seven AML fractions 
(mean AML samples) using t-test statistics, (c) List o f  genes upregulated in Lin 
/CD 3 4 VCD 3 8" AML fractions in comparison to normal bone marrow: top 12 o f the genes 
upregulated in Lin/CD34 f  CD38' AML fractions generated by statistical strategies 1 or
2 .
In strategy 2, List 1 was generated comparing the Lin'/CD34+/CD38' fraction of the mean 
of the two bone marrow samples (mean BM) to the mean value of the seven Lin' 
/CD34+/CD38' AML fractions (mean AML samples). List 2 was generated comparing the 
Lin'/CD34+/CD38+ fraction of the mean of the two bone marrow samples (mean BM) to 
the mean value of the seven Lin'/CD34+/CD38+ AML fractions (mean AML samples) 
(Figure III. 2 b, Strategy 2). This strategy supports the search for leukaemic stem cell 
specific features independent of the AML subtype.
The two strategies show 50% genes in common, although not always falling in the same 
list (between Lists 3, 4 and 5). Nevertheless, by further investigating List 4 (genes 
differentially expressed between HSC and LSC only) from both strategies, we found that 
haematopoietic cell kinase (HCK) was the gene the most overexpressed in the Lin' 
/CD34+/CD38‘ fraction of the seven AML patients in comparison to normal bone marrow 
(Figure III. 2 c). We therefore decided to study a potential role for HCK in 
leukaemogenesis by either knocking it down in a leukaemic background (cell lines, then 
AML patient samples) or by overexpressing it in stem cells enriched Lin- umbilical cord 
blood cells.
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3. Confirmation of microarray data in stem cell patient samples (qPCR)
Prior to manipulating HCK expression, we confirmed the microarray data for the Lin' 
/CD34+/CD38‘ and the Lin'/CD34+/CD38+ fractions from six of the seven AML patients 
and the bone marrow samples used in the microarray analysis by quantitative real-time 
PCR using SYBR® green (Figure III. 3). Leftover quantities of the mRNA used in the 
microarray were run in duplicate in this experiment. GAPDH was used to normalise the 
values of mRNA expression.
HCK e x p r e s s i o n  in  p a t i e n t  f r a c t i o n s  o n  m ic r o a r r a y s  
( c o m p a r e d  to  b o n e  m a r r o w  f r a c t io n s )
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Figure III. 3: Confirmation o f  microarray data by quantitative real-time PCR.
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Top panel: Microarray data displayed as a histogram. Bottom panel: Quantitative real­
time PCR, using SYBR® green, run onto leftover RNA from the microarray experiment. 
GAPDH was used to normalise the values o f  mRNA expression. Stars indicate samples 
for which the PCR reaction was not run.
Both microarray and quantitative real-time PCR analysis showed the same trend of HCK 
being overexpressed in Lin/CD34+/CD38‘ of all 7 patient samples analysed, in 
comparison to normal bone marrow. HCK was also overexpressed in Lin7CD34+/CD38+ 
of all 7 patient samples analysed but since Lin'/CD34+/CD38+ from normal bone marrow 
express more HCK than Lin7CD34+/CD38', a decrease in HCK relative expression was 
observed between Lin7CD34/CD38" and Lin7CD34+/CD38+ fractions of each of the 7 
patient samples analysed and normal bone marrow.
Of note, when comparing AML sample fractions to umbilical cord blood (UCB) 
fractions, HCK was also overexpressed in Lin7CD34+/CD38‘ and Lin /CD34+/CD38+ 
fractions of each of the 6 patient samples analysed by quantitative real time PCR but 
since Lin7CD34+/CD38+ from normal UCB express less HCK than Lin /CD34+/CD38', 
an increase in HCK relative expression was observed between Lin7CD34+/CD38' and 
Lin /CD34+/CD38+ fractions in 4 out of 6 patient samples analysed by quantitative real 
time PCR (.Figure III. 4).
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HCK e x p re s s io n  In AML p a t ie n t  v s  u m b ilica l co rd  b lood  f ra c tio n s
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Figure III.4: Comparison o f HCK expression in patient sample fractions to HCK 
expression in UCB fractions by quantitative real-time PCR.
Quantitative real-time PCR, using SYBR® green, run onto leftover RNA from the 
microarray experiment. GAPDH was used to normalise the values o f mRNA expression. 
PCR was not run for patient 4 due to lack o f leftover RNA.
When comparing HCK expression in bulk MNC of the same patient samples to UCB 
MNC, HCK expression was higher in leukaemic MNC than in UCB MNC for the 2 
patients, patient 1 and patient 3, with very high expression o f HCK in Lin7CD34+/CD38' 
and Lin7CD34+/CD38+ fractions. HCK expression was lower in leukaemic MNC than in 
UCB MNC for all the other patient samples, which displayed 2 to 10 fold increased HCK 
expression in their Lin7CD34+/CD38‘ fraction in comparison to UCB fraction.
Analysis by other members o f the laboratory posterior to the beginning o f this study 
suggest that patient patients 1 and 3 are CD34' AML patients whose Lin7CD34+/CD38‘ 
most probably gives rise to normal multilineage engraftment (confirmed for patient 1).
159
Chapter III
4. Comments on genes well known to be involved in AML and their expression in 
the current microarray data set
When looking at expression of genes such as FLT3, RUNX1 or HOXA9 that have been 
clearly established as markers for AML, it is interesting to see that they were found 
differentially expressed only in the Lin'/CD34+/CD38+ fraction of all 7 AML patients 
studied in comparison to normal bone marrow and not in the Lin7CD34+/CD38* fractions 
{Table III 2).
Other genes, such as LYN, SHIP1, IL6R, SHIP2, STAT6, SOCS2, PTP-PEST, that could 
be part of a common pathway (as described in the introduction chapter) and have been 
implicated in AML or other leukaemias, are also found differentially expressed in the 
Lin'/CD34+/CD38+ fraction and not in the Lin7CD34+/CD38‘ fraction. PIAS1 that could 
belong to the same pathway is also differentially expressed, but has so far not been 
implicated in leukaemia. Genes such as F0X03A, LEF1 and GATA1 have been 
implicated in leukaemia and related to FLT3 and are also found differentially expressed 
in Lin*/CD34+/CD38+ and not in Lin7CD34+/CD38' fractions.
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Fold difference in 
Lin7CD34+/CD38+
Implication in AML
LYN 3.833 to 12.12 (Dos Santos et a l , 2008; Okamoto et a l , 2007)
SHIP1 3.79 to 5.949 (Biethahn et a l , 1999; Whitman et a l , 2008)
RUNX1 3.319 to 6.306 (Satoh et a l , 2008; Takahashi et a l, 2005)
PIAS1 3.193 to 5.07
FOX03A 3.138 to 5.655 (Brandts et a l, 2005)
FLT3 2.984 to 10.51 (Birg et a l , 1992; Bullinger et ah, 2008)
IL6R 2.335 to 6.194 (Denizot, 2000; Graf et ah, 2004)
SHIP2 2.272 to 3.126 (Bentires-Alj et ah, 2004; Konieczna et ah, 2008)
STAT6 2.004 to 2.972 (Bruns and Kaplan, 2006; Reddy et al, 2003)
GATA1 -3.086 to -2.38 (Greene et al, 2003; Kawamura et al, 2008)
HOXA9 -9.433 to 5.209 (Casas et a l, 2003; Kroon et ah, 2001)
SOCS2 -10.152 to -2.544 (Puigdecanet et al, 2008)
LEF1 -10.152 to -7.518 (Li et ah, 2004; Petropoulos et a l, 2008)
PTP-PEST -10.548 to -2.267 (Heinonen et a l , 2006)
Table IIL2: Genes differentially expressed in AML Lin/CD34¥/CD38* fraction in 
comparison to normal bone marrow and not in the AML Lin/CD34f/CD38 fraction in 
comparison to normal bone marrow belonging to the JAK-STATpathway and related 
pathways.
As mentioned in the introduction chapter, the Lin/CD34+/CD38+ fraction of normal UCB 
was initially thought to not contain HSC. However, this fraction has recently been 
reported to contain long-term engrafting cells when recipient mice are pre-treated with 
immunosuppressive anti-CD 122 antibody when looking at either normal (McKenzie et 
al, 2005) or leukaemic engraftment (Taussig et al., 2008). When looking at normal cells, 
the Lin7CD34+/CD38+ fraction probably consists of progenitors with a restricted self­
renewal capacity since it is incapable of giving rise to secondary transplants (Hogan et 
al, 2002). However such data on secondary engraftment are not yet available on AML 
samples. Since the engraftment of AML sample fractions seems to be highly variable 
from patient to patient, it would be interesting to test the quality of engraftment of the
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Lin7CD34+/CD38+ fraction of the patient samples tested in this study with anti-CD122 
conditioning and to then proceed to secondary transplantation. Such an experiment would 
allow for determining whether the LSC is located in the Lin/CD34+/CD38' fraction or in 
the Lin7CD34+/CD38+ fraction of these patients. Of note, LSC could possibly present in 
both fractions for a few of the patients since they were found to cluster together when 
analysing the microarray data as non-oriented cluster analysis. In addition, microarray 
data presented in Table III. 2 show that a few hallmarks of AML, such as FLT3, HOXA9 
and RUNX1, are overexpressed in the Lin7CD34+/CD38+ fraction reinforcing the idea 
that it could potentially be an LSC containing fraction for the patient samples studied 
here. An important amount of work on detailed patient sample engraftment quality 
therefore seems needed before being able to exploit the current microarray data set with 
certainty.
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IV Knocking-down HCK
As explained in the previous chapter, Haematopoietic cell kinase (HCK) was the gene 
found the most overexpressed in the Lin'/CD34+/CD38' fraction of the seven AML 
patient samples tested in our microarray data in comparison to normal bone marrow. We 
therefore decided to study a potential role for HCK in leukaemogenesis by either 
knocking it down in a leukaemic background or by overexpressing it in stem cells 
enriched Lin' umbilical cord blood cells. The approach we used to set up and study HCK 
knock-down will be described in this chapter.
1. HCK expression and activity in AML cell lines
1.1 HCK expression in various AML cell lines at the RNA level
Prior to knocking-down HCK, we needed to establish in which leukaemic cell line this 
kinase is expressed. Willman et al. described a high expression of the myeloid Src family 
kinases (SFK), HCK and FGR in FAB M4 and M5 AML blasts, a low expression of FGR 
and low expression or no expression of HCK in FAB Ml and M2 AML blasts and 
expression of only HCK in FAB M3 AML blasts (Willman et a l , 1991). Since the 
expression of HCK in that study was exclusively done by Nothem blot in patient 
samples, we were interested in knowing if we would obtain similar results by quantitative 
real-time PCR in AML cell lines. AML cell lines available in our laboratory correlated 
with the FAB classification and the haematopoietic tree are shown on Figure IV. 1. This 
schematic is only approximate since the FAB classification is based on morphological 
criteria rather than on phenotypical features.
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Figure IV.I: Correlation between the French-British-American (FAB) classification 
and the haematopoietic tree.
The FAB classification consists o f 8 subclasses (MO to M8). Based on their cell 
morphology, cell lines can be allocated to one o f these classes.
RNA was extracted from the HL-60, NB4, Fujioka/P31, U937, THP1, Kasumi-1, Mono- 
mac-6 and K G la AML cell lines as well as from the K562 CML cell line, the Jurkat and 
J6A T-cell leukaemia cell lines and the SW28 (colon adenocarcinoma) and JAR 
(choriocarcinoma) cell lines as controls. HCK and FGR expression were assessed by 
quantitative real-time PCR using SYBR* green and each quantitative real-time PCR 
reaction has been run in duplicate (Figure TV. 2). The experiment shown is representative 
of two distinct experiments. HCK or FGR expression were normalised to the expression 
of the housekeeping gene GAPDH and are expressed as 1/ACt for ease o f visualisation. 
Cell lines for which the original Ct values for HCK or FGR is 40 (no expression) are
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indicated above the histogram bar. Ct values for GAPDH varied between 16.08 and 17.77 
depending on the cell line.
HCK e x p r e s s i o n  In  v a r i o u s  c e l l  l i n e s
FG R e x p r e s s i o n  in  v a r i o u s  c e l l  l i n e s
Figure IV. 2: HCK and FGR expression in leukaemic and non-leukaemic cell lines at 
the RNA level.
HCK expression (top panel) and FGR expression (bottom panel) were assessed by 
quantitative real-time PCR using SYBR" green. AML cell lines HL-60, NB4, 
Fujioka/P31, U937, THP1, Kasumi-1, Mono-mac-6 and KG la  are shown in blue 
histogram bars. K562, Jurkat, J6A, SW28 and JAR non-AML cell lines are shown in dark 
blue histogram bars.
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As expected, the expression of both HCK and FGR increased with cell differentiation. 
Non-myeloid cells and undifferentiated AML cells did not express HCK (1/ACt < 0.051). 
FGR was not expressed in non-myeloid cells and was expressed at low level in T-cell 
leukaemic cell lines (1/ACt < 0.074). HCK and FGR were expressed at low levels in 
CML, FAB M2 and M3 AML cell lines and at high levels in FAB M5 AML cell lines. 
FGR data for NB4 M3 AML cell line are different from what was reported by Willman et 
al. Variations exist between cell lines from the same FAB class due to properties that 
cannot be defined based on the FAB classification, but overall HCK expression was the 
highest in monocytic FAB M5 cell lines.
1.2 HCK expression in FAB M2, M3 and M5 AML cell lines at the protein level
We went on to assess HCK expression in AML cell lines at the protein level. For 
appropriate comparison between Western blot and quantitative real-time PCR, fold 
change in HCK expression was calculated using the 2^‘AACt'1 method taking Jurkat cells as 
a calibrator cell line and GAPDH as an endogenous housekeeping gene reference (Livak 
and Schmittgen, 2001). As seen in Figure IV.3 a, HL-60 cells express 54.3 times more 
HCK than Jurkat cells and NB4 and Mono-mac-6 cells express 92.4 and 4196 fold more 
HCK than Jurkat cells respectively. When comparing myeloid cells between themselves, 
NB4 cells express 1.7 fold more HCK than HL-60 cells and Mono-mac-6 cells express
77.3 times more HCK than HL-60 cells.
To appraise if knocking-down HCK in UCB Lin'would ultimately be worth pursuing, we 
also compared the level of HCK expression in Lin' to the potential cell lines to be used 
for setting up the knock-down. UCB Lin- expressed 667 fold more HCK than Jurkat cells 
what was considered a reasonable level to work with subsequently.
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Fisure I V. 3 : HCK expression in HL-60, NB4 and Mono-mac-6 by quantitative real 
time PCR and by Western blot.
(a) HCK expression in HL-60, NB4, Mono-mac-6, Jurkat and Lin cells, assessed by 
quantitative real-time PCR using SYBR * green, taking Jurkat cells as a calibrator cell 
line and GAPDH as an endogenous housekeeping gene reference, (b) HCK expression 
assessed by Western blot in HL-60, NB4, Mono-mac-6 cells. /3-actin was used as a 
loading control, (c) Western blot band quantification using the Image J software 
expressed as percentage o f  HCK expression in HL-60 cells.
To assess HCK expression in AML cell lines at the protein level, cells were lysed with 
RIPA buffer and proteins were separated by SDS-PAGE electrophoresis followed by 
Western blotting. Figure IV. 3 b shows a faint expression o f p61 and p59 HCK isoforms 
in HL-60 and NB4 cells while Mono-mac-6 cells highly express both HCK isoforms. P-
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actin was used as a loading control. Band quantification using the Image J software 
{Figure IV 3 c) indicates that NB4 cells express 1.75 more HCK than HL-60 cells and 
Mono-mac-6 cells express 27.34 fold more HCK protein than HL-60 cells. The blot 
presented here is representative of two distinct experiments.
Quantitative real-time PCR and Western blotting results are somewhat differing 
concerning high levels of HCK expression. This might be due to a better sensitivity of 
real-time PCR in comparison to Western blot quantification or to the effect of some post- 
translational degradation where all HCK mRNA would not be translated into protein. 
Since the trend in HCK expression is similar between the two methods (with FAB M5 
cell line expressing a lot more HCK than the FAB M2 and FAB M3 cell lines), we did 
not investigate this discrepancy any further.
Since we ultimately want to work with stem cells coming from UCB Lin" cells and each 
UCB collection does not allow for the isolation of a number of Lin" cells compatible with 
detection of protein expression via Western blot, we needed to establish an appropriate 
readout of HCK expression using flow cytometry. Of note, the size of a UCB collection 
varies between 60 and 100 mL from which we can approximately obtain 15,000-20,000 
Lin' cells/mL, so we therefore usually obtain a maximun of 2xl06 Lin" cells per 
collection. CD34+/CD38" HSC represent 5 to 10 % of Lin" cells, i.e 2,000 HSC/mL of 
UCB. HSC can thus only be phenotypically studied by flow cytometry.
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Figure IV. 4: HCK expression assessed by flow  cytometry.
Cells were fixed, permeabilised and stained using the same mouse monoclonal antibody 
as the one used for Western blot, followed by secondary staining with a FITC-conjugated 
secondary antibody, (a) HCK expression in Jurkat (black histogram), HL-60 (orange 
histogram), NB4 (blue histogram) and Mono-mac-6 (red histogram) cells assessed by 
flow cytometry, (b) Quantification o f  the fluorescent signal expressed as percentage of 
the Jurkat cells signal’s mean fluorescence intensity (MFI). (c) HCK expression in 
Jurkat, HL-60, NB4 and Mono-mac-6 cells (blue histogram) compared to a matching 
isotype control (grey histogram).
HCK internal staining using the same mouse monoclonal antibody as the one used for 
Western blot, followed by secondary staining with a FITC-conjugated secondary 
antibody, successfully allowed the detection of HCK in HL-60, NB4 and Mono-mac-6 
cells (Figure IV. 4 a). However, when comparing the mean fluorescence intensity (MFI) 
of each of these three cell lines to the MFI o f Jurkat cells, differences in HCK level of 
expression were very different from the ones measured by quantitative real time PCR:
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when quantified by flow cytometry, HL-60 express 1.73 fold more HCK than Jurkat 
cells, NB4 and Mono-mac-6 cells express 1.82 and 8 fold more HCK than Jurkat cells 
respectively (Figure IV. 4 b). The FACS plots shown are representative of two distinct 
experiments. Flow cytometry seems to be less sensitive than quantitative real-time PCR 
or Western blotting but show results following the same trend. It is therefore appropriate 
to use instead of Western blotting. When measuring protein expression by FACS, it is 
actually appropriate to use a mouse purified isotype control antibody as a background 
non-specific staining to allow for comparison between different cell lines (in a similar but 
less sensitive way to using a housekeeping gene as a reference in real-time PCR). 
Unfortunately isotype control staining gave a higher background signal than the HCK 
signal itself in HL-60, NB4 and Jurkat cells, indicating that mouse IgGl isotype control 
cannot be used as a reference when staining with the mouse anti-HCK antibody in these 
cells. Flow cytometry might not be appropriate to detect low levels of HCK in HL-60 and 
NB4 cells {Figure IV. 4 c). The later cell lines were therefore not used to establish HCK 
knock-down.
1.3 HCK activity in M5 AML cell lines
1.3.1 In vitro kinase assay
Once knowing that Mono-mac-6 or any FAB M5 AML cell lines can be a good cell line 
to establish HCK knock-down, we needed to validate a way of accessing any changes in 
HCK kinase activity. A classical way to detect changes in kinase activity is to proceed to 
an in vitro kinase assay. Such assays can be done based on the incorporation of 
radioactive ATP or based on the displacement and unquenching of a fluorescent ligand in 
a non-radioactive way. We decided to proceed with the latter method using the Antibody 
Beacon™ Tyrosine Kinase Assay Kit (Invitrogen). Since this kit is originally meant to 
work with recombinant kinases, we needed to validate it for HCK immunoprecipitated 
from cell lysate.
171
Chapter IV
HCK was immunoprecipitated overnight from KG la, Fujioka/P31, U937 and Mono-mac- 
6 cells lysed with buffer A, using either rabbit anti-HCK antibody (Figure IV.5 a) or a 
mouse anti-HCK antibody. Immunoprecipitation controls were also set up using a 
matching rabbit or mouse IgGl isotype control and the KG la  cell line, not expressing 
HCK, was used as a negative control for the kinase assay. Cells need to be lysed in buffer 
A in order to proceed with the in vitro kinase assay in the kinase buffer provided in the 
kit (MOPS based). Immunoprecipitates were either resolved by Western blotting {Figure 
IV.5 a) or pipetted into a well o f a black 394 well plate and subjected to kinase assay 
according to the manufacturer’s instructions.
The Antibody Beacon1 M Tyrosine Kinase Assay Kit is based on the following principle: 
when no phosphotyrosine containing specific sequence (specific phosphopeptide or 
tyrosine kinase specific phosphorylated substrate) is in the environment, the Oregon 
Green 488 ligand binds to the phospho-specific antibody provided in the kit and is 
quenched. When a phosphorylated substrate is in the environment it binds to the 
phospho-specific antibody with a higher affinity than the Oregon Green 488 ligand and 
displaces it. In this case, the Oregon Green 488 ligand is not quenched anymore and 
emits fluorescence that can be read at 530 nm. The intensity o f fluorescence is 
proportional to the kinase activity {Figure IV  5 b).
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Figure I V. 5: Assessment o f HCK kinase activity by in vitro non-radioactive kinase 
assay.
(a) Qualitative validation o f HCK immunoprecipitation in KGla, Fujioka/P31, U937 and 
Mono-mac-6 cell lines lysed with buffer A, using a rabbit anti-HCK antibody or matching 
rabbit isotype control for immunoprecipitation and a mouse anti-HCK antibody for 
immunoblotting. (b) Principle o f action o f the Antibody Beacon™ Tyrosine Kinase Assay 
Kit. (c) No substrate, no ATP, no kinase, phospho-peptide and Oregon Green 488 ligand 
only controls, (d) Serial dilution o f commercial recombinant purified HCK used as 
control. The green curve shows the kinase activity after 20 minutes incubation at RTand 
the blue curve shows the kinase activity after 45 minutes incubation at RT. (ej Specific 
HCK activity corresponding to immunoprecipitation o f450 mg of total protein lysate.
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No substrate, no ATP and no kinase controls were run in parallel to unknown samples, 
these controls indicate the baseline for which an unknown sample is negative {Figure 
IV. 5 c). No substrate and no ATP controls are set up with the commercial recombinant 
HCK kinase. In each of these three controls the phosphorylation reaction cannot take 
place, the Oregon Green 488 ligand therefore stays quenched and does not fluoresce. The 
phosphopeptide control is a positive control corresponding to an arbitrary volume of 3 pL 
of the provided phosphopeptide. The Oregon Green 488 ligand only control corresponds 
to the maximum fluorescence intensity that can be reached in these settings, since no 
antibody is in the well to quench the ligand. A serial dilution of commercial recombinant 
HCK was also run in parallel to unknown samples to ensure proper unwinding of the 
phosphorylation reaction (Figure IV  5 d).
Quantification of the amount of HCK protein present in any cell lysate is possible by 
using the serially diluted recombinant HCK as a standard curve. However, further tuning 
of the amount of recombinant HCK and total cell lysates to be run would have to be done 
since using the current settings of the experiments, recombinant HCK is saturated after 45 
min incubation {Figure IV  5 d, blue curve) while sample lysates display a too low kinase 
activity after 20 min incubation to be read against the standard curve and quantified 
{Figure IV 5 d, green curve and data not shown). The kit was therefore used in a 
qualitative way only. Figure IV  5 e shows that HCK immunoprecipitated from 
Fujioka/P31, U937 or Mono-mac-6 cell lysates is active and validates the use of the 
Antibody Beacon™ Tyrosine Kinase Assay Kit with cell lysates. This experiment is 
representative of four distinct experiments where HCK was immunoprecipitated with 
either a mouse or a rabbit anti-HCK antibody. Both antibodies give similar results and do 
not give any non-specific signal in the HCK negative KG la  cell line.
1.3.2 Set up of phospho-specific flow cytometry using SFK inhibitors
Since we ultimately wanted to work with stem cells coming from UCB Lin' cells and 
limited number of cells does not allow for immunoprecipitation, we needed to establish
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an appropriate readout for variation in HCK kinase activity in stem cells using flow 
cytometry.
As described previously in the introduction chapter, HCK is fully active when 
phosphorylated on the tyrosine Y 411 in its activation loop. We therefore tried to set up an 
intracellular staining to detect phospho-HCK by flow cytometry. Mercuric chloride 
(HgC12) which is known to activate SFK (Robbins et al., 2000) was used as a positive 
control and 10 p,M PP2, a SFK specific inhibitor, was used as a negative control. Since 
PP2 is resuspended in DMSO, DMSO was used as an internal control for the phospho- 
specific staining with anti-Y411 antibody (.Figure IV 6 a). Quantification of the signal 
intensity using a matching goat isotype control and taking non-treated Mono-mac-6 cells 
as a reference shows a 1.8 fold increase in HCK Y411 phosphorylation upon HgC12 
treatment and a 2 fold decrease following PP2 treatment (Figure IV.6 b). However, no 
difference is seen between PP2 treated and DMSO treated cells, indicating the possibility 
o f a non-specific signal. Although 10 ^M is a commonly used dose o f PP2 (Dos Santos et 
al., 2008; Meyn et al., 2005), we tried to assess if  any other dose of PP2 could give a 
change in signal intensity. Although a certain dose effect was observed when incubating 
the cells with 5, 10 or 20 p,M of PP2, the effect was once again the same when an 
equivalent volume of DMSO was added to the cells {Figure IV. 6 c). We decided to test 
another SFK inhibitor with a broader spectrum, SU6656 (Blake et al., 2000; Meyn et al., 
2005), however, a similar dose effect between SU6656 and DMSO was observed as well 
{Figure IV. 6 d). Each experiment shown is representative of two experiments.
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Fieure IV. 6: Set up o f phosp/to-speciflc flow  cytometry using anti-HCK Y411 goat 
antibody.
(a) Anti HCK-Y411 flow cytometry. Mercuric chloride is used as a positive control, PP2 
as a negative control, DMSO as an internal control, (b) Quantification of the signal 
observed in (a), (c) Dose effect o f PP2 on HCK Y411 phosphorylation. (d) Dose effect of 
SU6656 on HCK Y41I phosphorylation.
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1.3.3 Retrospective validation of phospho-specific antibody by Western blot
To assess if the inconsistent results observed when treating Mono-mac-6 cells with PP2 
or SU6656 and DMSO were due to the phospho-specific antibody anti-Y411 or due to the 
cells being refractory to the inhibitor, we went back to testing the antibody by Western 
blot. When tested on whole cell lysate, the goat anti-Y411 antibody gives a very high 
background {Figure IV. 7 a). Western blotting of Mono-mac-6 cells incubated with 5 or 
10 pM of PP2 or SU6656 or corresponding equivalent volume of DMSO with anti-HCK 
Y411 antibody confirms the flow cytometry results {Figure IV. 7 a and b). KG la  cells are 
taken as a negative control for phosphorylated HCK since they do not express HCK. 
When blotting modified RIP A buffer cell lysates with anti-HCK Y411 goat antibody, 
only the small isoform of HCK (p59HCK) seems to be phosphorylated {Figure IV  7 a, 
top panel). Stripping and reprobing the blot with anti-total HCK rabbit antibody (Figure 
IV.7 a, bottom panel), allowed for the putative localisation of the bands corresponding to 
the two isoforms of HCK (indicated by stars). This blot also confirms that HCK is not 
expressed in KG la  cells.
Duplicate Western blot immunoblotted with pan-Src Y416 antibody confirms that the 
current results are due to a possible resistance of the cells to the inhibitor {Figure IV. 7 b). 
Both sets of blots on Figure IV.7 a and b are representative of two experiments.
To make sure that anti-Y411 antibody is actually phospho-specific, we tested it on cells 
treated with shrimp alkaline phosphatase (SAP), taking HgCl2 treated cells as a positive 
control, Figure IV.7 c confirms the phospho-specificity of anti-Y411. On this blot again 
only p59HCK seem to be phosphorylated. Since the cells have not been stimulated in any 
way, we can actually hypothesise that in Mono-mac-6 p59HCK is constitutively active 
while p61HCK is not and therefore not detected with the current settings. We can 
however not rule out that p61HCK in the cells is active but simply not in a fully active 
conformation where Y411 is phosphorylated and detectable by the antibody (see figure 
2.5 in the introduction chapter for the different possible active conformation of HCK).
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Figure IV. 7: Validation o f the phospho-specific anti-HCK Y411 antibody by Western 
blot.
Mono-mac-6 and KG la cells were treated with different doses o f PP2 or SU6656 SFK 
inhibitor, (a) Whole cell lysate probed with a phospho-specific goat anti-HCK Y411 
antibody, stripped and probed with a rabbit anti- whole HCK antibody, (b) Whole cell 
lysate probed with a phospho-specific rabbit anti-pan-SRC Y416 antibody; stripped and 
probed with a mouse anti-whole HCK antibody, (c) Mono-mac-6 cells were treated with
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5fj.M PP2, HgCh or shrimp alkaline phosphatase (SAP). Western blot was probed with a 
phospho-specific rabbit anti-pan-SRC Y416 antibody, (d) HCK was immunoprecipitated, 
using a mouse anti-whole HCK antibody, from Fujioka/P31, U937, Mono-mac-6 or 
293T-HEK cells (overexpressing HCK) lysed in buffer A. ATP was added to the cell 
lysates or lysates were left untreated. Western blot was probed with a phospho-specific 
goat anti-HCK Y411 antibody, stripped and reprobed with a rabbit anti- whole HCK 
antibody.
To definitely confirm the proper binding of anti-Y411 antibody to phosphorylated HCK, 
we immunoprecipitated HCK from cells lysed with buffer A (in the same way as what 
was done for the in vitro kinase assay) using a mouse anti-HCK antibody. 
Immunocomplexes were washed with kinase buffer and ATP was added as a positive 
control. Immunoprecipitation using a matching mouse IgGl isotype control was used as a 
negative control. When immunoprecipitating from cell lysates prior to Western blotting, 
both phosphorylated isoforms of HCK are detected. Of note, incubation of the 
immunocomplex with ATP shows a higher level of phosphorylation corresponding to 
autophosphorylation in trans {Figure IV.7 d, top panel). 293T-HEK cells overexpressing 
p59HCK were also used as a positive control (see description of their establishment in 
Chapter VIII). Immunoprecipitation using a rabbit HCK antibody gives similar results 
(data not shown).
Thus we confirmed that anti-Y411 is specific when used on an immunoprecipitated HCK 
but otherwise gives a high background, which has to be taken into account when 
interpreting flow cytometry results. Although the background unspecific signal in flow 
cytometry might be similar to the background seen on Western blot from whole cell 
lysates, the HCK epitopes accessible to the anti-Y411 antibody in cells fixed and 
permeabilised in PFA and methanol are most probably in a different conformation from 
when the cells have been lysed and the protein lysate has been run on a Western blot.
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1.3.4 Verification of the pharmacological activity of the PP2 inhibitor in use
To make sure that the PP2 inhibitor we were using had a pharmacological effect on HCK, 
we added 10 pM PP2 into the non-radioactive kinase just prior to the addition of ATP 
{Figure IV. 8). Equivalent volume of DMSO was used as control and each reaction was 
run in duplicate.
Effect of 10 uM PP2 on 293T overexp ressin g  p59HCK, U 937 and M ono-mac-6
cells
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Figure IV. 8: Effect o f  PP2 on HCK activity in 293T-HEK cells overexpressing p59- 
HCK, U937 and Mono-mac-6 cells assessed by non-radioactive kinase assay.
293T-HEK cells, 293T-HEK cells over expressing HCK, KGla, U937 and Mono-mac-6 
cells were lysed in buffer A and HCK was immunoprecipitated using a mouse anti-HCK
TMantibody. An in vitro non radioactive kinase assay using the Antibody Beacon 1 Tyrosine 
Kinase Assay Kit was set up in a 384 well black plate, 10 pM  PP2 or equivalent DMSO 
volume was added to the well prior to addition o f ATP and fluorescence was read at 530 
nm after 45 min incubation. The fluorescence emitted is directly proportional to the 
kinase activity.
As expected, no kinase activity was detected in 293T-HEK cell immunoprecipitates since 
293T-HEK cells do not express HCK and addition of PP2 or DMSO to these samples 
does not influence the background signal. KGla cells were taken as a negative control.
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293T-HEK cells overexpressing p59-HCK, U937 and Mono-mac-6 highly express HCK 
and show kinase activity that is completely abolished by addition of PP2. Addition of 
DMSO to 293T-HEK cells overexpressing p59-HCK immunoprecipitate causes a 16% 
decrease in kinase activity. This experiment seems to indicate that PP2 is able to abolish 
HCK kinase activity when it is immobilised as an enzyme in an immunoprecipitate of a 
variety of cell lines, but does not have an effect when added to the growth medium of 
these same cell lines, possibly because it does not enter the cells.
1.3.5 Validation of phospho-specific flow cytometry using 293T-HEK cells 
overexpressing p59HCK
Since 293T-HEK cells overexpressing p59HCK are a good tool to evaluate HCK 
phosphorylation, we used them to further validate the use of the anti-Y411 antibody in 
flow cytometry {Figure IV. 9). Comparing mock transduced and p59HCK transduced cells 
clearly indicates that only HCK+GFP+ 293T-HCK show a Y411+ population {Figure IV 9 
c and d, black histogram compared to dark blue histogram). HCK is actually partially 
phosphorylated in these cells since we can distinguish two populations on the dark blue 
histogram {Figure IV  9 d). Mock transduced cells are Y411' {Figure IV 9 d, black 
histogram) therefore setting the background level of the anti-Y411 staining. The FACS 
plots shown here are representative of two distinct experiments.
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Fisure I V. 9: HCK phosphorylation in 293T-HEK cells overexpressing p59HCK.
Top panel: GFP expression in p59HCK transduced 293T-HEK cells (b) and control non­
transduced 293T-HEK cells (a). Bottom panel: (c) HCK expression: mock transduced 
293T-HEK cells do not express HCK (black histogram), p59HCK transduced GFP 
positive 293T-HEK cells highly express HCK (dark blue histogram). A matching mouse 
IgGl isotype control is used as a reference (solid grey histogram), (d) HCK 
phosphorylation (Y411 phosphorylation): mock transduced 293T-HEK cells are negative 
for anti-Y411 staining (black histogram), this staining gives a high background in 
comparison to the matching goat IgGl isotype control (solid grey histogram). p59HCK 
transduced GFP positive 293T-HEK cells are partially phosphorylated (dark blue 
histogram, two populations).
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1.3.6 Validation of phospho-specific flow cytometry using G-CSF signal transduction
Another way to assess HCK phosphorylation in Mono-mac-6 cells would be to stimulate 
them with G-CSF and look for a variation in HCK phosphorylation. As explained in the 
introduction chapter, HCK has been shown to be activated by G-CSF and to directly 
interact with the G-CSF receptor in the IL-3 dependent murine NFS-60 cell line (Ward et 
al., 1998). It is not known whether G-CSFR signals via HCK in human myelomonocytic 
cell lines. Prior to being stimulated with G-CSF, Mono-mac-6 cells have to be serum 
starved. We also looked at the effect of serum starvation on HCK phosphorylation to help 
determine the baseline level of HCK phosphorylation. To do so, cells were incubated for 
lh, 4h or 24h in serum-free medium and stained with anti-Y411 {Figure IV. 10 a). 
Quantification of the signal intensity, comparing MFI Y411 (normalised to MFI isotype 
control) at lh to normalised MFI Y411 at 4h and 24h of starvation, showed a 29% 
increase in HCK (Y411) phosphorylation 4h post starvation {Figure I V 10 a, blue 
histogram compared to light blue histogram which decreases by 24h starvation to 33% of 
the initial value at lh post starvation {Figure IV 10 a, dark blue histogram compared to 
light blue histogram).
We then took Y411 phosphorylation status 24h post starvation as a no stimulation control 
and compared it to starved Mono-mac-6 cells stimulated with G-CSF for 30 min. We 
observed that HCK phosphorylation increases by 27% upon G-CSF stimulation {Figure 
I V 10 b, red histogram compared to dark blue histogram), giving half the signal observed 
when cells are left to starve for lh  only {Figure IV. 10 b, red histogram compared to light 
blue histogram). This experiment is representative of two distinct experiments.
184
alh  starvation 
4h starvation
24h starvation
105
b
lh  starvation 
24h starvation
30 min G-CSF stimulation
Y411 Alexa 647 Y 4 1 1 A lexa 647
Figure IV. 10: Effect o f serum starvation followed by G-CSF stimulation on HCK 
phosphorylation (Y411) in Mono-mac-6 cell line.
(a) Effect o f serum starvation on HCK (Y411) phosphorylation over time. HCK 
phosphorylation level lh post starvation (light blue histogram), 4h post starvation (blue 
histogram), 24h post starvation (dark blue histogram). Matching goat IgGl isotype 
control is used as a reference for quantification of the signal (grey histogram), (b) Effect 
of G-CSF stimulation on HCK (Y411) phosphorylation. HCK phosphorylation level lh 
post starvation (open light blue histogram), 24h post starvation (dark blue histogram), 
after 24h serum starvation followed by 30 min stimulation with G-CSF (red histogram).
Thus, using 293T-HEK cells overexpressing p59HCK and M onom ac-6 cells stimulated 
with G-CSF, we successfully prove that the phospho-specific Y 411 antibody can be used 
in flow cytometry to detect activation of the protein kinase HCK. W e can therefore use 
this staining to assess a change in HCK activity upon HCK knock-down in AML cell 
lines (see following section and Chapter V), to assess the activity status o f HCK in AML 
samples (Chapter VI) or in UCB Lin' stem cell enriched fraction (Chapter VII and VIII). 
We also show that G-CSFR signals via HCK in Mono-mac-6 cell line.
Overall, we have shown in this first section of results that HCK is mostly expressed in 
AML FAB M5 myelomonocytic cell lines and that we can confidently use flow 
cytometry to measure its level of expression and its level of phosphorylation on tyrosine
185
Chapter IV
Y411 as a representation of its kinase activity. We went on to establish HCK knock-down 
in Mono-mac-6 cells.
2. Knocking-down HCK using siRNA
2.1 siRNA transfection method selection using an anti-GFP siRNA
Prior to working with anti-HCK targeted siRNA, incorporation of siRNA into the 
suspension cell line Mono-mac-6 was first set up using a RedFP labelled anti-GFP 
siRNA. Several methods of co-transfection of a GFP plasmid and an anti-GFP siRNA 
using polyethylimine (PEI), Effectene or Transmessenger were unsuccessfully tested 
(data not shown). Another approach, first transducing Mono-mac-6 cells with a lentiviral 
vector carrying GFP under the PGK promoter, then followed by two rounds of 
electroporation at 300 millivolts and 125 millifarradays for 3.3 miliseconds, to transfect 1 
pg of RedFP labelled anti-GFP, proved successful (Figure IV 11 h). One round of 
electroporation under these conditions allowed the siRNA to enter the cells (as the Red­
FP label is detected by FACS; Figure IV. I I  a) but RNAi was observed only after two 
rounds of electroporation. In low GFP sorted cells RNAi leads to a 2.09 fold decrease in 
GFP expression, while in high GFP sorted cells the decrease reached 3.28 fold. Fold 
decreases are calculated by dividing the GFP MFI of the electroporated control without 
siRNA by the GFP MFI of the electroporated sample with anti-GFP siRNA. The RedFP- 
label cannot be clearly detected in silenced high GFP cells because of compensation 
issues. Data were collected 24, 48 and 72 hours post electroporation. Variations in GFP 
expression in live cells are shown for the 72h time point only.
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Figure IV .ll:  Validation o f electroporation as an siRNA transfection method into 
suspension cells.
Mono-mac-6 cells were transduced with a lentiviral vector carrying GFP under the PGK 
promoter and sorted as GFP (low GFP sorted cells) and GFP +1 (high GFP sorted 
cells). Mono-mac-6 cells then underwent (a) one round o f electroporation or (b) two 
rounds o f electroporation at 300 millivolts and 125 millifarradays for 3.3 miliseconds, to 
transfect 1 pg o f RedFP labelled anti-GFP (blue histogram). Electroporated cells 
without addition o f  siRNA were taken as control (red histogram).
2.2 Choice of anti-HCK siRNA sequence
Four different siRNA sequences targeting the coding sequence o f HCK were ordered 
from Eurogentec and tested for RNA interference ability in the Monomac-6 cell line. One 
o f the four siRNA sequences was labelled with Alexa 488 to allow checking for the 
efficiency o f transfection. Two out o f the four anti-HCK siRNA sequences were able to 
induce silencing o f HCK at both the mRNA level {Figure IV. 12 a) and the protein level 
{Figure IV. 12 b). Monomac-6 cells electroporated with TE buffer were used as a no
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siRNA control. 24h post electroporation, siHCK4 achieved 46% knock-down o f HCK at 
the RNA level versus 27% for siHCK3. Western blot band quantification using the Image 
J software indicated an 82% decrease in HCK expression at the protein level 48h post 
electroporation for siHCK4 versus 51% for siHCK3. HCK band densities were 
normalised to their respective beta-actin band density.
HCK transcient silencing a t 24h by real-time PCR
200
SHCK2 S.HCK4
HCK tr a n s d e n t  s ile n c in g  at 4 8 h  by W estern  b lo t
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42 kDa S*I«M
Fieure I V. 12: Transient knock-down o f HCK in Monomac-6 cells.
(a) Testing the knock-down o f HCK by qRT-PCR: Silencing properties o f four distinct 
siRNA sequences targeting the coding sequence o f the HCK mRNA transcript were 
assessed by quantitative real-time PCR using SYBR® green. GAPDH was used to 
normalise the values o f  mRNA expression, (b) Testing the knock-down of HCK by 
Western blot: Silencing properties o f  four distinct siRNA sequences targeting the coding 
sequence of the HCK mRNA transcript were assessed by Western blotting. Beta-actin was 
used to normalise the intensities o f protein expression. Results are expressed as 
percentage of expression in Monomac-6 cells electroporated with TE buffer and no 
siRNA.
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Duration of HCK transient knock-down in Mono-mac-6 was followed up over four days. 
As seen on Figure I V 13 a HCK silencing is not stable over 24h at the mRNA level. 
Figure IV. 13 b and c show that HCK silencing at the protein level is delayed in 
comparison to the knock-down at the RNA level (24% less HCK expression at 24h for 
siHCK4 versus 53% decrease at 48h) and is not stable over 72h. In this experiment an 
additional non-coding scramble siRNA (scb on the graphs) was electroporated into 
Mono-mac-6 as a control for gene specificity of silencing using the electroporation 
technique. Figure I V 13 b shows band quantification expressing HCK protein level 
normalised to their corresponding actin band. Figure IV. 13 c renders these band 
quantifications into percentage of no siRNA control for easier comparison with the real­
time PCR data. The experiment shown here is representative of four distinct experiments.
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C
HCK silencing over 4 days (W estern blot)
Figure IV. 13: HCK expression follow up over 4 days.
(a) Testing the knock-down o f HCK by qRT-PCR: Silencing properties o f two distinct 
siRNA sequences targeting the coding sequence o f the HCK mRNA transcript, and a 
scrambled siRNA sequence, were followed for 96h and assessed by quantitative real-time 
PCR using SYBR® green. GAPDH was used to normalise the values o f mRNA expression.
(b) Testing the knock-down o f HCK by Western blot: Silencing properties o f two distinct 
siRNA sequences targeting the coding sequence of the HCK mRNA transcript, and a 
scrambled siRNA sequence, were followed for 12Oh and assessed by Western blotting. 
Beta-actin was used to normalise the intensities o f protein expression. Band 
quantification is shown as the level o f HCK protein expression normalised to their 
corresponding actin band, (c) The same results are expressed as percentage of 
expression in Monomac-6 cells electroporated with TE buffer and no siRNA.
Since the best knock-down we could reproducibly obtain with siHCK4 was only around 
50%, we tested three additional anti-HCK siRNA sequences from Ambion and compared 
them to siHCK4 using nucleofection as a transfection method. Solution R and program 
U-001 from Amaxa proved to be the most appropriate to nucleofect Mono-mac-6 cells, 
but none o f the new siRNA sequences tested lead to more than 50% HCK silencing (data 
not shown). We therefore went on to clone the siHCK4 sequence as a short hairpin RNA
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(shRNA) into a lentiviral backbone, in order to achieve stable silencing of HCK and 
possibly a higher level of knock-down.
3. Long term silencing of HCK using a lentivirus encoding an anti-HCK shRNA 
in Mono-mac-6 cell line
3.1 shRNA anti-HCK cloning into a lentiviral backbone
shHCK4 was designed by integrating the siHCK4 sequence into the long oligo sequences 
represented in Figure IV. 14 a. Prior to cloning the short hairpin into a ‘pHl-XhoT shuttle 
vector, the integrity of the latter was verified. As predicted from the map (Figure IV. 14 
d), a 260 base pair fragment is obtained when digesting the pHl-Xhol shuttle vector with 
the Xhol restriction enzyme and a 221 base pair fragment is obtained when digesting 
pHl-Xhol with the EcoRl and Bglll (Figure IV. 14 b). Oligos were annealed {Figure 
IV. 14 c) and cloned in between the Bglll and HindiII restriction sites of the pH 1-Xhol 
shuttle vector. This vector allows the positioning of the short hairpin under a RNA 
polymerase III specific promoter HI {Figure IV 14 d).
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Figure IV. 14: shRNA cloning strategy.
(a) Sequence o f the oligo backbone o f the short hairpin, (b) Restriction profile o f the 
pH 1-Xhol shuttle vector: u.d: undigested pH 1-Xhol shuttle vector; X: pH  1-Xhol shuttle 
vector digested with Xhol; E/B: pH  1-Xhol shuttle vector digested with EcoRI and Bglll.
(c) Sequence o f the annealed oligo encoding the siHCK4 (in capital letters), (d) Map o f 
the pHl-Xhol shuttle vector prior to incorporation o f the short hairpin, (e) Cloning o f 
shHCK4 into the pH  1-Xhol shuttle vector: positive colonies are indicated by a star, (f) 
Map o f the pHl-Xhol shuttle vector after incorporation o f the short hairpin. 
Confirmation o f the presence o f shHCK4 was done by sequencing using the T3 primer, 
(g) Cloning o f shHCK4 into the PRLL-SIN-cPPT-shHCK4-PGK-eGFP-WPRE lentiviral 
vector: the positive colony subsequently used for virus production is indicated by a star,
u.d: undigestedpRLL-S!N-cPPT-shHCK4-PGK-eGFP-WPRE and HI: empty pH 1-Xhol 
shuttle vector digested with Xhol are used as negative controls, (h) Map o f the pRLL- 
SIN-cPPT-shHCK4-PGK-eGFP-WPRE vector after incorporation o f the short hairpin 
anti-HCK.
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Presence of the shRNA insert into the pH 1-Xhol shuttle vector was confirmed by 
restriction digest with Xhol {Figure IV. 14 e) and by sequencing. The hHl-shHCK4 
fragment was cut out with Xhol and cloned into the CIPed pRLL-SIN-cPPT-PGK-eGFP- 
WPRE lentiviral backbone. Since a ligation based on molecular ratio cannot be applied 
with such a difference in size between insert and destination vector, we serially diluted 
the insert from 1:2 to 1:1000 and ligated 1:1 ratio of the destination vector to one of these 
insert dilutions. Ligation over the weekend at 16°C using the 1:2 or 1:10 insert dilution 
gave rise to shHCK4 positive bacterial colonies. Presence of the shRNA insert into 
pRLL-SIN-cPPT-PGK-eGFP-WPRE lentiviral vector was confirmed by restriction digest 
with Xhol {Figure IV. 14 g). The final map of the pRLL-SIN-cPPT-shHCK4-PGK-eGFP- 
WPRE lentiviral vector is shown in Figure I V 14 h.
In the following sections and chapters, the pRLL-SIN-cPPT-PGK-eGFP-WPRE 
lentivirus will be called “mock” and the pRLL-SIN-cPPT-shHCK4-PGK-eGFP-WPRE 
lentivirus will be called “sh”.
3.2 shRNA encoding lentivirus production and setup of efficient transduction
Highly concentrated mock and sh lentiviruses were produced using 293T-HEK cells as a 
packaging cell line as described in Chapter II. Mono-mac-6 transduction at multiplicity of 
infection (MOI) 5, 10 or 20 did not give any convincing HCK silencing (data not shown). 
These results could have three possible explanations: incapacity of the produced virus to 
knock-down HCK in a myelomonocytic cell line (Mono-mac-6 may have some 
reminiscent monocytic mechanisms for clearing out viral RNA), incapacity of the virus to 
enter a suspension cell line at this MOI or incapacity of the virus to knock-down native 
HCK due to the semi-silencing property of the siRNA sequence in a transient manner.
3.2.1 Validation of shRNA encoding lentivirus silencing function in 293T-HEK cells
To try to elucidate if any of these hypotheses could be validated, we performed a 
transient HCK overexpression/stable shHCK4 transduction experiment in 293T-HEK
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cells. The design o f this experiment is described in Chapter II and summarised in Table 
IV. 1.
Name on the 
graph
HCK sh HCK mock HCK alone YFP mock
YFP
alone
293T
1 ransfection p59HCK-YFP p59HCK-YFP p59HCK-YFP YFP YFP PEI only
Transduction shHCK4-GFP Mock GFP — Mock GFP — —
Table IV. I: Design o f the transient HCK overexpression/stable shHCK4 transduction 
experiment in 293T-HEK cells.
See Chapter II, section 3.6, for more detail.
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Figure I V. 15: HCK silencing in 293T-HEK cells detected by quantitative real time 
PCR.
See Chapter II, section 3.6, for more detail.
Taking untransfected and non-transduced 293T-HEK cells as a control ( ‘293T‘), we can 
see that both the YFP encoding overexpression vector and the GFP encoding silencing
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vector entered the cells, since the GFP primers used in this experiment can amplify both 
GFP and YFP mRNA {Figure IV. 15 h). 293T-HEK cells transduced with YFP only 
(‘YFP alone’) express it at a very low level that cannot be visualised with the Y-axis 
scale in use on Figure I V 15 b. In 293T-HEK cells transduced with p59HCK-YFP only 
(‘HCK alone’), the YFP mRNA amplicon gives a signal 560 fold higher than the basal 
unspecific signal given by GFP primer dimers in control 293T-HEK cells {Figure IV. 15 
b, first histogram bar). Regarding HCK expression {Figure IV. 15 a), shHCK4 encoding 
lentivirus induces a 35% decrease of HCK expression in ‘HCK sh’ cells in comparison to 
‘HCK mock’ or ‘HCK alone’ cells transduced with GFP encoding mock vector or non­
transduced cells respectively.
This experiment allows us to conclude that the silencing lentivirus produced is functional 
in adherent 293T-HEK cells overexpressing p59-HCK. We therefore carried on 
transducing suspension Mono-mac-6 cells with a higher MOI than previously.
3.2,2 Long-term silencing of HCK in Mono-mac-6 cells
Mono-mac-6 cells were transduced with mock or silencing virus at MOI 40 or 80 and 
followed up for 28 days. Stability of the GFP expression and maintenance of HCK 
silencing was confirmed at several time points by quantitative real-time PCR and by 
Western blot.
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Fisure IV. 16: HCK silencing follow up by real-time PCR and Western blot.
Mono-mac-6 cells were transduced at MOI 40 or 80 with mock or shHCK4 encoding 
lentiviruses. (a) Stable knock-down o f HCK by qRT-PCR: Silencing o f HCK was followed 
for 28 days and assessed by quantitative real-time PCR using SYBR® green. GAPDH was 
used to normalise the values o f  mRNA expression. Results are expressed as the 
percentage o f HCK expression in silenced Mono-mac-6 in comparison to their mock 
transduced counterpart, (b) Stable knock-down o f HCK by Western blot: Silencing of 
HCK was followed for 15 days and assessed by Western blotting. Beta-actin was used to 
normalise the intensities o f  protein expression. Band quantification is shown as the level 
of HCK protein expression normalised to their corresponding actin band, (c) The same 
residts are expressed as percentage o f mock transduced Monomac-6 cells.
As seen in Figure IV. 16 a, HCK silencing using a lentiviral vector is stable at the RNA 
level over the period of 28 days follow-up. Results are expressed as the percentage of 
HCK expression in silenced Mono-mac-6 in comparison to their mock transduced 
counterpart. Either MOI gives a knock-down o f about 50% all along the period o f time 
monitored. Figure IV. 16 b and c show that HCK silencing is also stable around 50% at 
the protein level. Figure IV. 16 b shows band quantification expressing HCK protein level 
normalised to their corresponding actin band. Figure IV. 16 c renders these band 
quantifications into percentage o f mock transduced control for easier comparison with the
HCK silencing com parison b etw een  tw o MOI at the protein level
■ mock reference 
II sh day a 
sh day 8
•  sh day 11
•  sh day  IS
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real-time PCR data. We also monitored HCK silencing at the protein level by flow 
cytometry {Figure IV 1 7) and compared results with Western blotting.
a
b HCK silencing by FACS
■  r~ ock rc'ercnce
•  sh day 11
■  sh day IS
•  sh day 19 
sh day 28
■ sh day 61
Mono MOI 80Mono MOI 40
Figure IV. 17: HCK silencing assessed by flow  cytometry.
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Mono-mac-6 cells were transduced at MOI 40 or 80 with mock or shHCK4 encoding 
lentiviruses. (a) Flow cytometry plots showing the follow up o f HCK stable knock-down 
for 61 days: Mock transduced Mono-mac-6 cells at MOI 40 (green histogram), at MOI 
80 (red histogram). shHCK4 transduced Mono-mac-6 cells at MOI 40 (orange 
histogram), at MOI 80 (blue histogram). Non-transduced Mono-mac-6 cells are taken as 
additional control (black histogram), (b) Quantification o f stable HCK silencing assessed 
by flow cytometry: Signal quantification was calculated as the mean fluorescence 
intensity (MFI) o f HCK AFC staining divided by the mean fluorescence intensity o f the 
corresponding mouse isotype control APC staining. Results are expressed as the 
percentage o f HCK expression in silenced Mono-mac-6 cells in comparison to their mock 
transduced counterpart.
Figure IV. 17 a shows flow cytometry plots corresponding to cells taken at the same time 
points as for Western blot, plus an additional point at 61 days post transduction. Figure 
IV. 17 b summarises these data on HCK expression as percentage of mock transduced 
Mono-mac-6. For each mock or silenced sample, run in duplicates, MFI is calculated as 
the mean fluorescence intensity of HCK APC staining divided by the mean fluorescence 
intensity of the corresponding mouse isotype control APC staining. Flow cytometry data 
confirm that HCK knock-down by about 50% is stable over 61 days.
To conclude the validation of proper HCK silencing, we needed to also establish if HCK 
activity was actually reduced. To this end, we performed a non-radioactive kinase assay 
where HCK was immunoprecipitated from Mono-mac-6 cell lysates obtained with buffer 
A and incubated with ATP, a peptide substrate, and an anti-phospho antibody presenting 
a particular affinity for a fluorescent Oregon Green 488 ligand. Procedural detail of the 
experiment is described in Chapter II and in part 1.3.1 of this chapter. An Oregon Green 
488 ligand only, a phosphopeptide, a no kinase, a no ATP and a no substrate control, as 
well as serially diluted recombinant HCK protein, were run in parallel to ensure the 
correct progression of the experiment.
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Fisure IV. 18: HCK activity measured by non-radioactive kinase assay.
Mock transduced, shHCK4 transduced and non-transduced Mono-mac-6 cells were lysed 
in buffer A and HCK was immunoprecipitated using a mouse anti-HCK antibody. An in 
vitro non-radioactive kinase assay using the Antibody Beacon™ Tyrosine Kinase Assay 
Kit was set up in a 384 well black plate and fluorescence was read at 530 nm after 45 
min incubation. The fluorescence emitted is directly proportional to the kinase activity.
The non-radioactive kinase assay confirms that a 50% knock-down o f HCK at the RNA 
and protein level in Mono-mac-6 cells corresponds to a 41% decrease in HCK activity in 
vitro (Figure IV. 18). This experiment is representative of two independent experiments.
Since achieving 50% silencing o f HCK in Mono-mac-6 cells was not completely 
satisfactory, we went on to try to see if  we could obtain a better silencing in two different 
AML cell lines: U937 and Fujioka/P31. These two cell lines are also classified as M5 in 
the FAB classification, but are reported to be slightly more immature than Mono-mac-6 
(Abrink et al., 1994; Erl et al., 1995; Ziegler-Heitbrock et al., 1988). As quantified in part
1.1 of this chapter, they also highly express HCK.
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4. Long term silencing of HCK in U937 and Fujioka/P31 cell lines
Since Mono-mac-6 transduction with lentivirus at MOI 40 or MOI 80 did not show any 
difference in the level of HCK silencing, we decided to transduce Fujioka and U937 cells 
at MOI 40 to use less virus. As shown on Figure IV. 19 a, we observe 57% HCK silencing 
at the protein level in Fujioka/P31 and 64% HCK silencing at the protein level in U937 
cells Figure I V 19 c. Interestingly, when we estimate HCK activity by staining for 
phosphorylated tyrosine Y411 in the active loop, the percentage of pY411+ in the 
shHCK4 transduced cells in comparison to the mock transduced cells decreases only by 
5% in Fujioka/P31 cells {Figure I V 19 b), while it decreases by 40% in U937 cells 
(Figure I V 19 d). Figure IV. 19 e summarises these data on HCK silencing as percentage 
of mock transduced Fujioka/P31 or U937 cells for total HCK or phospho-HCK staining. 
For each mock or silenced sample, run in duplicates, MFI is calculated as the mean 
fluorescence intensity of HCK Alexa 647 staining divided by the mean fluorescence 
intensity of the corresponding mouse isotype control Alexa 647 staining. However, when 
estimating kinase 
of 43% in kinase 
cells were taken 
looking at 55 min
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activity by non-radioactive kinase assay, we could observe a decrease 
activity in Fujioka/P31 cells and of 38% in U937 cells. Mono-mac-6 
for comparison and show a 54% decrease in kinase activity when 
incubation {Figure I V 1 9 f  n=6).
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Fisure I V. 19: HCK silencing in Fujioka/P31, U937 and Mono-mac-6 cell lines.
Fujioka/P31 and U937 cells were transduced with a mock (blue histogram) or shHCK4 
(red histogram) lentivirus at MOI 40. Untransduced cells were taken as controls (puple 
histogram) (a) Fujioka/P31 cells staining for HCK. (b) Fujioka/P3l cells staining for 
phosphorylated HCK Y411. (c) U937 cells staining for HCK (d) U937 cells staining for 
phosphorylated HCK Y41I. Matching isotype controls were used to normalise each 
staining (grey histogram), (e) Quantification o f  HCK expression and HCK 
phosphorylation post silencing assessed by flow cytometry: Signal quantification was
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calculated as the mean fluorescence intensity (MFI) o f HCK Alexa 647 staining divided 
by the mean fluorescence intensity o f the corresponding mouse isotype control Alexa 647 
staining. Results are expressed as the percentage o f HCK expression in silenced 
Fujioka/P3I or U937 cells in comparison to their mock transduced counterpart, (f) HCK 
kinase activity in Fujioka/P31 and U937 cells post silencing: Mock transduced, shHCK4 
transduced and non-transduced Fujioka/P31 or U937 cells were lysed in buffer A and 
HCK was immunoprecipitated using a mouse anti-HCK antibody. An in vitro non­
radioactive kinase assay using the Antibody Beacon™ Tyrosine Kinase Assay Kit was set 
up in a 384 well black plate and fluorescence was read at 530 nm after 45 min 
incubation. The fluorescence emitted is directly proportional to the kinase activity. HCK 
immunoprecipitated from lentivirally transduced Mono-mac-6 cells was taken for 
comparison.
The discrepancy observed between the flow cytometry and the non-radioactive kinase 
assay results might be explained by the fact that as seen via Western blot, only p59HCK 
is detected as phosphorylated in Fujioka/P31 cells when no ATP is added (Figure IV  7 d). 
The non-radioactive kinase assay takes into account any type of activation of HCK, since 
it measures substrate phosphorylation and not only autophosphorylation. Although these 
two events should be correlated, it seems that HCK activity is regulated differently in 
Fujioka/P31 cells in comparison to U937 or Mono-mac-6 cells.
However, at the total protein level, Fujioka/P31 and U937 cell lines transduction gave a 
similar level of HCK knock-down to Mono-mac-6 transduction. These later experiments 
demonstrate that semi-silencing of HCK is a property intrinsic to the siRNA sequence in 
use and is independent of the cell line studied. To try to obtain a better level of HCK 
silencing, we decided to try using an miRNA based strategy that might give better results.
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5. Attempt to knock-down HCK using an miRNA based strategy
miRNA present the advantage o f being transcribed by the RNA polymerase II which is 
supposedly more efficient than the RNA polymerase III used to transcribe siRNA . They 
can also easily be chained into a vector, either as several different miRNA targeted 
towards the same gene or as miRNA targeted against different genes. We took advantage 
o f the BLOCK-iT1M Pol II miR RNAi Expression Vector Kit commercialised by 
Invitrogen and ordered the package o f 4 anti-HCK miRNA on offer.
5.1 miRNA anti-HCK cloning
Each o f the 4 miRNA 604, 605, 606 and 607 were cloned into the pcDNA™6.2GW 
/EmGFP-miR plasmid according to the manufacturer’s protocol and as described in 
Chapter II. Subsequently each miRNA was chained to each other as a combination of 
either 2 o f each miRNA (12 constructs) and as a combination of either 3 o f each miRNA 
(24 constructs) by digesting ‘backbone’ miRNA carrying vectors with Bglll and Xhol and 
miRNA ‘insert’ with BamHI and Xhol {Figure IV.20). 
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Figure I V. 20: miRNA cloning strategy.
FA /(a) Map of the linearised pcDNA 1 6.2GW /EmGFP-miR plasmid, (b) Cloning strategy 
for chaining 2 miRNA expression cassettes combining restriction digests with Bglll, 
BamHI and Xhol. See Chapter II for detail.
5.2 Attempt of choosing the most efficient miRNA combination to silence HCK 
in Mono-mac-6 cells
Prior to cloning an miRNA or a combination o f miRNA into a lentiviral vector, we tried 
to select for the most silencing miRNA condition by nucleofecting the produced 
constructs in Mono-mac-6 cells (section 2.2, data not shown). Since solution R and 
program U-001 from Amaxa had proven successful to nucleofect Mono-mac-6 cells with 
siRNA, we tried nucleofecting miRNA547 and miRNA574 into Mono-mac-6 cells using 
the same conditions (the choice o f miRNA here is arbitrary and we assumed that triple 
miRNA might work better). We also tried solution R and program T-001 in parallel. This 
first attempt did not yield any GFP+ cells 24h post nucleofection, we therefore went on to 
produce new more concentrated plasmid DNA (from midiprep instead o f miniprep) and 
repeated the experiment using the same conditions, also using the pmax-GFP® plasmid 
provided by Amaxa as a positive control {Figure IV. 21).
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Figure IV.2I: Nucleofection test in Mono-mac-6 cell line using solution R, programs 
T-001 and U-001.
Top panel: GFP expression in Mono-mac-6 cells nucleofected with the control plasmid 
pmax-GFP®. Middle panel: GFP expression in Mono-mac-6 cells nucleofected with the 
miRNA547 expression cassette encoding pcDNA1' '6.2GW /EmGFP-miR plasmid. Bottom 
panel: GFP expression in Mono-mac-6 cells nucleofected with the miRNA574 expression 
cassette encoding pcDNA7 u6.2GW /EmGFP-miR plasmid.
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Program T-001 gave 9.06% GFP+ cells while program U-001 gave 17.9% GFP cells 
when using the pmax-GFP® plasmid, 48h post nucleofection. miRNA encoding plasmids 
gave less than 1% GFP+ cells in either condition used. We therefore decided to try to 
improve GFP+ yields by testing different programs with the pmax-GFP® plasmid prior to 
continuing working with miRNA encoding pcDNA™6.2GW /EmGFP-miR.
Based on an Internet search of Amaxa programs used with suspension cells by other 
scientists, we tested programs A-017, C-016, G-010, S-018, T-001, T-014, T-020, T-027, 
T-030, U-001, U-005 and V-001 with solution V as well as programs T-001, T-016, T- 
027 and V-016 with solution R. Forty-eight hours post transfection, solution V/program 
T-014 turned out to give the best results with 67.5% GFP+ cells and 75% viability. 
Solution R/program T-016, solution R/program T-027 and solution V/program U-005 
also gave good results with 60.3% GFP+ cells and 70% viability, 59.2% GFP+ cells and 
72.1% viability and 57.5% GFP+ cells and 72.9% viability respectively. We therefore 
went on to nucleofect miRNA547 and miRNA574 into Mono-mac-6 cells using solution 
V/program T-014, solution R/program T-016 and solution V/program U-005. 
Unfortunately, 48h post nucleofection, we could not obtain more than an average of 
2.83% GFP+ cells with solution V/program T-014, 4.8% and 1.58% GFP+ cells with 
solution R/program T-016 and solution V/program U-005 respectively (data not shown).
Suspecting that the CMV promoter driving GFP expression in both pmax-GFP® and 
pcDNA™6.2GW /EmGFP-miR plasmids may be downregulated in Mono-mac-6 cells, 
we tried to select for an appropriate miRNA in a different cell line.
5.3 Attempted choice of silencing miRNA sequence in U937 and K562 cells
Amaxa having released a new kit for nucleofecting U937 cells, we made use of solution 
C/program W-001 and tried to nucleofect miRNA547 as well as single miRNA 604, 605, 
606, 607 (in case unsuccessful transduction would be due to the chaining process). 
Having noticed from colleague’s experiments that K562 cells can be successfully 
transduced with lentivirus at lower MOI than myelomonocytic cells (MOI 10 instead of 
40) (Rangatia and Bonnet, 2006), we used K562 cells as a positive control for GFP
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positivity and nucleofected them with solution V/program T-016, as recommended by 
Amaxa. Forty-eight hours post transfection in K562 cells, miRNA 605, 606 and 607 yield 
44.2%, 62.3 % and 49.9% GFP' cells respectively and more than 86% cells were viable 
in every case (data not shown). In U937 cells, miRNA 604, 605, 606, 607 yield 3.09%, 
10.1%, 7.9% and 2.25% GFP' cells respectively while the pmax-GFP® plasmid gave 
23.6% GFP+ U937 cells (Figure IV.22). Of note, when transduced with the pmax-GFP® 
plasmid 61% of the U937 cells are viable, while 8.91%, 4.13 %, 10.3% and 68.7 cells are 
viable when transduced with miRNA 604, 605, 606, 607 respectively.
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Fieure I V.22: Nucleofection test in U937 cell line using solution C, program W-001.
Percentage o f live cells (TOPRO-3 negative cells) and GFP expression in non- 
nucleofected U937 cells, U937 cells nucleofected without addition o f DNA, U937 cells 
nucleofected with the Control plasmid pmax-GFP®, the mock lentiviral backbone used in 
the shRNA study, the miRNA604, 605, 606, or 607 expression cassette encoding 
pcDNA™6.2GW/EmGFP-miR plasmid.
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This experiment confirms that the CMV promoter used to drive GFP expression is 
functional in K562 cells, but not in myelomonocytic cell lines. Since K562 cells do not 
express HCK, we could not investigate HCK silencing using miRNA any further in 
suspension cells.
6. Conclusion
Since the miRNA based system we tried to use did not prove helpful, we went back to 
using the shHCK4 encoding lentivirus to study the effect of semi-silencing HCK on 
Fujioka/P31, U937 and Mono-mac-6 functionality.
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V Effect o f H C K  sem i-silencing on AM L cell lines
1. Effect of HCK semi-silencing on FAB M5 cell lines proliferation
1.1 XTT assay
We first looked at the metabolic activity of cell lines by the XTT assay. While 
Fujioka/P31 and U937 cell lines transduced with mock or silencing virus do not show any 
obvious change in metabolic activity that can be associated to proliferation (Figure V. 1,
top and middle panel), Mono-mac-6 cells transduced with shHCK4 encoding virus tend
to proliferate faster than controls (Figure V. 1, bottom panel) over 96h post transduction.
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XTT assay  In U937 cell line
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Figure V. 1: Cel! proliferation measured by X TT  assay.
Cells were plated at a density o f 50,000 cells/100 pL in triplicate in four flat bottom 96 
well plates and incubated at 37°C, 5% CO2 for 24h, 48h or 96h. Basal proliferation o f 
the cells (time point zero) was determined by adding 50 pL o f freshly mixed XTT reagents 
immediately after cell plating. After XTT reagents addition, plates were incubated 2h at 
37°C, 5% CO2 and cell proliferation was represented as absorbance at 450 nm corrected 
by absorbance at 650 nm over time.
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Explanations for these results can be looked at in more detail by examining the cell cycle 
status of the cells and by evaluating the proportion of apoptotic cells by combined 
Annexin V and DAPI staining.
1.2 Cell cycle analysis
The distribution of Fujioka/P31 cells in Go/G], S or G2/M phases of the cell cycle is not 
altered by HCK semi-silencing (Figure V.2 a) nor is the one of U937 cells {Figure V.2 b). 
However, 72h post transduction, Mono-mac-6 cells transduced with sh lentivirus have 
more cycling cells (20% cells in G2/M phase versus 12.4% and 10.2% in mock and non­
transduced cells respectively) and less resting cells than controls (57.4% cells in G0/G1 
phase versus 65.7% and 64.6% in mock and non-transduced cells respectively; Figure 
V.2 c). This experiment is representative of two distinct experiments.
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Figure V.2: Cell cycle analysis in Fujioka/P31, U937 and Mono-mac-6 cell lines 72h 
post transduction.
Panel (a): Cell cycle analysis o f  mock transduced, shHCK4 transduced and non­
transduced Fujioka/P31 cells. Panel (b): Cell cycle analysis o f mock transduced, 
shHCK4 transduced and non-transduced U937 cells. Panel (c): Cell cycle analysis o f  
mock transduced, shHCK4 transduced and non-transduced Mono-mac-6 cells.
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1.3 Apoptosis
shHCK4 transduced Fujioka/P31 cells present 8.7% more Annexin V+/DAPI' apoptotic 
cells than non-transduced cells 72h post transduction. However, the proportion of 
apoptotic cells does not differ from mock transduced cells, apoptosis is therefore due to 
virus transduction at this time point (.Figure V.3 a). Staining the cells 6 days post­
transduction confirms that HCK semi-silencing does not induce apoptosis in Fujioka/P31 
cell line {Figure V.3 d).
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Fisure V.3: Apoptosis analysis by Annexin V staining in Fujioka/P31, U937 and 
Mono-mac-6 cell lines 72h and 6 days post transduction.
Panel (a): Apoptosis analysis o f  mock transduced, shHCK4 transduced and non- 
transduced Fujioka/P31 cells 72h post transduction. Panel (b): Apoptosis analysis o f  
mock transduced, shHCK4 transduced and non-transduced U937 cells 72h post 
transduction. Panel (c): Apoptosis analysis o f  mock transduced, shHCK4 transduced and 
non-transduced Mono-mac-6 cells 72h post transduction. Panel (d): Apoptosis analysis 
o f mock transduced, shHCK4 transduced and non-transduced Fujioka/P31 cells 6 days 
post transduction. Panel (e): Apoptosis analysis o f  mock transduced, shHCK4 transduced
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and non-transduced U937 cells 6 days post transduction. Panel (j): Apoptosis analysis o f 
mock transduced, shHCK4 transduced and non-transduced Mono-mac-6 cells 6 days post 
transduction.
Mock transduced U937 cells show twice as many Annexin V+/DAPI+ dead cells than sh 
transduced cells 72h post transduction, but consist of only 2.17% of the total population. 
The percentage of apoptotic cells in sh transduced cells is also decreased in comparison 
to both mock transduced and non-transduced cells at this time point {Figure V.3 b). 
However, 6 days post-transduction sh transduced U937 show slightly more apoptotic and 
dead cells that the controls (9.38% versus 8.4% apoptotic cells and 7.2% versus 5.97% 
dead cells when comparing sh and mock transduced cells; Figure V.3 e). The variation 
being below 2% and seeing no obvious difference in the overall growth of U937 cells 
(see section 1.4), we considered that HCK semi-silencing does not influence apoptosis in 
the U937 cell line in the long term and did not investigate apoptotic pathways any further.
Seventy-two hours post transduction, sh transduced Mono-mac-6 cells show slightly less 
apoptotic and dead cells than the controls (11% versus 12.2% apoptotic cells and 2.83% 
versus 4.24% dead cells when comparing sh transduced and non transduced cells; Figure 
V.3 c). Six days post transduction, non-transduced Mono-mac-6 cells show twice as many 
apoptotic cells than sh transduced cells (18% versus 8.99% respectively; Figure V.3 e). 
The variation in proportion of dead cells is not as important (4.69% versus 3.64% of the 
total population respectively). From this experiment we can conclude that HCK semi- 
silencing may have a slight impact on Mono-mac-6 cells apoptosis, but cannot explain 
the increase in cell number observed associated with HCK silencing, as desribed below.
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1.4 Growth curve
While growing the cells we followed their doublings generation over time. HCK semi- 
silencing does not seem to influence Fujioka/P31 or U937 doublings generation. 
However, sh transduced Mono-mac-6 cells tend to grow faster than mock transduced or 
non-transduced Mono-mac-6 cells {Figure V.4).
D o u b l in g s  g e n e r a t i o n  In F u J i o k a / P 3 1  c e l l  l in e
mock40
sh40
D o u b l in g s  g e n e r a t i o n  in  U 9 3 7  c e l l  l in e
Chapter V
D o u b l in g s  g e n e r a t i o n  In  M o n o - m a c - 6  c e l l  l in e
1 10
 mock 40
 sh 40
20
days
Figure V.4: Growth curve o f Fujioka/P31, U937 and Mono-mac-6 cells.
Fujioka/P31, U937 and Mono-mac-6 cells growth represented as cumulative population 
doublings. Cumulative population doublings (PD) o f  each culture using the following 
formula: PD = flogw (nt2) - logio (n,/)J /  logi0 (2).
Overall HCK semi-silencing does not influence Fujioka/P31 and U937 proliferation or 
apoptosis as measured by XTT assay, cell cycle analysis, Annexin V staining and overall 
doublings generation follow up. Nevertheless, HCK semi-silencing influences Mono- 
mac-6 growth as reflected by a general increased doublings generation over time and 
more cycling and less apoptotic cells with an enhanced metabolic activity within six days 
post transduction.
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2. Effect of HCK semi-silencing on FAB M5 cell lines differentiation
2.1 Cell surface m arker phenotyping
Haematopoietic cells maturation and differentiation can be followed by phenotyping their 
cell surface markers. Early progenitor cells are defined as having a myeloid potential, in 
opposition to a lymphoid potential, by the acquisition of the CD33 marker. Expression of 
CD 15 distinguishes CFU-GM (colony forming unit-granulocyte monocyte) from platelet, 
erythrocyte and other polynuclear cell precursors. Loss of CD34 and acquisition of CD13 
defines CFU-G (colony forming unit-granulocyte) that would eventually mature to 
granulocyte/neutrophils by among others losing CD13, acquiring CD l l b  and lowering 
their expression of CD33 (Figure V.5). Loss of CD34 and acquisition of CD13, CD14 
and CDl l b  defines monoblasts that would mature to monocytes by losing CD 15 
(promonocyte stage) and then losing CD 13. Monocytes get activated into macrophages 
upon migration via the blood stream towards damaged tissue.
G-CFU and Myeloblast Granulocyte
O  — — ► — ► o
GM-CFU/ CD14- CD14-
GMP CD15+ CD15+
GEMM-CFU/ CD33+ CD33 low
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.  .CDllb*  
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O ) — ► o CD14-
CD14-
CD15+
CD33+ 0  — *
Q  —  U
Lin-, CD13- CD14+ CD14+ CD 14+
CD34+ CD15- CD34- CD15+ CD15- CD15-
CD38- CD33+ CD33+ CD33+ CD33+
CD34+ CD 13+ 
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Fieure V.5: Cell surface marker expression along the haematopoietic tree (adapted 
from KEGG pathways; http://www.genome.jp/kegg/pathway/hsa/hsa04640.html).
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Although the expression of a given set of markers by a leukaemic cell might not be 
corresponding to the same normal cell physiologically, we intended to assess if HCK 
silencing would impair Fujioka/P31, U937 or Mono-mac-6 cell surface phenotype.
2.1.1 Phenotyping of Fujioka/P31 cell line
Plotting CD33 versus CD15 we can observe that all Fujioka/P31 cells are CD33+/CD15+, 
but with two populations: one is CD33low/CD15hlgh, the other is CD33hlgh/CD15low 
{Figure V.6 a, top panel). Both populations express CD 13 at a similar level {Figure V.6 
a, bottom panel). To distinguish if the cells are monocytic or granulocytic, we need to 
look at CD 14 expression.
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Fisure V.6: Fujioka/P31 cell line phenotyping.
(a) Granulocytic branch: plotting CD33 versus CD15, all Fujioka/P31 cells are 
CD33/CD15 . but with two populations: one is CD33low/CD l 5hlgh, the other is 
CD33high/C D l5low (top panel). Both populations express CD l3 at a similar level (bottom 
panel), (b) Monocytic branch: gating on CD33 ^ /CD 14 cells (top panel), 100% o f  cells 
are CDl 3 (middle panel) and C D l5 (bottom panel), (c) Fujioka/P31 cell line is 
therefore monoblastic. The plots are representative o f  two distinct experiments.
Plotting CD33 versus CD14, we can observe that all Fujioka/P31 cells are CD33+/CD14+ 
{Figure V.6 b, top panel). Gating on this CD33+/CD14+ population, we see that all the 
cells express CD 13 (Figure V.6 b, middle panel) and CD 15 (using the CD 15 APC 
antibody we do not see a clearly distinct CD15,0W population anymore (Figure V.6 b, 
bottom panel)). Fujioka/P31 cells are CD33+/CD13+CD14+/CD15+; they are therefore 
monoblastic (Figure V.6 c). HCK semi-silencing does not seem to alter their phenotype 
when cells are grown in suspension.
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2.1.2 Phenotyping of U937 cell line
Plotting CD33 versus C D l5, we can observe that U937 cells are divided into a 
CD33+/CD15+ and a CD33+/CD15' population (.Figure V.7 a, top panel). Both 
populations express CDl 3 at a similar level {Figure V. 7 a, middle and bottom panels).
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Figure V. 7:_ U937 cell line phenotyping.
(a) Granulocytic branch: plotting CD33 versus C D l5, U937 cells are divided into a 
CD33+/CD15+ and a CD33+/CD15- population (top panel). Both populations express 
CD l3 at a similar level (middle and bottom panel).
(b) Monocytic branch: gating on CD33+/CD14+ cells (top panel), 100% o f  cells are 
CD13+ (middle panel) and divide into a C D l5+ and a C D l5- population (bottom panel).
(c) U937 cell line is composed o f  a CD33+/CD13+/CD14+/CD15+ monoblastic 
population and a CD33+/CD13+/CD14+/ CD15- promonocytic population. The plots 
are representative o f  two distinct experiments.
When plotting CD33 versus CD14, we can observe that all U937 cells are CD33+/CD14T 
(.Figure V.7 b, top panel). These cells all express CDl 3 at a similar level (Figure V.7 b, 
middle panel) and can still be separated into a CD14+/CD15" population and a 
CD14+/CD15+ population (Figure V.7 b, bottom panel). U937 cell line is therefore 
heterogeneous with a CD33+/CD13+/CD14+/CD15+ monoblastic line and a 
CD33+/CD13+/ CD14+/CD15' promonocytic line (.Figure V.7 c). HCK semi-silencing 
does not seem to alter its phenotype when cells are grown in suspension.
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2.1.3 Phenotyping of Mono-mac-6 cell line
Plotting CD33 versus C D l 5, we can observe that Mono-mac-6 cells are divided into a 
CD33+/CD15+, and a CD33+/CD15 population {Figure V.8 a, top panel). Both 
populations express CD 13 at a similar level {Figure V.8 a, middle and bottom panels).
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Figure V.8: Mono-mac-6 cell linephenotyping.
(a) Granulocytic branch: plotting CD33 versus C D l5, Mono-mac-6 cells are divided into 
a CD33+/CD15+ and a CD33+/CD15- population (top panel). Both populations express 
CDl 3 at a similar level (middle and bottom panels).
(b) Monocytic branch: gating on CD33+/CD14+ cells (top panel), 100% o f  cells are 
CD l3+ (middle panel) and divide into a C D l5+ and a CD l5- population (bottom panel).
(c) Mono-mac-6 cell line is composed o f  a CD33+/CD13+/CD14+/CD15+ monoblastic 
population and a CD33+/CD13+/CD14+/ CD15- promonocytic population. The plots 
are representative o f  two distinct experiments.
When plotting CD33 versus CD14, we can observe that all Mono-mac-6 cells are 
CD33+/CD14+ (Figure V.8 b, top panel). These cells all express CD 13 at a similar level 
(Figure V.8 b, middle panel) and can still be separated into a CD14+/CD15' population 
and a CD14+/CD15+ population {Figure V.8 b, bottom panel). Mono-mac-6 cell line is 
therefore heterogeneous with a CDSSVCDnVCDMVCDlS* monoblastic line and a 
CD33+/CD13+/ CD14+/CD15‘ promonocytic line {Figure V.8 c). HCK semi-silencing 
does not seem to alter Mono-mac-6 phenotype when cells are grown in suspension.
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2.2 Colony forming cell assay in methylcellulose without cytokines
2.2.1 Methylcellulose assay for Fujioka/P31 cell line
Only one out of three attempts to obtain colonies by plating Fujioka/P31 cells into 
methylcellulose without cytokines gave rise to one type of colony {Figure V. 9\ cells were 
plated in duplicate). They resemble colony category 2 described below for U937.
Total n u m b er of Fujioka co lon ies
m ock
Figure V. 9: Spontaneous colony formation by Fujioka/P31 cells.
For each condition, 1,000 cells were plated in duplicate in H4330 MethoCult media 
(Stem Cell Technologies) and scored after 14 days (n=2).
No major difference in number o f colonies was found between sh and mock transduced 
Fujioka/P31 cells {Figure V.9). Non-transduced cells, however, give rise to nearly twice 
as many colonies as transduced cells. This result indicates a possible toxicity of the virus 
impairing colony formation.
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2.2.2 Methylcellulose assay for U937 cell line
When plating U937 cells in methylcellulose without cytokines, we observed spontaneous 
formation of colonies with different sizes, all quite compact and resembling CFU-GM. 
As confirmed previously by phenotyping, U937 is a heterogeneous cell line. Colonies 
were scored according to their size (category 1 to 3) as exemplified on Figure V.10. All 
colonies are GFP* when U937 have been transduced with mock virus or with shFlCK4 
encoding virus.
Category 1
■
Category 3
Category 3
Category 2
Fie ure V.10: Types o f  colonies spontaneously formed by U937 cells in methylcellulose 
without cytokines.
Category 1 to 3 colonies spontaneously form ed by U937 cells when plated in H4330 
MethoCult media (Stem Cell Technologies) and scored after 14 days.
As seen in Figure V I 1, the U937 cell line forms, in general, more category 2 colonies 
than category 3 or category 1. U937 transduction with shHCK4 encoding virus does not 
seem to affect the number o f colonies generated in each category. Since transduction with 
either mock or sh virus does not alter the total number of colonies produced, this trend is 
visible both when counting the absolute number of colonies arising (Figure V I 1 a) or 
when assessing the percentage o f colonies from the total colonies falling into the different
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categories (Figure V. I I  b). HCK semi-silencing does therefore not affect U937 
differentiation when cells are grown in methylcellulose.
a
b
Fieure V .ll: HCK silencing does not affect the size o f the colonies formed by U937 
ceils.
For each condition, 1,000 cells were plated in duplicate or triplicate in H4330 
MethoCult media (Stem Cell Technologies) and scored after 14 days (n=5).
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2.2.3 Methylcellulose assay for Mono-mac-6 cell line
When plating Mono-mac-6 in methylcellulose without cytokines, we observed 
spontaneous formation of colonies with different sizes. As confirmed previously by 
phenotyping, Mono-mac-6 is a heterogeneous cell line. Colonies were scored according 
to their size (category 1 to 3). The smallest colonies (category 1) looked like CFU-G 
colonies, but if waiting long enough they most of the time progress towards category 3. 
Colony categories are exemplified in Figure V. 12 a. All colonies are GFP+ when Mono- 
mac-6 have been transduced with mock virus {Figure V. 12 b) or with shHCK4 encoding 
virus (picture not shown).
r.
Category 1 Category 2
Category 3
Category 3
X
,  -
Fisure V.12: Types o f colonies spontaneously formed by Mono-mac-6 cells in 
methylcellulose without cytokines.
Category 1 to 2 colonies spontaneously form ed by Mono-mac-6 cells when plated in 
H4330 MethoCult media (Stem Cell Technologies) and scored after 14 days. All colonies 
were GFP .
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As seen in Figure V.13 d , Mono-mac-6 cell line give rise in general to more category 2 
colonies than category 3 or category 1. However, Mono-mac-6 cells transduction with 
shHCK4 encoding virus significantly affects the number of total colonies generated in 
each category. As shown in Figure V.13 b, Mono-mac-6 cells transduced with shHCK4 
virus produce smaller and more compact colonies than mock transduced or non­
transduced controls {Figure V. 13 a and c respectively). This is reflected in Figure V.13 d 
where we can see that HCK semi-silencing results in formation of more category 2 
colonies than the controls and this effect is even more pronounced in category 1 colony 
formation. Category 3 colony formation does not seem affected by HCK silencing. Since 
transduction with sh virus also increases the total number of colonies arising, we needed 
to also assess the impact of HCK silencing on the production of these different type of 
colonies by calculating the percentage of colonies from the total colonies falling into the 
different categories {Figure V. 12 e). With this representation, we can observe that HCK 
semi-silencing increases the percentage of category 1 colonies while decreasing the 
percentage of category 3 colonies. The percentage of category 2 colonies produced is not 
significantly affected by HCK semi-silencing.
Mono mock: mostly Category 3 Mono sh: mostly Category 2 Mono NT: mostly Category 3
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Figure V.13: HCK silencing affects the size o f the colonies form ed by Mono-mac-6 
cells.
(a) Overall view o f  the colonies spontaneously form ed by mock transduced Mono-mac-6 
cells, (b) Overall view o f  the colonies spontaneously formed by shHCK4 transduced 
Mono-mac-6 cells, (c) Overall view o f  the colonies spontaneously form ed by non­
transduced Mono-mac-6 cells. For each condition, 1,000 cells were plated in triplicates 
in H4330 MethoCult media (Stem Cell Technologies) and scored after 14 days (n=6).
(d) Categories scoring o f  the colonies spontaneously formed by Mono-mac-6 cells 
represented as absolute number o f  colonies per plate, (e) Category scoring o f the 
colonies spontaneously form ed by Mono-mac-6 cells represented as percentage o f total 
colonies per plate. Stars highlight statistically significant differences (p value <0.001).
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Overall, HCK semi-silencing affects Mono-mac-6 cells growth on methylcellulose. We 
observe an increase in total number of colonies generated upon HCK knock-down, which 
confirms the impact of HCK on Mono-mac-6 cells proliferation observed in previous 
experiments. It is however difficult to interpret if the change in colony morphology 
detected is due to alteration in differentiation or in migration abilities of the cells. We 
therefore thought that assessing the migration of Mono-mac-6 cells towards serum in a 
transwell assay might shed some light on this issue. Moreover, the fact that a difference 
in colony type and number spontaneously occur in Mono-mac-6 cells but not in U937 
cells, when both present a similar surface marker phenotype and give rise to colonies in 
methylcellulose (with somewhat different morphologies), directed us to investigate an 
eventual paracrine and/or autocrine production of cytokines by Mono-mac-6 cells.
3. Effect of HCK semi-silencing on FAB M5 cell lines migration
To assess if HCK silencing affected monocytic cell line migration properties, we 
proceeded to a transwell migration assay. We seeded 90,000 cells of each cell type in the 
upper chamber to migrate towards 5% FCS for 4h30 at 37°C, 5% CO2 . Cells were seeded 
in duplicate or triplicate and the graphs presented below are representative of 3 distinct 
experiments (n=8).
We observed that in the absence of serum in the bottom chamber, Fujioka/P31 and U937 
cells do not migrate {Figure V.14 a and b respectively) while Mono-mac-6 cells migrate 
transiently {Figure V.14 c). This transient migration is decreased by HCK silencing in a 
significant manner (p < 0.01). In the presence of serum, Fujioka/P31 cells migrate 1.5 
fold more than non-transduced Mono-mac-6 cells and this cell migration is not affected 
by HCK silencing. Similarly, HCK silencing does not alter U937 cell migration. When 
looking at Mono-mac-6 migration, sh transduced cells migrate 1.43 fold less than mock 
transduced cells. Thus, HCK silencing significantly reduces Mono-mac-6 cells migration 
towards FCS.
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a Effect of HCK sem i-silencing  on Fujioka cells m igration  tow ards FCS
b Effete of HCK s c m i-s i le n d n g  on  U 937 ce lls  m ig ra tio n  to w a rd s  FCS
c Effect of HCK sem i-silencing on M ono-m ac-6 cells m igration  to w ard s FCS
Figure V.14: Migration assay.
(a): Migration o f  mock transduced, shHCK4 transduced and non-transduced 
Fujioka/P31 cells towards 5% FCS after 4h30 incubation, (b): Migration of mock 
transduced, shHCK4 transduced and non-transduced U937 cells towards 5% FCS after 
4h30 incubation, (c): Migration of mock transduced, shHCK4 transduced and non- 
transduced Mono-mac-6 cells towards 5% FCS after 4h30 incubation.
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Looking at the CFC assay results in light o f the migration data, we can conclude that the 
variation in number o f colonies per category observed for Mono-mac-6 cells is due to the 
influence o f HCK silencing on their migration properties.
4. Effect of HCK semi-silencing on cytokine signal transduction towards ST AT 
transcription factors in FAB M5 cell lines
STAT3 and STAT5 constitutive phosphorylation have been reported in leukaemic cell 
lines and in leukaemic patients that could not always be linked to a constitutive activation 
o f the canonical JAK/STAT pathway. As described in the introduction, growing evidence 
is implicating SFK as acting upstream o f  STAT. We therefore were interested in knowing 
if HCK semi-silencing would have an impact on STAT3 and STAT5 phosphorylation on 
the cell lines studied.
Since IL-6, G-CSF and GM-CSF have been reported as signalling upstream o f HCK and 
have also been linked to STAT activation, we thought o f assessing if  stimulation o f the 
cell lines studied with either growth factor would trigger a signal transduction via HCK 
towards STAT3 or STAT5. To make sure we were specifically studying the effect of 
growth factor stimulation, the cells were starved for 24h prior to stimulation.
4.1 Signal transduction towards STAT3
4.1.1 In Fujioka/P31 cell line
We first wanted to follow the effect of serum starvation on STAT3 phosphorylation 
status in the Fujioka/P31 cell line as a means to validate pSTAT3 staining and establish 
the level o f background signal. The cells were therefore incubated for lh , 4h or 24h in 
serum-free medium and stained with anti phospho-STAT3 antibody (Y705) {Figure VI 5, 
top panel). Since the corresponding IgG2a isotype control gave a background signal 
higher than the phospho-STAT3 signal itself, we used unstained cells for normalisation
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of the signal (solid grey histogram). FACS plots presented below are representative of 
two distinct experiments.
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Figure V. 15: STATS phosphorylation in Fujioka/P31 cells.
Top panel: Effect o f  serum starvation on ST AT3 phosphorylation. Cells were incubated 
for Ih, 4h or 24h in serum-free medium and stained with anti-phospho-STAT3 antibody 
(Y705). Since the corresponding IgG2a isotype control gave a background signal higher 
than the phospho-STAT3 signal itself unstained cells were used for normalisation of the 
signal (solid grey histogram). Super imposition o f the lh, 4h and 24h starvation plots o f a 
given sample (sh transduced cells) allows for a better visualisation o f the control and 
sample histograms used to calculate MFI ratios for signal quantification and its variation 
over time. Indeed, with 24h starvation data being acquired on a different day, isotype 
histograms do not always superimpose with the Ih and 4h corresponding histograms and 
need to be used for correction. Bottom panel: Effect of cytokine stimulation on STAT3 
phosphorylation. Cells were starved for 24h then stimulated with either IL-6 or G-CSF 
for 30 min or with GM-CSF for lh  or left unstimulated, as control.
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When comparing the normalised pSTAT3 MFI of the mock transduced sample lh  post 
starvation to the normalised pSTAT3 MFI o f the other samples at different time points, 
no difference in signal intensity was seen over 24h o f serum free incubation {Figure V. 15, 
top panel).
STAT3 phosphorylation status 24h post starvation was then taken as a  no stimulation 
control {Figure V I 5, bottom panel, black line histogram) and compared to Fujioka/P31 
cells starved for 24h then stimulated with either IL-6 or G-CSF for 30 min or with GM- 
CSF for lh. Both IL-6 and G-CSF stimulation led to STAT3 phosphorylation while 
stimulation with GM-CSF did not. Since sh transduced or control Fujioka/P31 cells 
showed the same level o f STAT3 phosphorylation than mock transduced cells, we can 
conclude that STAT3 phosphorylation following IL-6 or G-CSF stimulation is 
independent of HCK in Fujioka/P31 cells.
4.1.2 In U937 cell line
In order to follow the effect of serum starvation on STAT3 phosphorylation status in the 
U937 cell line, the cells were incubated for lh , 4h or 24h in serum-free medium and 
stained with anti-phospho-STAT3 antibody (Y705) {Figure V.16, top panel). FACS plots 
presented below are representative o f two distinct experiments.
Quantification o f the signal intensity comparing normalised MFI pSTAT3 at lh  and at 
24h o f starvation showed a 45% increase in STAT3 phosphorylation 24h post starvation 
that is more visible upon the superimposition of the lh , 4h and 24h starvation plots. This 
observation could correlate with data published by (Spiekermann et a l,  2001), reporting 
that STAT3 is constitutively active in U937 cells.
STAT3 phosphorylation status 24h post starvation was then taken as a no stimulation 
control {Figure V.16, bottom panel, black line histogram) and compared to U937 cells 
starved for 24h then stimulated with either IL-6 or G-CSF for 30 min or with GM-CSF 
for lh. Both IL-6 and G-CSF stimulation led to STAT3 phosphorylation, independent of 
HCK level o f expression. Here, again, GM-CSF did not signal towards STAT3.
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Fisure V.16: STAT3 phosphorylation in U937cells.
Top panel: Effect o f  serum starvation on STAT3 phosphorylation. Cells were incubated 
for lh, 4h or 24h in serum-free medium and stained with anti-phospho-STAT3 antibody 
(Y705). Since the corresponding IgG2a isotype control gave a background signal higher 
than the phospho-STA T3 signal itself unstained cells were used for normalisation o f the 
signal (solid grey histogram). Superimposition o f the lh, 4h and 24h starvation plots o f a 
given sample (sh transduced cells) allows for a better visualisation o f the control and 
sample histograms used to calculate MFI ratios for signal quantification and its variation 
over time. Indeed, with 24h starvation data being acquired on a different day, isotype 
histograms do not always superimpose with the lh  and 4h corresponding histograms and 
need to be used for correction. Bottom panel: Effect o f cytokine stimulation on STAT3 
phosphorylation. Cells were starved for 24h then stimulated with either IL-6 or G-CSF 
for 30 min or with GM-CSF for lh or left unstimulated, as control.
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4.1.3 In Mono-mac-6 cell line
To follow the effect o f  serum starvation on STAT3 phosphorylation status in the Mono- 
mac-6 cell line, the cells were incubated for lh , 4h or 24h in serum-free medium and 
stained with anti-phospho-STAT3 antibody (Y705) (Figure V.17, top panel). FACS plots 
presented below are representative o f two distinct experiments.
Quantification o f the signal over time indicated a 20% decrease in STAT3 
phosphorylation 4h post starvation that persisted over to the 24h time point. STAT3 
phosphorylation status 24h post starvation was then taken as a no stimulation control 
(Figure V.17, bottom panel, black line histogram) and compared to Mono-mac-6 cells 
starved for 24h then stimulated with either IL-6 or G-CSF for 30 min or with GM-CSF 
for lh. Both IL-6 and G-CSF stimulation led to STAT3 phosphorylation, independent of 
HCK level o f expression, while GM-CSF did not lead to STAT3 phosphorylation.
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Figure V. 17: ST A T3 phosphorylation in Mono-mac-6 cells.
Top panel: Effect o f  serum starvation on STAT3 phosphorylation. Cells were incubated 
for lh, 4h or 24h in serum-free medium and stained with anti-phospho-STAT3 antibody 
(Y705). The corresponding IgG2a isotype control was used for normalisation of the
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signal (solid grey histogram). Super imposition o f the lh, 4h and 24h starvation plots o f a 
given sample (sh transduced cells) allows for a better visualisation o f the control and 
sample histograms used to calculate MFI ratios for signal quantification and its variation 
over time. Bottom panel: Effect o f  cytokine stimulation on STAT3 phosphorylation. Cells 
were starved for 24h then stimulated with either IL-6 or G-CSF for 30 min or with GM- 
CSF for lh or left unstimulated, as control.
Thus, serum starvation led to an increase in STAT3 phosphorylation in U937 cells and a 
decrease in STAT3 phosphorylation in Mono-mac-6 cells, suggesting that STAT3 is 
active in a different way in these two cell types, while it is not phosphorylated in 
Fujioka/P31 cells. Moreover, we observed that GM-CSF does not lead to STAT3 
phosphorylation in the 3 cell lines studied while IL-6 and G-CSF did induce STAT3 
phosphorylation in the 3 cell lines studied in an HCK independent fashion.
4.2 Signal transduction towards STATS
4.2.1 In Fujioka/P31 cells
We then assessed the effect o f serum starvation on STAT5 phosphorylation status in the 
Fujioka/P31 cell line as a means to validate pSTAT5 staining and establish the level o f 
background signal. The cells were incubated for lh , 4h or 24h in serum-free medium and 
stained with anti-phospho-STAT5 antibody (Y654) {Figure V I 8, top panel). In this 
experiment a matching Alexa 647 conjugated IgG l isotype control was used for 
normalisation o f the signal (solid grey histogram). FACS plots presented below are 
representative o f 2 distinct experiments.
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Fisure V. 18: STATS phosphorylation in Fujioka/P3l cells.
Top panel: Effect o f  serum starvation on STA T5 phosphorylation. Cells were incubated 
for lh, 4h or 24h in serum-free medium and stained with anti-phospho-STAT5 antibody 
(Y694). The corresponding IgGl isotype was used for normalisation o f the signal (solid 
grey histogram). Superimposition o f the lh, 4h and 24h starvation plots o f  a given sample 
(sh transduced cells) allows for a better visualisation o f the control and sample 
histograms used to calculate MFI ratios for signal quantification and its variation over 
time. Indeed, with 24h starvation data being acquired on a different day, isotype 
histograms do not always superimpose with the lh  and 4h corresponding histogram and 
need to be used for correction. Bottom panel: Effect o f cytokine stimulation on STA T5 
phosphorylation. Cells were starved for 24h then stim ulated with G-CSF for 30 min or 
with GM-CSF for lh or left unstimulated, as control.
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When comparing the normalised pSTAT5 MFI o f the mock transduced sample lh  post 
starvation to the normalised pSTAT5 MFI o f sh transduced or non-transduced samples, 
we observed a decrease in STAT5 phosphorylation after 24h starvation - superimposed 
plots allow us to visualise this decrease better. Although the 50% decrease in STAT5 
phosphorylation at 24h is shown here by a shift in the isotype control histogram, this 
result was reproducibly obtained twice.
STAT5 phosphorylation status 24h post starvation was then taken as a no stimulation 
control (.Figure V.18, bottom panel, black line histogram) and compared to Fujioka/P31 
cells starved for 24h then stimulated with G-CSF for 30 min or GM-CSF for lh. 
Stimulation o f Fujioka/P31 cells with G-CSF or GM-CSF led to STAT5 phosphorylation 
with GM-CSF effect being more pronounced. In both cases STAT5 phosphorylation was 
independent o f HCK.
4.2.2 In U937 cell line
To assess the effect o f serum starvation on STAT5 phosphorylation status in U937 cell 
line, the cells were incubated for lh , 4h or 24h in serum-free medium and stained with 
anti-phospho-STAT5 antibody (Y654) {Figure V.19, top panel). FACS plots presented 
below are representative o f two distinct experiments.
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Figure V. 1 9 :  STAT5 phosphorylation in U937 cells.
Top panel: Effect o f  serum starvation on STAT5 phosphorylation. Cells were incubated 
for lh, 4h o r  24h in serum-free medium and stained with anti phospho-STAT5 antibody 
(Y694). TTie corresponding IgGl isotype was used for normalisat ion o f the signal (solid 
grey histogram ). Superimposition o f the lh, 4h and 24h starvation plots o f a given sample 
(sh transduced cells) allows for a better visualisation of the control and sample 
histograms used to calculate MFI ratios for signal quantification and its variation over 
time. Indeed , with 24h starvation data being acquired on a different day, isotype 
histograms d o  not always superimpose with the lh  and 4h corresponding histogram and 
need to b e  used for correction. Bottom panel: Effect o f cytokine stimulation on STATS 
phosphorylation. Cells were starved for 24h then stimulated with G-CSF for 30 min or 
with G M -C S F for Ih or left unstimulated, as control.
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Over the 24h time period, we observed a progressive decrease o f STAT5 phosphorylation 
where STAT5 phosphorylation at 24h post starvation represented 70% o f the MFI lh  post 
starvation. The effect o f  starvation on STAT5 phosphorylation was, however, not 
affected by HCK semi-silencing.
STATS phosphorylation status 24h post starvation was then taken as a no stimulation 
control {Figure V I 9, bottom panel, black line histogram) and compared to U937 cells 
starved for 24h then stimulated with G-CSF for 30 min or GM-CSF for lh. It can be 
noticed that after stimulation with G-CSF, a consistent proportion o f U937 cells remained 
unphosphorylated after 30 min stimulation, but the amount o f cells in the STATS 
phosphorylated or the STAT5 unphosphorylated fractions did not vary between sh 
transduced and control U937. After stimulation with GM-CSF the proportion o f STATS 
unphosphorylated cells remains very low. In both cases STAT5 phosphorylation was 
independent of HCK.
4.2.3 In Mono-mac-6 cell line
To assess the effect o f serum starvation on STATS phosphorylation status in the Mono- 
mac-6 cell line, the cells were incubated for lh , 4h or 24h in serum-free medium and 
stained with anti-phospho-STAT5 antibody (Y654) {Figure V20, top panel). FACS plots 
presented below are representative o f two distinct experiments.
One hour post starvation, we observed two distinct populations, one with phosphorylated 
STAT5 and one where STATS was not phosphorylated. The Mono-mac-6 population 
with phosphorylated STATS progressively disappeared over 24h o f serum free starvation. 
Percentage o f cells falling into phospho-STATS positive or negative populations did not 
differ between sh transduced and control Mono-mac-6 cells. The effect o f starvation on 
STATS phosphorylation is therefore not affected by HCK semi-silencing.
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Figure V.20: STATS phosphorylation in Mono-mac-6 cells.
Top panel: Effect o f serum starvation on STA T5 phosphorylation. Cells were incubated 
for lh, 4h or 24h in serum-free medium and stained with anti-phospho-STAT5 antibody 
(Y694). The corresponding IgGl isotype was used for normalisation o f the signal (solid 
grey histogram). Superimposition o f the lh, 4h and 24h starvation plots o f a given sample 
(sh transduced cells) allows for a better visualisation o f the control and sample 
histograms used to calculate MF1 ratios for signal quantification and its variation over 
time. Indeed, with 24h starvation data being acquired on a different day, isotype 
histograms do not always superimpose with the lh and 4h corresponding histogram and 
need to be used for correction. Bottom panel: Effect o f cytokine stimulation on STAT5 
phosphorylation. Cells were starved for 24h then stimulated with G-CSF for 30 min or 
with GM-CSF fo r  lh  or left unstimulated, as control.
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STAT5 phosphorylation status 24h post starvation was then taken as a no stimulation 
control {Figure V20 , bottom panel, black line histogram) and compared to Mono-mac-6 
cells starved for 24h then stimulated with G-CSF for 30 min or GM-CSF for lh. Upon 
stimulation with either G-CSF or GM-CSF, we observed a STAT5 phosphorylated and a 
STAT5 unphosphorylated population, with proportions differing between sh transduced 
and control Mono-mac-6 cells.
4.2.3.1 Quantification o f differential STAT5 phosphorylation signal in Mono-mac-6 
cells following G-CSF stimulation
Quantification o f the overall signal intensity (MFI pST AT 5/isotype), whilst taking the 
signal intensity value for the mock transduced cells as a reference, showed a 23% 
decrease in phospho-STAT5 signal intensity in HCK silenced cells following G-CSF 
signal transduction {Figure V2J,  top panel).
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Figure V.21: Quantification o f  STAT5 phosphorylation following G-CSF stimulation 
in Mono-mac-6 cells.
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Top panel: Quantification o f  the overall signal intensity (MFI pSTAT5/isotype) expressed 
as percentage o f  the signal obtained fo r  the mock transduced cells. Middle panel: 
Quantification o f  the phospho-STAT5 positive and negative populations after G-CSF 
stimulation in mock transduced, shHCK4 transduced and non-transduced Mono-mac-6 
cells. Bottom panel: Representation o f  the percentages o f  phospho-STAT5 positive and 
negative populations after G-CSF stimulation in mock transduced, shHCK4 transduced 
and non-transduced Mono-mac-6 cells.
Quantification o f the phospho-STAT5 positive and negative populations after G-CSF 
stimulation showed 11.5 % more cells falling into the STATS unphosphorylated 
population in sh transduced Mono-mac-6 in comparison to mock transduced cells (25.4 
% of mock transduced cells are phospho-STATS negative while 36.9% of sh transduced 
cells are phospho-STATS positive; Figure V21,  middle and bottom panels). This 
difference corresponds to a 45.3% increase in the phospho-STATS negative population in 
HCK silenced cells, which means that HCK is part o f the signal transduction pathway 
linking G-CSF receptor stimulation to STATS silencing in Mono-mac-6 and that HCK 
semi-silencing provokes a 45% decrease in signal transduction towards STATS via G- 
CSFR.
4.2.3.2 Quantification o f differential STATS phosphorylation signal in Mono-mac-6 
cells following GM-CSF stimulation
As mentioned previously, stimulation o f Mono-mac-6 with GM-CSF gave a similar 
differential profile in STATS phosphorylation as stimulation with G-CSF. Quantification 
of the overall signal intensity (MFI pSTAT5/isotype), taking the value for the mock 
transduced cells as a  reference, showed a 30% decrease in phospho-STATS signal 
intensity in HCK silenced cells following GM-CSF signal transduction {Figure V.22, top 
panel).
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Figure V.22: Quantification o f  STATS phosphorylation following G-CSF stimulation 
in Mono-mac-6 celts.
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Top panel: Quantification o f  the overall signal intensity (MFI pSTAT5/isotype) expressed 
as percentage o f  the signal obtained fo r  the mock transduced cells. Middle panel: 
Quantification o f  the phospho-STAT5 positive and negative populations after GM-CSF 
stimulation in mock transduced, shHCK4 transduced and non-transduced Mono-mac-6 
cells. Bottom panel: Representation o f  the percentages o f  phospho-STATS positive and 
negative populations after GM-CSF stimulation in mock transduced, shHCK4 transduced 
and non-transduced Mono-mac-6 cells.
Quantification o f the phospho-STATS positive and negative populations after GM-CSF 
stimulation showed 11.6 % more cells falling into the STAT5 unphosphorylated 
population in sh transduced M ono-mac-6 in comparison to mock transduced cells (24.8 
% o f mock transduced cells are phospho-STATS negative while 36.4% o f sh transduced 
cells are phospho-STATS positive; Figure V.22, middle and bottom panels). This 
difference corresponds to a 46.8% decrease in signal transduction towards STAT5 via 
GM-CSFR in HCK semi-silenced Mono-mac-6 cells.
4.2.3.3 Signal transduction pathway linking HCK to STAT5 phosphorylation 
following G-CSF stimulation
In order to characterise in more detail the newly identified signalling pathway G- 
CSF/HCK/STAT5, we assessed ERK and MEK phosphorylation in Mono-mac-6 cells 
starved for 24h then stimulated with G-CSF for 30 min {Figure V23).  The FACS plots 
shown below are representative o f two independent experiments.
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Fieure V.23: Phosphorylation o f  ERK and MEK in Mono-mac-6 cells upon HCK 
silencing.
(a) HCK Y411 phosphorylation in sh and mock transduced Mono-mac-6 cells upon G- 
CSF phosphorylation: mock and sh transduced Mono-mac-6 cells have a different level 
of background HCK phosphorylation after 24h starvation due to HCK silencing (black 
and grey histograms respectively). Upon G-CSF stimulation, HCK phosphorylation 
increases in both cell types, (b) ERK phosphorylation in sh and mock transduced Mono- 
mac-6 cells upon G-CSF phosphorylation: ERK is phosphorylated upon G-CSF 
stimulation, independently o f  HCK. (c) MEK phosphorylation in sh and mock transduced 
Mono-mac-6 cells upon G-CSF phosphorylation: MEK is phosphorylated upon G-CSF 
stimulation, independently o f HCK. (d) STAT5 Y694 phosphorylation in sh and mock 
transduced Mono-mac-6 cells upon G-CSF phosphorylation: STAT5 is less 
phosphorylated upon G-CSF stimulation in sh transduced Mono-mac-6 cells than in 
mock transduced Mono-mac-6 cells.
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As shown on Figure V.23, G-CSF stimulation led to ERK and MEK phosphorylation but 
these phosphorylations were independent o f HCK level o f expression. Co- 
immunoprecipitation experiments failed to reveal a direct interaction between HCK and 
STATS, thus intermediary signalling proteins between HCK and STATS still remain to 
be identified.
In this section, we have shown that serum starvation led to a decrease in STAT5 
phosphorylation in the 3 cell lines studied, suggesting that STATS is active in these cell 
lines. Moreover, we observed that G-CSF and GM-CSF stimulations induced STATS 
phosphorylation in the 3 cell lines studied. However, STATS phosphorylation was 
mediated by HCK only in M ono-mac-6 cells.
Since G-CSF has been shown to increase haematopoietic stem cells mobilisation and to 
decrease neutrophils migration ability, we were interested in linking the phenotypes 
observed in methylcellulose colony assays and the results obtained in transwell migration 
assays to G-CSF or GM-CSF stimulation.
5. Correlation between G-CSF/GM-CSF stimulation and migration of semi­
silenced Mono-mac-6 cells
Since G-CSF is a known chemoattractant and SFK can act differentially on inside-out or 
outside-in integrins signalling, we tried to separate the two possible effects by either pre­
incubating Mono-mac-6 cells with G-CSF or GM-CSF for 15 min, then to have them 
migrating towards FCS in a transwell assay setting (inside-out signalling assessment) or 
by having the cells in serum free conditions and assessing their migration potential 
towards G-CSF, GM-CSF or both (outside-in signalling assessment).
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5.1 Effect of HCK silencing on Mono-mac-6 cells migration following G-CSF or
GM-CSF stimulation
Mono-mac-6 cells were incubated with G-CSF or GM-CSF at a final concentration of 
lOOng/mL for 15 min at 37°C, 5% CO2 (Figure V.24). 90,000 cells o f each cell type were 
then seeded in triplicate in the upper chamber o f a fibronectin coated transwell system 
and allowed to migrate towards 5% FCS for 4h30 at 37°C, 5% C 0 2. Unstimulated cells 
were taken as controls. The graphs presented below are representative o f 3 distinct 
experiments (n=9).
As described previously, HCK silencing led to a 31% decrease o f Mono-mac-6 migration 
towards FCS. Pre-stimulation of control cells with G-CSF or GM-CSF significantly 
diminished this migration (50% and 34% decrease respectively). However, in shHCK4 
transduced cells, G-CSF prestimulation led to a 50% increase in Mono-mac-6 cells 
migration towards FCS, while GM-CSF prestimulation led to a 33% decrease in Mono- 
mac-6 cells migration towards FCS.
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Effect o f HCK silencing  on  M ono-m ac-6 cells m igra tion  follow ing G- 
CSF o r GM-CSF stim u la tion
3000 t      ------------------
■ji 2000
■  mock
■ sh
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w 1000
-/5%  FCS G-CSF/5% FCS GM-CSF/5% FCS
Fieure V.24: Effect o f  H CK silencing on Mono-mac-6 cells migration towards FCS 
following cytokine pre-stimulation.
Migration o f  mock transduced, shHCK4 transduced and non-transduced Mono-mac-6 
cells, prestimulated for 15 min with G-CSF or GM-CSF, towards 5% FCS after 4h30 
incubation.
The differential effects o f G-CSF and GM-CSF pre-stimulation observed in this 
migration assay suggest that cytokine stimulation triggered opposite inside-out signalling 
pathways involving engagement o f integrin fibronectin receptors mediated by HCK. 
Integrins a5|31 and aV|33 are the principal fibronectin receptor (W u et a l., 1993), HCK 
has been shown to specifically associated with aMf>2 (Tang et al., 2006) and a5|31and 
aM(32 have been shown to differentially regulate neutrophils migration (Lishko et al., 
2003). It would therefore be interesting to assess integrins expression profile in sh or 
mock transduced Mono-mac-6 cells to try to understand the observed migration pattern in 
more details.
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5.2 Effect of HCK silencing on Mono-mac-6 cells migration towards G-CSF or
GM-CSF
G-CSF, GM-CSF or a mix o f both cytokines were added in the bottom chamber of a 
fibronectin coated transwell system at a final concentration o f lOOng/mL. Mono-mac-6 
cells were resuspended in serum-free medium and 90,000 cells o f  each cell type were 
seeded in triplicate in the upper chamber and allowed to migrate towards the cytokines 
for 4h30 at 37°C, 5% CO2 (Figure V.25). Cells migrating towards medium without 
cytokines were taken as transient migration controls and cells migrating towards 5% FCS 
were taken as positive controls for successful migration. As expected, G-CSF acted as a 
potent chemoattractant whose effect was not affected by HCK silencing. GM-CSF did 
not display any chemoattractant properties and cancelled G-CSF chemoattractant 
potential when the two cytokines were mixed together, this phenomenon was not 
influenced by HCK silencing. Suppression o f  G-CSF chemotactic effect by GM-CSF has 
been suggested to be due to a down-regulation o f G-CSFR induced by GM-CSF (Avalos 
et a l , 1997; Nicola et a l , 1986), an aspect that HCK silencing does not modulate.
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Effect of HCK silencing  on M ono-m ac 6 cells m igration  to w a rd s  G-CSF
o r GM-CSF
2 5 0 0
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Figure V.25: Effect o f  H CK silencing on Mono-mac-6 cells migration towards G-CSF  
or GM-CSF.
Migration o f mock transduced, shHCK4 transduced and non-transduced Mono-mac-6 
cells, towards G-CSF, GM-CSF or both cytokines. Cells migrating towards 5% FCS or 
towards serum-free medium were taken as controls. Migration was assessed after 4h30 
incubation.
Thus, we demonstrated that HCK mediates G-CSF and GM-CSF induced Mono-mac-6 
cells migration in an opposite manner via mechanisms that still remain to be elucidated.
6. Conclusion
In this chapter, we have shown that HCK semi-silencing did not have any major effect on 
FAB M5 cell line proliferation, apoptosis or differentiation as shown by XTT assay, cell 
cycle analysis, Annexin V staining, population doublings calculation and specific cell 
surface marker staining respectively. However we observed that HCK knock-down had 
an influence on the spontaneous colony forming capacity o f Mono-mac-6 cells that was
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essentially due to an effect o f  HCK semi-silencing on their migration capacity. 
Furthermore we have demonstrated that HCK is involved in the mediation o f G-CSF and 
GM-CSF signal transduction towards STATS exclusively in Mono-mac-6 cells, 
illustrating the point that the 3 AML FAB MS cell lines studied are heterogeneous and 
use different signalling pathways to convey a given signal. Additionally we could show 
that G-CSF or GM-CSF pre-stimulation o f Mono-mac-6 cells had an opposite effect on 
Mono-mac-6 cells migration, further stating a role o f HCK in integrin mediated migration 
and G-CSF chemotaxis.
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VI Effect o f  H C K  silencing on UCB Lin' cells
1. Effect of HCK silencing on ex vivo expanded Lin’ growth
Equal numbers o f mock transduced, shHCK4 transduced or non-transduced Lin’ cells 
were resuspended in a final volume o f 100 pL o f StemSpan containing 300 ng/mL SCF, 
300 ng/mL Flt3-L and 20 ng/mL TPO (Levac et al., 2005). Lin’ cells were numerated 
every 3 days on an LSRII analyser using counting beads. An appropriate number o f cells 
were used for various in vitro assays (CFC assay, cell cycle analysis, HCK expression by 
flow cytometry) and unused cells were replated, adding fresh cytokines each time.
1.1 Absolute number o f cells
Transduced Lin' absolute numbers o f  cells were followed up for 11 days. As shown in 
Figure VI. 1, HCK silencing led to an increase in absolute number o f Lin' cells over time.
ex-vivo expansion of transduced Lin- 
with SCF, Flt3, TPO
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Fieure VIA: Ex vivo expansion o f  transduced Lin cells.
Equal numbers o f  mock transduced, shHCK4 transduced or non-transduced Lin cells 
were expanded in StemSpan containing 300 ng/mL SCF, 300 ng/mL Flt3-L and 20 ng/mL 
TPO. Lin cells were numerated every 3 days on an LSRII analyser using counting beads.
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1.2 Population doublings
To have a more accurate representation o f the population behaviour during expansion, we 
calculated the cumulative population doublings (PD) of each culture using the following 
formula: PD = [logio (na) - logio (nt!)] / logio (2) (Cristofalo et al., 1998). After 4 days in 
culture, shHCK4 transduced Lin" cells showed a 1.66 fold increase in population 
doubling in comparison to mock transduced Lin" (Figure VI. 2). Past four days in culture, 
cumulative population doubling curves from both shHCK4 and mock transduced Lin" 
cells are growing parallel, indicating that both populations are not in an exponential 
growth phase anymore and proliferate at the same pace. The difference in PD observed 
initially suggests that HCK silencing could have an influence on the initial Lin" cells 
expansion capacity, but does not improve Lin" cells expansion beyond the classical 4 days 
window.
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Figure VI. 2: Ex vivo expansion o f  transduced Lin cells represented as cumulative 
population doublings.
Cumulative population doublings (PD) o f each culture were calculated using the 
following formula: PD = [logio (na) - logio (no)] /  logio (2).
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The use o f mathematical formulae taking into account the non-exponential nature of stem 
cell growth as well as proportions o f  cycling or differentiating cells within the population 
would, however, allow a better representation o f Lin' growth (Deasy et al., 2003).
1.3 G FP+ population over tim e and  cell cycle analysis
The data presented so far takes into account the bulk Lin' population. Following up the 
percentage o f GFP+ cells within the total Lin' population would allow us to see if  HCK 
silencing gives any growth advantage to the shHCK4 transduced cells. Surprisingly, the 
percentage of GFP+ cells remained constant over time (.Figure VI. 3).
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Figure VI.3: Percentage o f  GFP+ cells in culture over time.
Assessment o f GFP expression at earlier time points, such as one or two days post 
transduction, would give an insight into any influence o f  HCK silencing on Lin' cells 
initial expansion. However, the reporter gene is usually not detectable prior to 48h 
making it technically unpractical to follow GFP expression within 4 days of transduction.
m o c k  TPO  m e d iu m  G FP+ 
s h  TPO m e d iu m  G FP+
267
Chapter VI
Cell cycle analysis using Ki67 as a marker o f proliferation confirmed that shHCK4 and 
mock transduced G FPf cells had a similar cell cycle status 16 days post transfection when 
maintained in TPO containing medium (Figure VI.4).
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Figure VI. 4: Cell cycle analysis o f  mock and shHCK4 transduced GFP+ cells 16 days 
post-transduction.
2. Effect of HCK silencing on CFC potential of Lin' cells with or without 
expansion in SCF, Flt3-L, TPO medium
In parallel to being expanded in liquid culture, 1,000 shHCK4 and mock transduced Lin 
cells were plated in triplicate for CFC assay at day 1, day 4 and day 11 post-transfection. 
Two million cells from day 1 and day 4 primary CFC assays were also replated for 
secondary CFC assays.
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2.1 Effect on absolute number of total primary and secondary colonies
HCK silencing did neither significantly influence the overall total number o f colonies 
formed by non expanded Lin' cells nor the overall total number o f colonies formed by 
Lin' cells expanded for 4 days or 11 days in TPO medium (Figure VI. 5, top panel). 
However, shHCK4 transduced primary colonies formed by non expanded or expanded 
Lin' cells gave rise to about 2.5 times (2.63 and 2.21 respectively) more secondary 
colonies than mock transduced cells {Figure VI.5, bottom panel). Absolute numbers of 
colonies are represented per plate (i.e. per 1000 cells for primary colonies and per 2x106 
cells for secondary colonies). As expected, expanded Lin' cells generate less secondary 
colonies than non-expanded Lin' cells. HCK silencing does not influence the secondary 
CFC potential o f expanded cells since expanded cells generate about half the number of 
secondary colonies, in comparison to non-expanded cells, in each condition.
Effect o f HCK silencing  on a b so lu te  to ta l n um ber of Lin- colony 
fo rm atio n  (ex p a n s io n  w ith  SCF, Flt3L,TPO)
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Effect of HCK silencing on abso lu te  num ber of total Lin- 2nry colony 
form ation (expansion with SCF, Flt3L,TPO)
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Figure VI.5: Absolute number o f  total prim ary and secondary colonies generated by 
expanded and non-expanded Lin cells.
Top panel: 1,000 Lin cells were plated in triplicate in H4434 MethoCult media and 
scored after 14 days for primary colonies. Bottom panel: Primary CFC plates were 
pooled and 2xl06 cells were replated in H4434 MethoCult media for secondary CFC 
assays and scored after 12 days.
2.2 Effect on overall percen tage of G FP positive colonies
To have a closer look at the effect o f  HCK silencing on colony formation, we scored the 
number o f GFP+ cells in each condition. HCK silencing a priori led to a decrease in GFP+ 
colonies formation from either expanded or non-expanded Lin' cells (Figure VI. 6, top 
panel). However, since the transduction efficiency determined at day 4 in liquid culture 
was 77.2% GFP+ cells for mock transduced cells and 46.7% for shHCK4 transduced 
cells, it was necessary to correct the number o f GFP+ colonies generated by the 
percentage o f GFP+ cells they are originating from {Figure VI. 6, top panel). Although the 
original percentage o f GFP+ cells seeded for non-expanded Lin' cells cannot be 
determined at such an early time point, we extrapolated the correction based on the fact 
that the percentage o f GFP+ colonies generated by expanded or non-expanded cells was
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stable {Figure VI. 6, bottom panel). After correction, the shHCK4 transduced Lin' cells 
are actually more potent than previously estimated and produce 1.34 times more GFP+ 
cells than mock transduced cells when non-expanded and 10% more colonies when 
expanded {Figure VI. 6, top panel). However, no significant difference is observed when 
comparing the percentage o f GFP colonies produced by shHCK4 and mock transduced 
cells {Figure VI. 6, bottom panel).
O f note, the percentage o f GFP+ colonies formed by transduced cells, expanded or not, 
did not significantly vary (around 50% for mock transduced cells and around 60% for 
shHCK4 transduced cells). This indicates that, as expected, 4 days Lin' cells expansion 
does not influence their intrinsic colony forming capacity.
Effect of HCK silencing on abso lu te  num ber of GFP+ Lin- colony 
form ation (expansion  w ith SCF, Flt3L,TPO)
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Effect of HCK silencing on %  of GFP+ Lin- colony 
form ation (expansion  w ith SCF, Flt3L,TPO)
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Fisure VI. 6: Scoring o f  prim ary GFP colonies generated by expanded and non- 
expanded Lin cells.
Top panel: Absolute number o f primary GFP colonies generated by expanded and non- 
expanded Lin cells were scored and corrected by the percentage o f GFP ' cells they are 
originating from. Bottom panel: Percentages o f  primary GFP colonies were calculated 
from the corrected absolute number o f  GFP cells. Uncorrected percentages o f primary 
GFP colonies are indicated to explain the extrapolation o f correction to unexpanded 
cells.
When looking at secondary GFP+ colonies, HCK silenced primary colonies gave rise to 
more GFP+ secondary colonies than mock transduced primary colonies {Figure VI. 7, top 
panel). Since the percentage o f GFP4 cells seeded for secondary CFC was not 
determined, no correction can be applied to this graphical representation. However, when 
looking at uncorrected percentages o f GFP+ cells, we can conclude that although 
shHCK4 transduced primary colonies gave rise to more total secondary colonies than 
mock transduced Lin' colonies, they contain a constant proportion o f GFP4 colonies, 
indicating that HCK silencing does not confer any advantage to the shHCK4 transduced 
cells.
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Effect of HCK silencing on abso lu te  num ber of GFP + Lin- 2nry colony 
form ation  (expansion with SCF, Flt3L,TPO)
■  mock
■  sh
total GFP+ CFU NE total GFP+ CFU 4d TPO
Effect of HCK silencing on %  of GFP + Lin- 2nry colony form ation 
(expansion w ith SCF, Flt3L,TPO)
90
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Fisure VI.7: Scoring o f  secondary GFP+ colonies generated by expanded and non- 
expanded Lin cells.
Top panel: Absolute number o f  secondary GFP colonies generated by expanded and 
non-expanded Lin cells were scored 12 days after replating. Bottom panel: Percentages 
of secondary GFP+ colonies were calculated from the total number o f secondary colonies 
and the uncorrected absolute number o f GFP cells.
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Thus, HCK silencing does not seem to confer any proliferative or self-renewing 
advantage to transduced Lin' cells when looking at total colonies.
2.3 Effect of H C K  silencing on percentage of d ifferent type of G FP positive 
colonies
When looking at individual types o f colonies, no major differences are observed between 
colonies produced from shHCK4 or mock transduced cells except for CFU-Gs, where 
shHCK4 transduced Lin' cells produce half the number o f CFU-G than mock transduced 
Lin' cells (.Figure VI. 8, top panel). This production o f CFU-G is maintained upon 
expansion in HCK silenced Lin' cells but not in mock transduced expanded Lin' cells.
Effect of HCK silencing on %  of GFP+ Lin- colony 
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Effect of HCK silencing on °/o of GFP+ Lin- 2nry colony form ation 
(expansion with SCF, Flt3L,TPO)
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Fisure VI. 8: Percentage o f  prim ary and secondary GFP+ CFU-G, CFU-GM, CFU-M, 
BFU-E, CFU-E and CFU-GEM M  generated by expanded and non-expanded Lin 
cells.
Top panel: 1,000 Lin cells were plated in triplicate in H4434 MethoCult media and 
scored after 14 days for individual type o f primary colonies. Bottom panel: Primary CFC 
plates were pooled and 2x106 cells were replated in H4434 MethoCult media for 
secondary CFC assays and scored after 12 days for individual type ofprimary colonies.
When looking at individual types o f  secondary colonies, non-expanded shHCK4 
transduced primary colonies gave rise to twice as many CFU-G and half the CFU-GM 
than mock transduced primary colonies (Figure VI. 8, bottom panel). Mostly, CFU-GM 
were produced by primary colonies originating from expanded Lin' cells with no 
significant difference between colonies produced from shHCK4 or mock transduced 
cells.
Thus, HCK silencing decreases the percentage o f CFU-G generated in vitro but not when 
Lin' cells have previously been expanded in culture. This observation should however be 
verified in an LTC-IC assay.
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3. HCK expression after 4 days expansion and relative cell cycle analysis
[’he fact that the GFP percentage o f cells did not vary over time seemed unusual, we 
therefore assessed HCK expression in non-transduced Lin' cells and in Lin' cells 
expanded for 4 days. When calculating the difference in HCK expression between mock 
and shHCK4 transduced GFP+ cells as percentage o f mock HCK APC MFI, only 32% 
silencing is detected (Figure VI9 a and b). However, when looking at HCK expression as 
a function o f GFP expression and comparing the percentage o f HCK+GFP+ cells in mock 
and shHCK4 transduced Lin- cells, 61% silencing is detected (Figure VI. 9 d).
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Fisure VI. 9: H CK expression in GFP+ cells after 4 days expansion.
(a) HCK expression in mock and shHCK4 transduced GFP+ cells, (b) HCK expression in
mock and shHCK4 transduced GFP+ cells represented as percentage o f mock HCK APC 
MFI. (c) HCK expression as a function o f Lin expression in non-expanded Lin enriched 
UCB. (d) HCK expression as a function o f  GFP expression in mock transduced, shHCK4 
transduced and non-transduced Lin cells.
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O f note, after 4 days expansion only 26% o f non-transduced cells (NT) were HCK+ while 
staining o f unmanipulated Lin cells showed that more than 95% of Lin' cells originally 
express HCK at the protein level {Figure VI9 c). In mock transduced cells, 18% of the 
cells express HCK but were left non-transduced (HCK+GFP'), a percentage that did not 
vary in shHCK4 transduced cells. Moreover, 42% o f mock transduced cells were GFP+ 
but did not express HCK (in this experiment 50% for both mock and shHCK4 transduced 
Lin' cells, as detected by flow cytometry prior to fixation). Thus, the fact that the 
percentage o f GFP+ cells in ex vivo expansion liquid culture comprises cells that are 
GFP+ and have lost HCK expression upon expansion, as well as cells that still express 
HCK at a lower level in shHCK4 transduced cells than in mock transduced cells, has to 
be taken into account. Following the percentage o f GFP+ cells in liquid culture is 
therefore biased and cannot properly reflect the effect o f HCK silencing on Lin' 
expansion.
Interestingly, the fact that Lin' cells seem to lose HCK upon expansion reminds us what 
has been reported for mouse embryonic stem cells losing HCK expression upon 
differentiation to embryonic bodies.
Analysis o f the cell cycle o f expanded and non-transduced Lin' cells revealed that HCK+ 
cells are slightly more In G2/M  phase o f the cell cycle {Figure VI. 10, top panel), a 
tendency also observed in mock and shHCK4 transduced cells {Figure VI10, middle and 
bottom panel). Upon HCK silencing, there are fewer cells in S phase and more cells in 
G0/G 1 phase, but this difference is not significant.
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Fisure VI. 10: Cell cycle analysis in H C K  and HClC cells after 4 days expansion.
Top panel: Cell cycle analysis o f  HCK and HCK non-transduced cells. Middle panel:
Cell cycle analysis o f  GFP+ H CK and GFP H O C  mock transduced cells. Bottom 
panel: Cell cycle analysis o f  GFP H CK and GFP HCK shHCK4 transduced cells.
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4. Conclusion
HCK semi-silencing does not seem sufficient to exert an important influence on Lin' cells 
physiology, mainly due to  the fact that HCK expression is lost within four days o f ex vivo 
expansion. It would therefore be interesting to correlate HCK expression with CD34 
expression during this four day window. HCK silencing seems to have an influence on 
the CFU-G potential o f non-expanded Lin' cells. This effect could be correlated with 
what has been reported in hck '/' mice, where HCK has a negative regulatory role on G- 
CSF induced granulocytic precursors proliferation (Mermel et al., 2006). Effect of HCK 
silencing in liquid differentiation culture would be closer to the conditions used in this 
mouse study, however knock-out and knock-down being different tuning o f HCK protein 
level, the results have to be interpreted in term o f disrupting SFK balance in Lin' cells. 
Nevertheless, this preliminary study on the effect o f HCK silencing on Lin' cells could 
serve as a basis to study the effect o f  HCK silencing in AML patient stem cell enriched 
fractions, provided an influence o f  HCK silencing is seen on STAT5 activation, for 
reasons that will be discussed in the next chapters.
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VII HCK expression in patient samples
Blood patient samples obtained by leukapheresis or venepuncture were collected with 
informed consent and stored in the Centre for Medical Oncology, John Vane Science 
Centre, Charterhouse Square, London. Whole mononuclear cells were enriched from the 
patient sample by density centrifugation as described in Chapter II. Mononuclear cells 
from 34 patient samples were used to produce the results presented below. These samples 
were processed for RNA extraction, W estern blot or flow cytometry analysis.
1. Karyotype, FAB class and NPM11 mutation status of the AML patients used 
in this study
AML patient samples used in this chapter are summarised in Table VII.l, organised 
according to their FAB class (M l to M5).
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Patient Karyotype FAB class
NPM11
mutation
23 -5q M l ND
17 +8 M l ND
1 N K M l Yes
12 N K M l Yes
24 +13 M l ND
13 t(6 ,l l ) ,  +9 M l t-AML ND
18 del5 ,der 12 ,ins 12(q22) M l tAML No
25 ND M l ND
26 +12,+21 M2 ND
14 +11,+13 M2 No
6 Complex M2-tAML No
27 t(8,21)+8, -5q M2 No
7 t(8;21) M2 No
28 t(8,21) M2 No
2 NK M2 ND
5 N K M2 ND
19 NK M2eo No
20 NK M2eo ND
3 +3, +10 M4 Yes
29 NK M4 Yes
15 NK M4 No
21 NK M4 ND
4 NK M4 ND
30 ins (6;11) M4 ND
31 inv(16) M4eo ND
16 (3-9) del M5 No
32 NK M5a ND
33 t( l l ,1 9 ) M5a No
34 inv(3),-7 ND No
35 +13 ND ND
36 t(3;14) ND ND
37 inv(16) ND ND
38 NK ND Yes
22 ND ND ND
Table VII. 1: Karyotype, FAB class and nucleophosmin (NPM11) mutation status of 
the AML patient samples used in this study.
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2. HCK expression in MNC at the RNA level
Since we could successfully relate HCK expression and FAB classification in AML cell 
lines, we assessed if the same would be true for MNC from patient samples. We could 
however not find any correlation between FAB class and HCK expression, all patient 
samples were expressing HCK at levels superior to that o f Mono-mac-6 cells (one o f the 
cell lines tested expressing the highest level o f HCK) (Figure VII. 1). Two individual 
UCB MNC samples and one pool UCB MNC sample, used for comparison, also express 
higher levels o f HCK than Mono-mac-6 cells, probably due to their high content in 
macrophages and granulocytes known to highly express HCK.
HCK expression in a variety of AML patient MNCs in comparison to Mono-
mac-6 cells
Patient sam ples: * NPM1 mutant - NPM1 wild type
Fisure VII. 1: H CK expression in mononuclear cells from  26 AML patient samples.
HCK expression was assessed by quantitative real-time PCR using SYBR' green.
GAPDH was used to normalise the values o f mRNA expression. Results are expressed as 
fold change in comparison to the Mono-mac-6 cell line.
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3. HCK expression in M NC at the protein  level assessed by W estern Blot
We went on to look at HCK isoforms expression by Western blot in two AML samples 
and two UCB pools (Figure VII. 2). We could observe that p59HCK is preferentially 
expressed in UCB in comparison to p61HCK. Both isoforms seem to be expressed in 
similar quantities in patient sample 12 in either fraction tested while in patient 25, HCK 
isoforms expression seems to be similar to what was observed in UCB. Relative 
quantitation data between Lin', Lin" and bulk MNC fractions cannot be extracted from 
the blots since less total protein seems to have been loaded in the MNC lane according to 
the (3-actin loading controls. However, the difference in isoforms expressed by MNC 
from UCB or patient samples might reflect a difference in maturation and functionality of 
the subcellular compartments o f  these cells, since p59HCK has been reported to be 
exclusively found in lipid rafts while p61HCK is not (Robbins et al., 1995). Also, 
p61HCK has been shown to play a role in the lysosomal compartment (Carreno et al., 
2000). Proper screening o f additional patient samples would allow determining whether 
HCK isoforms are differentially expressed amongst AML patient samples.
UCB UCB
MNC Lin* Mono MNC Lin*
75 15 —•    p61
50 50
p59
patient 25 patient 12
Lini - + MNC Lin - + MNC ^
r  m m  i .
~  ■ + -  beta-actin
Fisure VII.2: H CK expression in L in , Lin and bulk mononuclear cells from  two 
AML samples and fro m  umbilical cord blood.
Top panel: HCK expression in UCB bulk MNC and Lin'cells from 2 independent UCB 
pool. Mono-mac-6 cells were taken as control. Bottom panel: HCK expression in Lin, 
Lin and bulk MNC from 2 AML patient samples (patient 25 and patient 12). Lin and
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Lin cells were separated by magnetic separation using a colloid labelled Lineage 
antibody cocktail
4. HCK expression in MNC at the protein level assessed by flow cytometry
We also assessed, by flow cytometry, if HCK was expressed uniformly within MNC 
from 8 AML patient samples and whether we could fractionate subpopulations 
expressing different levels o f HCK {Figure VIL3). Umbilical cord blood MNC pools 
were used as a reference and gave rise to 3 distinct populations expressing various levels 
of HCK {Figure VII. 3 a) that could also be separated into two distinct populations 
according to HCK phosphorylation level {Figure VII. 3 b). Levels o f HCK expression 
were variable between the patient samples tested and cells could be separated into 2 to 3 
distinct subpopulations, according to their level o f HCK expression, in 7/8 cases {Figure 
VII. 3 c, e, g, /, k, m, o; except for patient 25 where only one population is observed 
Figure VII. 3 q). HCK was found constitutively activated in 4/7 cases, as shown by 
staining for phosphorylated HCK Y411 {Figure VII. 3 d, f  h, j, I, p, r; except for patient 
30 where the Y 411 staining is not reliable Figure VII. 3 n).
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Fisure VI 1.3: H CK expression and phosphorylation status in M NC from  8 AML 
patient samples.
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MNC from patient samples were stained for HCK (plots c, e, g, i, k, m, o, q) or for 
phosphorylated HCK Y411 (plots d, f  h, j, I, n, p, r). UCB MNC were taken as reference 
(plots a and b).
5. H CK  activity in M NC from  7 A M L patien t samples
We assessed HCK activity in AML MNC by in vitro non-radioactive kinase assay 
(Figure VII. 4) and observed that AML MNC display variable levels o f HCK kinase 
activity that is always more elevated than HCK activity in UCB MNC. Each sample was 
run in duplicate. M ono-mac-6 cells were taken as a positive control. MNC from patient 
12 lysed in RIPA buffer (abrogating the kinase activity) were used as a negative control.
HCK activity in MNC from 7 AML patient sam ples (45  min incubation)
BOOOOO 
700000
|T  600000
c
«  500000
8  400000 
O
»  300000 
o
= 200000  
IL
100000  
0
Mono- patient patient patient patient patient patient patient CB MNC patient
mac-6 12 24 32 36 38 37 31 12 RIPA
Fisure VII. 4: H CK activity in M NC from  7 AML patient samples.
MNC from  7 AML patient samples were lysed in buffer A and HCK was
immunoprecipitated using a mouse anti-HCK antibody. An in vitro non-radioactive 
kinase assay using the Antibody Beacon™ Tyrosine Kinase Assay Kit was set up in a 384 
well black plate and fluorescence was read at 530 nm after 45 min incubation. The 
fluorescence emitted is directly proportional to the kinase activity. Mono-mac-6 cells 
were taken as a positive control. MNC from patient 12 lysed in RIPA buffer were used as 
a negative control.
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We then compared in vitro HCK activity to HCK expression and phosphorylation levels 
measured by FACS {Table VII2). Fold differences in HCK expression, HCK 
phosphorylation and HCK activity were calculated as fold difference between the 
normalised MFI o f the HCK positive population(s) o f a given AML sample (as indicated 
by a gate on the flow cytometry plots in Figure VII. 3) in comparison to the normalised 
MFI o f the HCK positive populations o f UCB MNC; fold difference between the 
normalised MFI o f the Y 411 population(s) o f a given AML sample in comparison to the 
normalised MFI o f the Y411 populations o f UCB MNC and fold difference between the 
fluorescence intensity o f a given AML sample in comparison to the fluorescence intensity 
o f UCB MNC.
HCK expression and HCK activity show the same trend for each sample studied, e.g. 
samples with the highest levels o f HCK expression have also the highest HCK in vitro 
activity. Patients 31 and 24 are shown to overall express less HCK than UCB MNC 
because they consist o f  a quite large HCK negative subpopulation. O f note, these two 
samples were not assessed by quantitative real-time PCR, we can therefore not establish 
if HCK expression at the protein level in these samples is different from the RNA level. 
HCK phosphorylation status does not seem reliable, which is contradictory with what has 
been obtained in the FAB M5 cell lines. This difference is most probably due to the 
thawing o f the sample and long handling prior to staining and fixation, that might not 
have allowed for the stability o f the phosphorylated epitope.
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Patient 
Fold change''''''"— 12 31 24 32 30 38 25 35 36 37
HCK + — - ++ + ++ = + ND ND
Y411 - - ND ND
HCK activity + + + ++ ND + ND N D -F +
Table VII.2: Comparison between HCK expression, HCiK Y411 phosphor}' Nation
measured by flow cytometry and HCK activity measured by non-radioactive in vitro 
kinase assay in MNC from AML patient samples,
‘+ + ’ indicates a tw o fo ld  increase (or higher), '+ ' indicates less than tw o  f o ld  increase, 
-- ' indicates a tw o fo ld  decrease (or lower), - '  indicates less than tw o  f o ld  decrease. 
Fold differences in H C K  expression, H C K  phosphorylation and H C K  activity  were 
calculated as f o ld  difference between the normalised M FI o f  the H C K  positive  
population(s) o f  a given  AML sam ple (as indicated by a gate on the f lo w  cytom etry p lo ts  
on Figure VII. 3) in com parison to the normalised MFI o f  the H C K  p o s itiv e  populations 
o f  UCB MNC; fo ld  difference between the normalised M FI o f  the Y411 popu lation(s) o f  a 
given AML sam ple in com parison to the normalised MFI o f  the Y411 popu la tion s o f  UCB 
MNC and fo ld  difference between the fluorescence intensity o f  a  g iven  AM L sample in 
comparison to the fluorescence intensity o f  UCB MNC.
6. HCK expression in the stem cell compartment assessed by flow cytometry
Ultimately we were interested in knowing if  the HCK overexpression in  the AML sample 
Lin/CD34+/CD38‘ fractions observed in the microarray at the RNA level, in comparison 
to normal bone m arrow  and UCB, could also be detected at the protein level and, more 
importantly, to determine if  this overexpression was reflecting an  increase in HCK 
activity. For this purpose, we established a protocol for external cell surface marker 
staining (i.e. Lineage) combined with an internal staining for HCK or phospho-HCK 
Y411. CD34 and CD38 antigens could not be used to successfully fractionate MNC, due 
to technical difficulties, we therefore went on to quantify HCK expression and 
phosphorylation in Lin" versus Lin+ populations in 3 patient and 2 UCB samples {Figure 
VII. 5).
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Fisure VII. 5: H C K  expression an d  phosphorylation in the Lin and Lin fractions from  
3 AM L patien t samples.
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MNC from  2 UCB and 3 pa tien t sam ples were stained fo r  Lineage, CD34 and HCK or 
phosphorylated H C K  Y4JJ. H C K  expression and phosphorylation was studied within the 
Lin and Lin populations: H C K  in Lin cells from  UCB and patien t samples (plots h, g, I, 
q), H CK in L in h cells from  UCB and pa tien t sam ples (plots c, h, m, r), phosphorylated  
HCK Y411 in Lin cells from  UCB and patien t samples (plots d, i, n, s), phosphorylated  
HCK Y411 in Lin+ cells from  UCB and patien t samples (plots e, j ,  o, t). F old difference in 
H CK expression or phosphorylation were calculated between Lin and L irf populations 
within a given sample.
Surprisingly, the overall HCK expression and phosphorylation were very similar in both 
populations (less than 1.5 fold difference when comparing MFI Lin' versus MFI Lin+ 
within a given sample, table in Figure VII. 5).
However, CD34' AML samples (patient 32: Figure VII. 5 k and patient 25: Figure VII. 5 p )  
displayed strictly overlapping levels o f HCK expression in their Lin' {Figure VII. 5 I and 
q) and Lin+ (Figure VII. 5 m and r) populations. The same was true for their levels o f 
HCK phosphorylation (patient 32: Figure VII. 5 n and o; patient 25: Figure VII. 5 s and t), 
while UCB and CD34+ AML sample BM displayed a completely different profile.
Indeed, UCB and patient 35 Lin' cells could be separated into two discrete populations 
expressing two levels o f HCK cells (Figure VII. 5 b and g  respectively) corresponding to 
two levels o f HCK phosphorylation (Figure VII.5 d  and i respectively). Similarly, UCB 
and patient BM Lin+ cells could be separated into two discrete populations expressing 
two levels o f HCK cells (Figure VII. 5 c and h respectively) corresponding to two levels 
of HCK phosphorylation (Figure VII. 5 e and j  respectively) that were distinct from what 
was observed for Lin' cells. Regardless o f their CD34 expression status, HCK was 
overexpressed in Lin' cells from the 3 patient samples in comparison to UCB Lin' cells.
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7. Conclusion
Thus, staining Lin and Lin+ AML populations for HCK expression (and 
phosphorylation) reveals a complex pattern o f expression. Managing staining that allows 
fractionation o f Lin' cells, could allow distinguishing o f a clearer pattern o f HCK 
expression. Screening o f additional AML samples and correlating the data to Western 
blot data on HCK isoforms expression might allow determining whether HCK expression 
specifically correlates with a degree o f differentiation o f the primitive cells.
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VIII Effect of HCK overexpression on UCB Lin" cells
Since in our microarray analysis, we found HCK overexpressed in the Lin'/CD34+/CD38‘ 
fraction from AML samples in comparison to normal bone marrow and UCB, we decided 
to also try to study a potential role for HCK in leukaemogenesis by overexpressing it in 
stem cells enriched Lin- umbilical cord blood cells. In order to ultimately work with 
HSC, the HCK cDNA had to be cloned into a lentiviral vector.
1. HCK cloning
1.1 Cloning of p59HCK cDNA into the pENTRlA-IRES-GFP shuttle vector
RNA was extracted from Mono-mac-6 cells and reverse transcribed into cDNA as 
described in Chapter II. Since we found p59HCK preferentially expressed in leukaemic 
MNC and this HCK isoform is known to be the one responsible for signalling in lipid 
raft, p59HCK cDNA was amplified by PCR using the Takara polymerase and the PCR 
product was cloned into the pCR® 2.1-TOPO vector by TA ligation, according to the 
manufacturer’s instructions (Invitrogen). Presence o f the p59HCK cDNA insert into the 
pCR® 2.1-TOPO vector was assessed by restriction digest with Kpnl and Notl and four 
clones were sequenced using the M l 3 forward and reverse primer to verify the 
orientation o f the cDNA sequence {Figure VIII. 1 a).
p59HCK was further cloned into the pENTRl A-IRES-GFP or pENTRlA-IRES-YFP 
shuttle vectors to allow for subsequent Gateway crossover into a lentiviral backbone. The 
p59HCK fragment was cut out o f the pCR® 2.1-TOPO vector with the EcoRI restriction 
enzyme and cloned into a linearised and CIPed pENTRl A-IRES-GFP or pENTRl A- 
IRES-YFP shuttle vector. After ligation, presence o f the p59HCK insert into the 
pENTRl A-IRES vectors was confirmed by restriction digest with Xmal for pENTRl A- 
IRES-GFP and BstXI for pENTRl A-IRES-YFP. The final map o f the pENTRl A-IRES- 
GFP shuttle vector is shown in Figure VIII1 b.
295
Chapter VIII
Reverse
—  ►
Jk Zis ATQM13 | H*^3* Kpn I S#c! ea.TH I S^o>
8* Z& S5 »c S I $£  S3 *88 0® 82* 88? $88 2E8 8*2 88* 82*
® T ! f c |f ' AC-1 , c n  A l S * '
CTA ACC CCC COC ACT CIO CTC dfcA T i t  CCC C T tIS M W W W JW . COCCTCK TIC TOC 
CAT TOC COO COO TCA CMC. OAC CIT AAC CCC .A ^ fc ti l i r tM H -T C  c c ,- CTT AAC AGO
fcoRV a »  r Moil XfOl HsJIXiWt A,9»l
I I I I  I I  T  _____
ACA TAT CCA TCA CA TOO CCC OCC CTC GAG CAT CCA TCT A«0A GOO OCC AAT TCC ECC TAT 
TCT ATA GOT ACT CTC ACC OCC OOC CAC CTC |CTA CCT A.OA TCT COC OCC TTA AOC |iOCG AT A
T7 ftotratt
7Cu TAT TM AAT TCA
TCA CTC ACC ATA AT 0 TTA AOT
M13 ForwanJ (-iO| Rr»n«-
C CCC CTC CTT TIA qAA 
CAC COG CAC CAA AAT cJjT
CCT CGI CAC TOC CAA AAC 
CCA CCA CIO ACC CTT TTC
Chapter VIII
b
PENTR1a-HCK-IRES-GFP
Fisure V III.l: C loning o f  p59H C K  cDNA into the pE N T R lA -IR E S-G F P  shuttle 
vector.
(a) pCR® 2.1-TOPO vector multiple cloning site (MCS) map and localisation of the 
primers used to assess proper cloning ofp59HCK cDNA. (b) Map o f the pENTRl A-HCK- 
IRES-GFP plasmid.
1.2 C loning o f p59H C K  cDNA into the LNT-Sffv-cddB-M CS lentiviral backbone
pHCK59-IRES-GFP was recombined with the LNT-Sffv-cddB-MCS lentiviral vector 
using the Gateway recombination technology (Invitrogen). Presence o f the p59HCK- 
IRES-GFP insert into the lentiviral backbone was confirmed by restriction digest with 
SacII and Age I, which would give a 4 kb and a 8 kb fragment when HCK-IRES-GFP is
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inserted and a 4 kb and a 5 kb fragment when the crossover did not occur. The final map 
of the LNT-Sffv-HCK-IRES-GFP lentiviral vector is shown on Figure VIII. 2.
LTN-HCK-IRES-GFP
Fieure VIII.2: C loning o f  p59H C K  cDNA into the LNT-Sffv-cddB-M CS lentiviral 
backbone.
Map o f the LNT-Sffv-HCK-IRES-GFP plasmid.
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1.3 Assessment o f p59HCK overexpression in 293T-HEK cells
The lentiviral backbone encoding p59HCK (also termed ovHCK in this manuscript) was 
transiently transfected into 293T-HEK cells and p59HCK expression was assessed by 
flow cytometry and Western blot.
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F u n c t i o n a l  k i n a s e  a c t i v i t y  o f  p 5 9 H C K  o v e r e x p r e s s e d  b y  2 9 3 T -H E K  c e l l s
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Fie u re VII1.3: p59HCK expression and phosphorylation in 293T-HEK cells 
overexpressing p59HCK.
GFP expression in (a) control non-transfected 293T-HEK cells and in (b) p59HCK 
transfected 293T-HEK cells, (c) HCK expression: mock transduced 293T-HEK cells do 
not express HCK (black histogram), p59HCK transduced GFP positive 293T-HEK cells 
highly express HCK (dark blue histogram). A matching mouse IgGI isotype control is 
used as a reference (solid grey histogram), (d) HCK phosphorylation (Y411 
phosphorylation): mock transduced 293T-HEK cells are negative fo r  anti-Y411 staining 
(black histogram), this staining gives a high background in comparison to the matching 
goat IgGI isotype control (solid grey histogram). p59HCK transduced GFP positive 
293T-HEK cells are partially phosphorylated (dark blue histogram, two populations), (e) 
p59HCK expression by Western blot, (f) HCK functional kinase activity: HCK antibody 
immunoprecipitate from  non-transduced 293T-HEK does not display any kinase activity, 
while immunoprecipitate from  293T-HEK cells overexpressing p59HCK shows a 
(specific) kinase activity that can be successfully abrogated by the addition o f the SFK 
inhibitor PP2 to the kinase assay reaction.
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2. Effect of p59HCK overexpression on ex vivo expanded Lin" growth and 
differentiation
Highly concentrated mock and p59HCK encoding lentiviruses were produced using 
293T-HEK cells as a packaging cell line and used to transduce equal numbers of Lin 
cells overnight as described in Chapter II.
Equal numbers of mock transduced, ovHCK transduced or non-transduced Lin" cells were 
resuspended in a final volume of 100 jjlL  of StemSpan containing 300 ng/mL SCF, 
300ng/mL Flt3-L and 20 ng/mL TPO. Lin" cells were numerated one day after 
transduction using Trypan blue exclusion. An appropriate number of cells were used for 
various in vitro assays (restricted myeloid differentiation, neutrophil differentiation, 
erythroid differentiation, CFC assay, signalling pathway analysis by flow cytometry) and 
unused equal numbers of cells were replated for each condition, adding fresh cytokines 
every 3 days.
2.1 Cell cycle analysis
To assess if HCK overexpression had any influence on Lin" proliferation, we analysed the 
cell cycle status of GFP+/Lin" after 4 days expansion using Ki67 as a marker of 
proliferation (Figure VIII. 4). HCK overexpression did not influence Lin" cell cycle status. 
Of note, the percentage of GFP+/Lin" overexpressing HCK cells was quite low (10% 
versus 45% in mock transduced cells) therefore not allowing the acquisition of GFP+ 
events in the FACS plots pictured below. These FACS plots represented below are 
representative of two independent experiments.
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Figure VIII.4: Cell cycle analysis o f Lin overexpressing p59HCK 4 (lays after 
transduction.
2.2 Influence of p59HCK overexpression on myeloid differentiation in liquid 
culture
To assess the effect of HCK overexpression on the myeloid differentiation potential of 
Lin' cells, 20,000 Lin' cells/mL were seeded in triplicate and maintained for 12 days in 
restricting myeloid differentiation medium (IMDM, 15% FCS, 20 ng/mL IL-3 and 20 
ng/mL SCF (Barabe et al., 2007)) or in terminal granulocytic differentiation medium 
(IMDM, 20% FCS, 50 ng/mL G-CSF and 50 ng/mL SCF (Edvardsson et al., 2004)). 
Fresh cytokines were added to the cells every 3 days. Figure VIII.5 indicates the different 
types of cells produced in either differentiation conditions.
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Figure VIII. 5: Schematic representation o f  myeloid differentiation (adapted from  
KEGG path ways; http://www.genome.jp/kegg/path way/hsa/hsa04640. html)
After 12 days in culture with restricting myeloid differentiation medium, 21% of mock 
transduced cells have not yet entered the myeloid pathway since they are CD33' (Figure 
VIII. 6). About 75% of them are myeloid progenitors that are CD33+/CD14'/CD15' and 
about 4% of them are myeloblast or monoblast that are CD33+/CD14‘/CD15+ or 
CD33+/CD14+/CD15+ respectively. No differentiated promonocytes (CD33+/CD14+/ 
CD15‘ cells) or granulocytes (CD33+/CD147CD15+ cells) are detectable in this 
differentiation condition, since the medium in use does not promote further 
differentiation. Interestingly, after 12 days in culture in the same conditions 90% of HCK 
overexpressing Lin’ cells became CD33+/CD14’/CD15’ progenitors and, similarly to 
mock transduced cells, about 4.5% of Lin- cells have differentiated to myeloblasts or 
monoblasts (Figure VIII. 6).
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Fisure VII 1.6: Restricted myeloid differentiation analysis.
Top panel: CD33 and CD 14 expression in mock transduced or p59HCK overexpressing 
GFP+ cells. Bottom panel: CD33 and CD 15 expression in mock transduced or p59HCK 
overexpressing GFP+ cells.
After 12 days in culture with terminal granulocytic differentiation medium, 11% of mock 
transduced cells have not yet entered the myeloid pathway since they are CD33' (Figure 
VIII. 7). About 30% of them are myeloid progenitors (CD33+/CD15‘ cells), 44.5% are 
myeloblasts (CD33+/CD15+ cells) and 15% are granulocytes (CD33low/CD15+ cells). 
Interestingly, after 12 days in culture in the same conditions, HCK overexpressing Lin' 
cells all entered the myeloid pathway, mostly giving rise to myeloblasts and to four times
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less terminally differentiated granulocytes than mock transduced Lin' cells {Figure 
VIII. 7).
CO
CO
O
O
mock ovHCK
44.5.112 9 .4 *  2 61x10 -
10000* 10000
’ a* : T V-?•. ,?.« -- . '. Fr
■ V  ♦  • >  .  •
100
11.O i l  .5 1512
r-,-»■■'"•i— • > i"n — ..........  — .......   **
0 100 1000 10000 1x10
2 6 . l r l  .4 6 9 .6 1 2 .4
-  ' -  • • .  V
0 .2 2 + 0 .1 4. 110.9
0 100 1000 1 0000 1x105
CD15
Fisure VIII. 7: Terminal granulocytic differentiation analysis.
CD33 and CD 15 expression in mock transduced orp59HCK overexpressing GFP' cells.
Data obtained from both differentiation conditions suggests that HCK overexpression 
promotes the production of myeloid progenitors, while impairing their maturation into 
neutrophils.
2.3 Influence of p59HCK overexpression on erythroid differentiation in liquid 
culture
To assess the effect o f  HCK overexpression on the erythroid differentiation potential of 
Lin cells, 10,000 Lin' cells/mL were seeded in triplicate and maintained for 8 days in 
primary erythroid differentiation medium (Giarratana et al., 2005). Cells were split 1:5 
after 4 days and supplemented with fresh cytokines. Figure VIII.8 illustrates the different 
types of cells produced in these differentiation conditions.
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Fisure VIII. 8: Schematic representation o f erythroid differentiation (adapted from  
(Spivak, 2005).
After 8 days in culture with primary erythroid differentiation medium, 20% of mock 
transduced Lin- cells became erythroid progenitors that are CD71+/Glycophorin-A", 67% 
became erythroblasts that are CD71 /Glycophorin-A and 12.5% became reticulocytes 
that are CD717Glycophorin-A {Figure VIII. 9). After 8 days in culture in the same 
conditions, HCK overexpressing Lin' cells seem to have a delay in the erythroid 
differentiation process since 38% of HCK overexpressing Lin' cells became erythroid 
progenitors, 57% became erythroblasts and 4% became reticulocytes.
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Fisure VII 1.9: Primary erythroid differentiation analysis.
CD7I and Glycophorin A (GLYA) expression in mock transduced or p59HCK 
overexpressing GFP cells.
2.4 Influence of p59HCK overexpression on CFC potential of Lin' cells
In parallel to being expanded in liquid culture, 1000 ovHCK and mock transduced Lin' 
cells were plated in triplicate for CFC assay at day 1 and day 4 post-transduction.
2.4.1 Influence of HCK overexpression on the morphology of erythroid colonies
Upon p59HCK overexpression Lin' cells gave rise to small GFP" structures which, most 
of the time, surrounded a BFU-E, as pointed out by an arrow in Figure VIII. 10. The small 
GFP+ structures were mainly in a different focal plane than the central BFU-E they 
surrounded, which were often GFP' confirming a distinct origin {Figure VIII. 10 d). We 
therefore scored the small structures that were not in the same focal plane as any 
surrounding BFU-E as individual CFU-Es {Figure VIII. 10 c), while the small structures
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that were in the same focal plane as a BFU-E were considered as part of the BFU-E 
{Figure VIII. 10 a and b). O f note, the mock transduced and non-transduced Lin" cells did 
not display any abnormal BFU-E or an abnormal number of CFU-E.
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Fisure VIII. 10: Erythroid colonies formed by Lin cells overexpressing p59HCK in 
CFC assay (14 days).
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(a) Phase contrast picture o f a BFU-E formed by Lin overexpressing p59HCK. (b) The 
same BFU-E as in (a) under UV light o f  a fluorescent inverted microscope, (c) Phase 
contrast picture o f  a BFU-E and several CFU-Es formed by Lin over expressing 
p59HCK. (d) The same BFU-E and CFU-Es as in (c) under UV light o f a fluorescent 
inverted microscope. Only the CFU-Es are GFP+.
2.4.2 Influence of p59HCK overexpression on the type of colonies formed by Lin' 
cells
Since the Lin' cells overexpressing p59HCK displayed a very high number of CFU-E 
(132 fold higher than mock transduced cells), the overall total number of CFU formed by 
these cells was 4.6 fold higher than in control cells (Figure VIII. 11 a). Consequently, 
percentages of other CFU types appeared very low in Lin' cells overexpressing p59HCK 
in comparison to mock transduced and non-transduced cells (Figure VIII. 11 c), we 
therefore show the absolute number o f each type of CFU numerated in each condition to 
be able to consider if  formation of CFU-G, CFU-GM, BFU-E and CFU-GEMM occurred 
normally upon HCK overexpression {Figure VIII. 11 b). 
a
E f f e c t  o f  p 5 9 H C K  o v e r e x p r e s s i o n  o n  t h e  a b s o l u t e  n u m b e r  o f  c o l o n i e s  in  
n o n - e x p a n d e d  L in -  c e l l s
■  mock 
■ ovHCK
■  NT
total CFU
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E f f e c t  o f  p 5 9 H C K  o v e r e x p r e s s i o n  o n  t h e  a b s o l u t e  n u m b e r  o f  
i n d i v i d u a l  C FU  t y p e  ( e x c e p t  C F U -E ) in  n o n - e x p a n d e d  L in -  c e l l s
G-CFU M-CFU GM-CFU BFU-E GEMM-CFU
E ff e c t  o f  p 5 9 H C K  o v e r e x p r e s s i o n  o n  t h e  %  o f  i n d i v i d u a l  CFU  t y p e  in  
n o n - e x p a n d e d  L in -  c e l l s
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Fisure VI 11.11: Influence o f p59HCK overexpression on absolute numbers and 
percentages o f  individual CFU types formed by Lin cells one day post-transduction.
Top panel: Absolute number o f  total colonies and absolute number o f  CFU-E formed by 
mock transduced, p59HCK overexpressing and non-transduced Lin cells, per plate. 
Middle panel: Absolute number o f  CFU-G, CFU-M, CFU-GM, BFU-E and CFU-GEMM 
formed by mock transduced, p59HCK overexpressing and non-transduced Lin cells, per 
plate. Bottom panel: Percentge o f  CFU-G, CFU-M, CFU-GM, BFU-E, CFU-E and 
CFU-GEMM form ed by mock transduced, p59HCK overexpressing and non-transduced 
Lin cells, per plate.
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Upon p59HCK overexpression, non-expanded Lin' cells gave rise to 66% less CFU-Gs, 
29% more CFU-Ms, 22% less CFU-GMs, 65% more BFU-Es and 33% less CFU- 
GEMMs than mock transduced cells when comparing absolute number of colonies per 
plate {Figure VIII. 11 b). To have a proper estimate of p59HCK overexpression effect on 
Lin' cells CFC potential, however, we needed to look at GFP+ colonies. As shown in 
Figure VIII. 12, p59HCK overexpressing Lin' cells exclusively gave rise to erythroid 
GFP+ colonies while mock transduced Lin’ cells gave rise to reasonable percentages of 
myeloid and erythroid colonies.
Effect of p59HCK overexpression on the  %  of GFP+ individual 
CFU type in non-expanded Lin- cells
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«
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8 60
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§  40S
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20
10
G-CFU M-CFU GM-CFU BFU-E CFU-E GEMM-CFU
Fisure VIII. 12: Influence o f p59HCK overexpression on GFP+ colony formation by 
non-expanded Lin cells.
Percentage o f GFP+ CFU-G, CFU-M, CFU-GM, BFU-E, CFU-E and CFU-GEMM 
formed by mock transduced and p59HCK overexpressing non-expanded Lin cells, per 
plate.
To determine whether the results obtained in CFC assay could be modulated by 
expanding the Lin' cells, in vitro, prior to proceeding with the CFC assay, Lin' cells were 
cultured for 4 days in StemSpan containing 300 ng/mL SCF, 300ng/mL Flt3-L and 20
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ng/mL I PO {Figure VIII. 13). Expanded Lin' cells overexpressing HCK gave rise to 27 
fold less GFP+ CFU-G, 29 fold less GFP+ CFU-GM, 2.24 fold less GFP+ BFU-E, 10 fold 
more GFP^ CFU-E and 16 fold less GFP* CFU-GEMM than mock transduced cells 
{Figure VIII. 13). Once again, most HCK overexpressing GFP+ colonies were CFU-E. 
Since we could detect myeloid GFP+ colonies in CFC assay from expanded Lin' cells 
overexpressing p59HCK, we can conclude that p59HCK overexpression does not 
completely abrogate myeloid differentiation but rather skew Lin' cells differentiation 
towards the erythroid lineage.
Effect of p59HCK overexpression on th e  %  of GFP+ individual 
CFU type in 4 days ex  vivo  expanded Lin- cells
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90Q)I 80
uV
a  70
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Fisure VI 11.13: Influence o f  p59HCK overexpression on GFP+ colony formation by 
Lin cells 4 days post-transduction.
Percentage o f  GFP+ CFU-G, CFU-M, CFU-GM, BFU-E, CFU-E and CFU-GEMM 
formed by mock transduced and p59HCK overexpressing expanded Lin cells, per plate.
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Thus, in a CFC assay supporting both myeloid and erythroid growth simultaneously, 
p59HCK overexpression led to a block in production of myeloid colonies while 
increasing the production of CFU-E by 10 fold.
Although the identity of the colonies specifically produced by Lin' cells overexpressing 
p59HCK that we scored as CFU-E were difficult to establish, both liquid cultures, 
supporting either myeloid or erythroid differentiation, and CFC assays, supporting both 
differentiation simultaneously, provide evidence to conclude that p59HCK 
overexpression impairs myeloid differentiation while promoting erythroid differentiation.
2.5 Influence of HCK overexpression on STATS signalling pathway
Based on the results obtained in Mono-mac-6 cells indicating that HCK is upstream of 
STAT5, we decided to assess the phosphorylation status of HCK, cRaf, ERK and STAT5 
in GFP+ Lin' overexpressing p59HCK as well as in mock transduced cells by flow 
cytometry {Figure VIII. 14).
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Fisure VIII. 14: Phosphorylation status o f HCK, cRaf ERK and STATS in Lin 
overexpressing p59HCK analysed by flow  cytometry.
(a) HCK phosphorylation status in mock transduced (grey histogram), p59HCK 
overexpressing (black histogram) and non-transduced (solid grey istogram) Lin cells, (b) 
c-Raf status phosphorylation in mock transduced, p59HCK overexpressing and non- 
transduced Lin cells, (c) ERK phosphorylation status in mock transduced, p59HCK 
overexpressing and non-transduced Lin cells, (d) STATS phosphorylation status in mock 
transduced, p59HCK overexpressing and non-transduced Lin cells, (e) Schematic 
representation o f  the pathways linking SFK c-Raf, ERK and STATS adapted from  
(McCubrey et al., 2008).
We found out that overexpression of p59HCK in Lin' cells induces c-Raf, ERK and 
STAT5 phosphorylations, while this pathway is not active in mock transduced Lin' cells. 
The FACS plots displayed are representative of two independent experiments.
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3. Conclusion
When plating Lin* cells in methylcellulose in conditions supporting myeloid and 
erythroid progenitor growth simultaneously, HCK overexpression provokes an excessive 
and almost exclusive erythroid differentiation (increase in both CFU-E and BFU-E 
colony formation), suggesting that HCK overexpression promotes erythroid 
differentiation. However, when the cells are cultured in conditions exclusively supporting 
myeloid differentiation, HCK overexpression is not sufficient to completely block 
myeloid differentiation but seems to prevent terminal myeloid differentiation into 
granulocytes. This phenotype is underlied by c-Raf, ERK and STATS phosphorylation 
(and potentially activation) and indeed correlates with the phenotype described 
consequently to STATS overexpression (Schuringa et a l, 2004; Wierenga et al., 2008).
3 1 6
Chapter IX
Chapter IX
317
Chapter X
IX Discussion
AML is a clonal, malignant proliferation of undifferentiated haematopoietic cells that is 
morphologically, genetically and therapeutically heterogeneous. AML mostly consists of 
a bulk of leukaemic blasts with low proliferative potential that are maintained by a rare 
population of LSC responsible for propagating the disease. Elucidating the identity of the 
LSC and the mechanisms underlying its ability to self-renew is of great interest and LSC 
have been proposed to reside in the CD34+/CD38' (Bonnet and Dick, 1997), 
CD34+/CD38+ (Taussig et al., 2008) or the CD34" (Blair et al., 1997) compartment, 
depending on the AML sample studied.
In an attempt to identify genes differentially expressed between the Lin'/CD34+/CD38' 
and Lin7CD34+/CD38+ potential leukaemic stem cell compartments and their normal 
counterparts, microarray analyses were carried out in our laboratory. Haematopoietic cell 
kinase (HCK) was identified as the gene most overexpressed in the Lin'/CD34+/CD38' 
fraction from 7 AML patients in comparison to normal bone marrow. HCK was also 
overexpressed in the Lin7CD34+/CD38+ fraction from these 7 AML patients in 
comparison to normal bone marrow. Although a decrease in HCK expression was 
observed when comparing Lin7CD34+/CD38' and Lin7CD34+/CD38+ data from 
leukaemic samples, HCK was still overexpressed by at least two folds in all leukaemic 
subfractions studied in comparison to normal bone marrow.
In order to elucidate if HCK could have a part in leukaemogenesis, we decided to study 
its role in haematopoietic cells by either downregulating it in leukaemic cells or 
overexpressing it in normal stem cells. Since ST AT have been shown to be constitutively 
active in leukaemic AML patient samples (Gouilleux-Gruart et al., 1996; Xia et al, 
1998) and this phenomenon could not be exclusively explained by the disruption of the 
canonical JAK-STAT pathway (Biethahn et al., 1999; Steensma et a l, 2006), and since a 
parallel role for HCK or at least SFK in STAT5 or STAT3 activation was emerging from 
various publications using various cell type background (Ernst et a l, 1996; Klejman et 
al, 2002), we were also interested in establishing if a link between HCK level of
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expression and STAT activation was existing in normal HSC and/or in AML cells.
In this study we demonstrated that HCK acts upstream of STATS and that the pathways 
engaged in this axis of signal transduction are highly cell type dependent, therefore 
leading to very distinct phenotypes within leukaemic cell lines and in stem cell enriched 
cell fractions.
1. HCK is involved in G-CSF and GM-CSF signal transduction and is implicated 
in the migration of the ‘mature’ myelomonocytic cell line Mono-mac-6
We first confirmed that HCK expression could be correlated to the FAB class of the 
leukaemic cell lines tested and that AML FAB M5 cell lines were the AML cell lines 
expressing the most HCK. We then showed that a similar correlation could not be 
established between the FAB class of MNC from primary leukaemic samples and HCK 
expression; all samples tested were expressing HCK at higher level than AML FAB M5 
cell lines at the RNA level. After showing that the two isoforms of HCK, p59 and p61, 
were expressed at similar levels in the 3 AML FAB M5 cell lines tested, Fujioka/P31, 
U937 and Mono-mac-6, we noticed that only p59 seemed to be autophosphorylated in 
Fujioka/P31, while both p59 and p61 were autophosphorylated in U937 and Mono-mac-6 
cells, as shown by phospho-specific Western blotting. However, the kinases had a similar 
catalytic activity when tested in an in vitro non-radioactive kinase assay that measured 
substrate phosphorylation rather than autophosphorylation. We also showed that UCB 
MNC expressed more p59 than p61 HCK and that MNC from UCB and various patient 
samples had variable levels of HCK activity.
Since we showed by surface marker phenotyping that U937 and Mono-mac-6 cells are 
more mature than Fujioka/P31 cells and since p61HCK has been reported to be 
exclusively associated with lysosomes (Carreno et a l, 2000), the differential expression 
of the HCK isoforms in the 3 cell lines studied might be reflecting their degree of 
maturation, which is most likely associated with a distinct organisation and functionality 
of their subcellular compartments.
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Primarily in leukaemic cell lines, but later in normal or leukaemic stem cells, we wanted 
to knock-down HCK using RNA interference (RNAi). To do so we tested two different 
strategies of RNAi: testing several siRNA sequences and also trying to establish knock­
down using an miRNA based system. We could only achieve 50% knock-down of HCK 
using an shRNA expressing lentiviral system. The relative efficiency of the knock-down 
turned out to be sequence inherent and independent of the cell line (293T-HEK 
overexpressing HCK, Fujioka/P31, U937 or Mono-mac-6 cell lines) or way of silencing 
used (transient by electroporation, nucleofection or PEI mediated transfection, or stable 
by lentiviral transduction). We, however, decided to further study HCK semi-silencing 
assuming that 50% HCK knock-down, representing a disruption in the balance of SFK 
expression as a whole, might be sufficient to trigger a distinct phenotype.
In myelomonocytic cell lines, we showed that HCK semi-silencing did not have any 
major effect on their proliferation, apoptosis or differentiation as shown by XTT assay, 
cell cycle analysis, Annexin V staining, population doublings calculation and specific cell 
surface marker staining respectively. However, we observed that HCK knock-down had 
an influence on the spontaneous colony forming capacity of Mono-mac-6 cells that was 
essentially due to an effect of HCK semi-silencing on their migration capacity. 
Furthermore we could demonstrate that HCK is involved in the mediation of G-CSF and 
GM-CSF signal transduction towards STATS exclusively in Mono-mac-6 cells, 
illustrating the point that the 3 AML FAB M5 cell lines studied are heterogeneous and 
use different signalling pathways to convey a given signal. Additionally we could show 
that G-CSF or GM-CSF pre-stimulation of Mono-mac-6 cells had an opposite effect on 
Mono-mac-6 cells migration, further stating a role of HCK in integrin mediated migration 
and G-CSF chemotaxis. These results are in accordance with the reduced in vitro motility 
observed for macrophages taken from Hck^VFgr^ knock-out mice (Suen et a l , 1999), 
however such a phenotype was not reported for Hck'A knock-out mice (Lowell et al, 
1994). Additionally, evidence for a role of HCK in adhesion of human cells has only 
been reported in one overexpression study in human fibroblasts and activated 
macrophages (Carreno et al., 2002). Thus it would be of interest to study in more detail
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the link between G-CSF stimulation, integrin engagement, HCK activation and cell 
migration.
It would especially be interesting to study the relationship between G-CSF stimulation, 
integrin engagement, HCK activation and cell migration in a stem cell context since SFK 
have recently been implicated in G-CSF mediated HSC mobilisation (Borneo et a l , 
2007), as well as in G-protein-coupled receptors signalling in a cell type dependent 
manner (Vichalkovski et al., 2005). Moreover, ectopic expression of HCK in Jurkat cells 
lacking LCK has recently been shown to restore responsiveness to SDF1 induced 
chemotaxis of the mutant Jurkat cells, suggesting a potential role for HCK in the 
SDF1/CXCR4 signalling pathway. It would therefore be interesting to assess if 
modulation of HCK expression would affect human HSC migration towards SDF-1 
and/or mobilisation in vivo by disrupting the SFK expression balance.
2. HCK semi-silencing does not alter Lin' CFC capacity
HCK semi-silencing of the stem cell enriched Lin' fraction did not impair their 
differentiation capacity as shown in CFC assays. We observed a significant increase in 
total cell numbers after 4 days ex vivo expansion but could not be linked it to any change 
in cell cycle status of the cells. Since it was observed that 75% of normal Lin' cells lose 
HCK expression within 4 days of ex vivo expansion, it was concluded that 50% HCK 
silencing would not affect Lin" physiology beyond this natural HCK downregulation with 
differentiation and thus studying the effect of HCK silencing in this ex vivo expansion 
assay was impractical. However, it would be worth assessing whether the level of STATS 
activation is decreased upon HCK semi-silencing in Lin" cells and, if it is, to study the 
effect of HCK semi-silencing on stem cell enriched fractions in LTC-IC assays.
Indeed, recent studies by Schuring and Vellanga’s group showed that intermediate levels 
of STAT5 activity had the maximal effect on increasing HSC self-renewal capacity in 
vitro (Wierenga et al., 2008), while silencing of STAT5 was leading to a decrease in 
LTC-IC frequency and progenitor numbers in CFAC assay (Schepers et a l , 2007). It is 
therefore likely that HCK semi-silencing would have an effect on HSC self-renewal
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capacity only if it is sufficient to down-regulate STATS activity. However, LYN activity 
has been shown to increase upon HCK knock-out in mice (Lowell et a l, 1994), LYN has 
also been linked to STATS signalling (Karur et a l, 2006; Xiao et a l, 2008) and Lynf' 
knock-out mice display an increased number of HSC with an impaired repopulating 
capacity (Orschell et a l, 2008). Endogenous LYN expression (and activity) may then 
counterbalance the effect of HCK silencing on STATS activation. Achievement of a 
stronger HCK knock-down might therefore be necessary to trigger a proper phenotype 
and if proven successful could eventually be used to study the effect of HCK silencing in 
AML patient samples.
Indeed, Schepers’ study also showed that silencing STATS in leukaemic CD34+ cells 
displaying a constitutive STATS activity led to a decrease in expansion of the leukaemic 
cells grown in stromal culture (Schepers et a l , 2007). Hence, it would be interesting to 
see if HCK plays a role in such a phenotype by sorting patient samples according to their 
level of STATS activity and HCK expression prior to silencing HCK.
3. HCK overexpression promotes erythroid differentiation at the expense of 
myeloid differentiation in Lin' cells
HCK overexpression in Lin" cells exhibited a clear phenotype of enhanced erythroid 
differentiation at the expense of myeloid differentiation underlined by the activation of c- 
Raf, ERK and STATS. Liquid culture exclusively supporting myeloid differentiation 
indicated a delay in myeloid differentiation and a block in terminal differentiation upon 
HCK overexpression, while liquid culture exclusively supporting primitive erythroid 
differentiation indicated a delay in erythroid differentiation. However, CFC assays 
supporting both myeloid and erythroid progenitor differentiation simultaneously showed 
a skew in differentiation towards erythropoiesis. Interestingly this later phenotype 
correlates with phenotypes observed upon overexpression of constitutively active STAT5 
or mutant Flt3-ITD in UCB CD34+ cells by CAFC assays (Chung et a l, 2005; Moore et 
a l, 2007; Schuringa et a l , 2004). Since erythropoietin (EPO) independence and 
enhanced self-renewal have also been observed in the later studies, it could be interesting
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to test if HCK is also involved in such phenotypes by conducting CFC assays in the 
absence of EPO, performing colony replating and assaying for repopulating capacity in 
vivo using the NOD/SCID model. Additionally, since intermediary levels of STAT5 
overexpression have been reported to positively impact on LTC-IC frequency (Wierenga 
et a l 2008), the use of an inducible system to modulate HCK overexpression could yield 
more insight into the implication of HCK in STAT5 activation regulation.
Although it can appear contradictory that we observed HCK overexpression in Lin' 
/CD34+/CD38' cells from leukaemic patients and that overexpression of HCK in Lin' 
cells led to the increase formation of CFU-E accompanied by a decrease in myeloid 
colony formation, these results have to be looked at in light of the following studies. First 
of all, it is interesting to see that Lyn'A mice display a block in erythropoiesis, as early- 
stage erythroblasts fail to expand upon EPO and SCF stimulation (Karur et a l , 2006). It 
could therefore be of interest to see if LYN silencing in human Lin' cells would give rise 
to a similar phenotype to the one observed in murine HSC, suggesting an opposite role 
for HCK and LYN in erythroid cell expansion at different stages of erythropoiesis. In 
addition, it would be interesting to see what happens upon LYN overexpression. 
Moreover, Lyn^'/Hck'7' mice display a STAT5 dependent skewed differentiation towards 
macrophages that evolves into mild MPD (Xiao et a l , 2008). It is intriguing to observe 
that LYN knock-out led to a decrease in STAT5 activation in Lyn_/' erythroblasts, while 
Lyn^THck'7" mouse HSC and macrophages displayed an increased STAT5 activation. It 
would therefore be important to confirm whether HCK silencing in Lin' cells leads to a 
decrease in STAT5 activity and to establish whether LYN silencing in human cells also 
results in decreased STAT5 activity, in order to clarify if the regulatory relationships 
between HCK and LYN that have been established in mouse studies are exactly the same 
in humans.
In light of these intricate mechanisms of STAT5 activity regulation, it has to be 
remembered that we found LYN as well as HCK overexpressed in the Lin'/CD34+/CD38+ 
AML fraction in comparison to normal bone marrow in our microarray data, while only 
HCK was overexpressed in the Lin'/CD34+/CD3 8' AML fraction in comparison to 
normal bone marrow. Thus, modulating HCK expression in Lin'/CD34+/CD38' or Lin'
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/CD34+/CD38+ subset might have a different impact on their differentiation and self­
renewal capacity. When working with AML patients, screening for the expression (and 
activity) of different SFK, or at least HCK and LYN, as well as STAT5 and STAT3 
activity prior to manipulating them might allow to stratify normal karyotype patient 
samples and could also be looked at in correlation to FLT3 or SHIP1 mutation status. 
Indeed these different proteins are all involved in the same signalling pathway that 
culminates in the modulation of differentiation specific transcription factors such as 
CEBPa, PU.l and GATA1 (Choudhary et a l, 2007; Ingley et a l, 2005; Olthof et a l, 
2008; Rimmele et a l, 2007; Wierenga et a l, 2006) and are also implicated in 
leukaemogenesis involving chromosomal translocations. Ultimately such studies would 
help to understand which critical transducer of this signalling pathway should be 
specifically targeted in order to induce differentiation of AML blasts and/or abrogate 
their maintenance by LSC.
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